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ABSTRACT

Malignant Mesothelioma (MM) is a fatal disease with a low median survival between 8 to
12 months after diagnosis. MM has a long latency period (10-60 years), is causally related
to asbestos exposure, and is refractory to all available modes of therapy. Despite the causal
association between asbestos exposure and MM however, the mechanisms by which
asbestos induces this deadly disease remain unclear. Chronic inflammation due to the
presence of asbestos fibers is believed to play an important role in all aspects of MM
pathogenesis, from development to progression and resistance. Chronic inflammation has
been shown to promote dysregulated wound repair, fibrosis and epithelial to mesenchymal
transition (EMT). One of the inflammatory pathways that asbestos activates is the
inflammasome (a multiprotein scaffold that assembles in response to various stimuli to
facilitate the activation of caspase-1), which has been implicated in several chronic
inflammatory diseases and disorders. The nucleotide binding oligomerization domain
(NOD) - like receptor containing a pyrin domain 3 (NLRP3) inflammasome, both as a
whole or via its components [NLRP3, apoptosis related speck-like protein containing a
CARD (caspase activating and recruitment domain) (ASC) and caspase-1] as well as its
products, IL-1β and IL-18, has been implicated in the development of EMT during chronic
inflammation.
Asbestos fibers, especially the amphiboles, are non-biodegradable and thus persist in
tissues of the body for years after exposure. In mesothelial cells, the squamous epitheliallike cells that line the serosal cavities of the body, from which MM originates, asbestos
chronically activates the NLRP3 inflammasome. Asbestos also activates the NLRP3
inflammasome in human macrophages that can lead to the establishment of a chronic
inflammation environment. We therefore hypothesized that asbestos dependent regulation
of the inflammasome played a role in mesothelial to fibroblastic transition to facilitate
eventual neoplastic transformation of the mesothelial cells.
Using in vitro models, siRNA knockdown approaches as well as in vivo models of asbestos
exposure utilizing inflammasome component knockout mice, we demonstrate that
asbestos-induced reactive oxygen species generation modulates the redox state of the
endogenous antioxidant, thioredoxin, causing its dissociation from thioredoxin interacting
protein to promote activation of the inflammasome. We also show that the inflammasome
plays a role in asbestos-induced mesothelial to fibroblastic transition (MFT) (a form of
EMT occurring in the mesothelial cells) both in vitro and in vivo with a requirement for
caspase-1 in vivo to promote thickening of the submesothelium. Through our studies, we
have identified tissue factor pathway inhibitor 2 (TFPI2) and fibroblast growth factor 2
(FGF2) as molecules that are upregulated in response to asbestos exposure with potential
roles in the progression of asbestos-induced MFT. There is a dearth of diagnostic
biomarkers that enable early detection of MM, thus with further studies these two
molecules could be explored as biomarkers of asbestos exposure/disease progression.
TFPI2 levels were downregulated in response to blockage of IL-1β signaling and thus could
be harnessed as a potential marker for therapy efficiency with further studies.
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CHAPTER ONE: COMPREHENSIVE LITERATURE REVIEW

Asbestos-Induced Inflammation in Malignant Mesothelioma and Other
Lung Diseases

Joyce K. Thompson and Arti Shukla
Department of Pathology and Laboratory Medicine, College of Medicine, University of Vermont,
Burlington, VT, 05405

1.1 Introduction
Malignant mesothelioma (MM) is a deadly disease arising from the parietal mesothelium
of the pleura, peritoneum and in some rare cases, the pericardium or the tunica vaginalis of
the testis (Manning et al., 2002, Neumann et al., 2013, Chekol and Sun, 2012). Malignant
mesothelioma has been causally linked to asbestos exposure since the late 1950s into the
early 60s (Wagner et al., 1960, Wagner, 1965). MM has a very long latency period
(Thompson et al., 2014b) and the exact mechanisms involved in the development of this
terrible disease in response to asbestos exposure still remains elusive. MM has a lag time
between 10-60 years after initial asbestos exposure and only affects 5% of workers
occupationally exposed to asbestos. As such, a genetic predisposition to the development
of MM has been proposed. In fact, a small subset of MM patients have been recently shown
to harbor a germline mutation in the BRCA1 associated protein (BAP1) (Testa et al., 2011,
1

Ohar et al., 2016) which also predisposes affected individuals to uveal and cutaneous
melanoma and pancreatic cancer among others (Pilarski et al., 1993). In addition, a
significant percentage of MM tumors have also been found to carry a somatic BAP1
mutation (Bott et al., 2011, Nasu et al., 2015). Recent studies have shown that loss of one
copy of the BAP1 gene is enough to increase the sensitivity of mice to asbestos-induced
MM when compared to their wildtype litter mates (Kadariya et al., 2016a). Other causes
of MM include ionizing radiation (Li et al., 2015) and injury to the mesothelium, but the
exact etiology of the disease and the potentiating factors that determine whether an asbestos
exposed individual will develop MM remain unclear. The Simian virus large antigen 40
(SV40) has also been found in a subset of MM tumors giving rise to a debate that SV40 is
an important etiological factor in MM development (Qi et al., 2011, Yang et al., 2008). To
further complicate matters, the occult location of MM tumors makes their early detection
and diagnosis difficult (Addis and Roche, 2009). Wrong diagnosis due to shared symptoms
(Henderson et al., 2013a, Henderson et al., 2013b) as well the fact that symptoms usually
only manifest when the tumors are large enough to compromise breathing or cause pain
usually means that MM is diagnosed most frequently in its late stages (Rodriguez
Panadero, 2015, van Meerbeeck et al., 2011). Unlike other cancers in which tumors from
all stages are observed frequently, thereby allowing for the development of those diseases
to be studied, the majority of MM cases encountered are from late stage patients. The
restricted sample size as well as heterogeneity in the histological subtype also hinder an
accurate assessment of tumor progression and determination of biomarkers that can point
to the initial development of MM and aid in early detection. Several breakthroughs have
2

been made over the years in MM research but none of these have succeeded in improving
the dismal overall survival of the disease (average survival 8-12 months) (van Meerbeeck
et al., 2011). In order to design new therapies with improved efficacy, we need a better
understanding of the mechanisms employed by asbestos to cause mesothelioma. An
understanding

of

these

mechanisms

will

help

unlock

potential

targets

for

chemotherapeutics that are essential for recurrence thereby improving the prognosis of MM
patients. Additionally, studying how asbestos causes MM will yield biomarkers that can
then be followed for early diagnosis as well as treatment efficacy.
In this body of work, we investigate the role of the inflammasome and its regulation in
response to asbestos in asbestos-induced mesothelial to fibroblastic transition which we
believe may serve as a point of initiation for MM.
1.2 Asbestos
The group of hydrated silica fibers, collectively referred to as asbestos fibers, was used
extensively during the industrial age due to their high tensile strength, thermal and fire
resistance.

As such, they were employed in construction work for insulation and

fireproofing as well as in shipbuilding. Any endeavor that required insulation from high
temperatures and provided great fire risks relied on asbestos. The name asbestos,
originating from the Greek and meaning “unquenchable”, is actually a commercial name
referring to six hydrated silica fibers of economic importance. These fibers can further be
divided in two groups- serpentine asbestos which refers to the curly asbestiform fibers, the
most economically relevant member being chrysotile asbestos. Chrysotile asbestos
accounts for 95% of all mined and commercially available asbestos presently in use. The
3

second group is referred to as the amphibole asbestos fibers which possess a needle-like
morphology. The remaining five asbestos fibers (amosite, crocidolite, tremolite, actinolite
and anthophyllite) are found in this group. While the serpentine asbestos fibers have Mg2+
ions in their chemical structure (Mg3(Si2O5)(OH)4) (Gaze, 1965) (which leaches out of the
fiber in the presence of biological fluids (Morgan et al., 1977), the amphiboles vary in their
iron content (both in the valency state and location of the iron ions in their crystal structure
(Ghio et al., 2008, Gaze, 1965, Srivastava et al., 2010, Turci et al., 2011). Due to the
organization of the asbestos crystals, serpentine fibers occur as rolled up sheets that form
hollow fibers while the amphiboles form solid alternating tetrahedral sheets of silicate and
octahedral cation-oxides that result in their needle-like morphology (Gaze, 1965).
Now that asbestos use has been reduced and banned in the construction industry, we are
left with large numbers of buildings and ships that contain copious amounts of asbestos.
Members of the workforce that were involved in the mining, weaving into textile,
application of and plumbing with asbestos fibers were exposed to asbestos fibers from their
work environment. Unfortunately, these workers also carried the fibers home with them
in the form of the dust on their work clothes, which were handled and laundered by family
members, exposing them to asbestos fibers in the process (Rom and Palmer, 1974). Towns
that surrounded asbestos mines and textile mills were not spared this exposure either, as
their air was filled with dust from these activities (Lemen et al., 1980). So long as asbestos
sheets and other products are intact, they are relatively safe. Should they break or fracture
in any way, however, they then pose a health risk to those exposed. One might ask, why
is this the case? The answer lies in the friable nature of the asbestos fiber. Once broken,
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the fiber and any product made from it continues to break into ever smaller pieces like
fabric that is unraveling and fraying. This produces fiber particles that are small enough
to become airborne and, thus, respirable. It was noted well before the twentieth century
that people who worked with asbestos died earlier than others and presented with
symptoms that were in the early twentieth century referred to as pneumoconiosis (Seiler,
1928). The only common thread between these cases was the occupation of the individuals
and the role asbestos played in those occupations.
Reports indicate that miners of asbestos who happened to smoke have a 95%
increase in their risk of developing lung cancer (Norbet et al., 2015). Cases referred to as
pneumoconiosis, and later on determined to be asbestos-induced lung or pleural fibrosis,
seemed to be most common in individuals with a history of occupational exposure
(Manning et al., 2002). In some cases, individuals developed pleural plaques with and
without pleural effusions, which were sometimes termed malignant. However, the
deadliest disease ascribed to asbestos exposure is malignant mesothelioma (MM), which
affects only a small subset of exposed individuals (Norbet et al., 2015, Neumann et al.,
2013, Broaddus et al., 2011). An underlying thread found in these asbestos-related diseases
is their latency period, which ranged in duration from 10-60 years after initial exposure.
The level of exposure and time span of exposure also plays a role in the latency period of
these diseases (Hesterberg et al., 1998, Craighead, 2011). Asbestos fibers, especially the
amphiboles such as crocidolite, are non-degradable and persist in parts of the body where
they are eventually deposited (typically the pleural cavity). Macrophages and other
phagocytic cells attempt to clear the asbestos fibers, but they only succeed in removing
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short fibers (Hesterberg et al., 1998, Davis and Jones, 1988, Donaldson et al., 2013,
Murphy et al., 2012). Long asbestos fibers, because of their high aspect ratio, pose a
problem for these cells, as they are not able to engulf the fibers fully (Moolgavkar et al.,
2001, Sanchez et al., 2009, Davis and Jones, 1988, Murphy et al., 2012). As a result, there
are repeated attempts to phagocytose the fibers, which results in frustrated phagocytosis,
the accompanying release of superoxide, and the eventual death of the cells involved
(Sanchez et al., 2009, Murphy et al., 2013). This process of frustrated phagocytosis and
cell death leads to the establishment of a vicious cycle in which inflammatory cells are
repeatedly recruited to sites of asbestos fiber deposition accompanied by the secretion of
inflammatory factors and chemokines that facilitate an inflammatory environment/niche
(Mossman et al., 2013). In this chapter, we cover some of the ways in which asbestos
promotes chronic inflammation and how such an environment can engender the
development of asbestos-related diseases.
1.3 Asbestos and Oxidant Generation
The surface of the asbestos fiber is a highly reactive one. The stereochemistry of the crystal
structure as well as the valency state of iron ions determines the availability of these ions
to participate in reactions at the cellular/interstitial fluid-fiber interface (Gazzano et al.,
2005). While the chemical structure of chrysotile asbestos lacks iron, studies employing
artificially generated iron free chrysotile have shown that chrysotile fibers are capable of
drawing iron out of solution onto its surface (Gazzano et al., 2007) in cell free systems as
well as under biological conditions. Chrysotile asbestos exposure also cause hemolysis in
vivo leading to a buildup of iron on the asbestos fibers (Elferink and Kelters, 1991). Of the
6

amphibole asbestos fibers, amosite contains the most iron in its chemical structure (28%)
followed by crocidolite (27%) by weight (Ghio et al., 2008, Srivastava et al., 2010).
However, due to the stereochemistry of the crocidolite fibers and the valency state of iron
ions on crocidolite, the iron ions are more motile and crocidolite asbestos generates the
most reactive oxygen species (ROS) under both biological and cell free conditions
(Srivastava et al., 2010, Pascolo et al., 2013). ROS generated in response to asbestos fibers
in vivo are not only cytotoxic but genotoxic as well (Srivastava et al., 2010, Aljandali et
al., 2001). The mobilization of iron by asbestos in subjects that have been exposed to
asbestos leads to a dysregulation of iron homeostasis (Ghio et al., 2008) as the body
attempts to detoxify the high iron on the fibers by covering the asbestos fibers with iron
storage proteins like ferritin (Pascolo et al., 2013). The increased generation of reactive
species also increases the synthesis of intracellular antioxidants like glutathione and
glutathione synthetase, extracellular superoxide dismutase (Hillegass et al., 2010b) and
thioredoxin (Thompson et al., 2014a) in an attempt to rectify the oxidant/antioxidant
balance. Exposure to asbestos also increases lipid peroxidation and generation of reactive
nitrogen species (Shukla et al., 2003a, Howden and Faux, 1996, Faux and Howden, 1997,
Nymark et al., 2008, Haegens et al., 2005) thus promoting an environment in which
signaling cascades that are usually briefly stimulated by various reactive species are
upregulated due to a surge in activating stimuli. Among such cascades are the various proinflammatory signaling pathways which while useful as the body attempts to clear the
foreign bodies quickly become detrimental as they become imbalanced and chronically
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active due to the duration of the biopersistent stimulus (Shukla et al., 2003a, Shukla and
Mossman, 2004, Shukla and Mossman, 2008, Faux and Howden, 1997).
Asbestos exposure can also lead to the production of peroxynitrites (ONOO-) through the
reaction of superoxide and nitric oxide (NO), when excess amounts of either are present
(Matsuzaki et al., 2012, Nymark et al., 2008). Alveolar macrophages are among the first
cells to encounter inhaled asbestos fibers and as they try to clear fibers (Mossman and
Churg, 1998, Miserocchi et al., 2008), they undergo a superoxide burst via the activity of
NADPH oxidases to produce superoxide to clear pathogens/fibers (Dostert and Petrilli,
2008, Hansen and Mossman, 1987). In the case of asbestos fibers however, the superoxide
produced serves to reduce Fe3+ ions on the fiber surface and to Fe2+ which can also reduce
molecular oxygen to superoxide (Wang et al., 2006) leading to the overproduction of
superoxide. Infiltrating neutrophils also express inducible nitric oxide synthase and
produce large amounts of NO into the extracellular milieu in response to the foreign bodies
(i.e. fibers) they encounter (Turci et al., 2012). Under these conditions, the superoxide and
NO present can then react to yield peroxynitrites which can attack and damage DNA by
forming 8-nitrosoguanine adducts (Zhu et al., 1998, Iwagaki et al., 2003, Murata et al.,
2012).
1.3.1 Effects of Asbestos-Induced Oxidant Generation
Asbestos fibers have been shown to activate the epidermal growth factor (EGFR) in a
ligand-independent manner which was suggested to be more potent than the engagement
of the receptor by its endogenous ligands (Zanella et al., 1999, Taylor et al., 2013). Due to
the persistence of asbestos fibers and their ability to rapidly bind and dissociate from the
8

EGFR (Taylor et al., 2013), activation of EGFR by asbestos leads to a sustained activation
of the EGFR signaling cascade that is much longer than signaling in response to EGF and
other endogenous ligands. Under normal EGFR signaling conditions, hydrogen peroxide
(H2O2) is produced in minute quantities as a transient signaling molecule (Hansen et al.,
2006, Su et al., 2012). In the presence of asbestos however, sustained signaling by the
EGFR would lead to an increase in H2O2 levels in excess of the amount needed for
signaling. Whereas H2O2 is normally reduced to two molecules of water by peroxiredoxins
or catalase (Goth, 2006, Rhee and Woo, 2011), the production of H2O2 in excess of what
the peroxiredoxins or catalase can quickly convert to water, combined with the presence of
Fe2+ on asbestos fibers will promote Fenton reactions which lead to the generation of the
hydroxyl radical (OH•) (Miller et al., 2014). Thus, through the direct or indirect generation
of ROS and other reactive species asbestos can promote the destruction of lipid membranes
via lipid peroxidation, irreversible oxidation of essential enzymes and DNA damage. One
indirect way by which asbestos skews the antioxidant/oxidant balance is through the
inhibition of the pentose phosphate pathway. Studies have shown that asbestos-induced
oxidants inhibit the rate limiting step of the pentose phosphate pathway by oxidizing
glucose-6-phosphate dehydrogenase (G6PD) (Riganti et al., 2002, Riganti et al., 2003).
G6PD is required for production of ribulose 5-phosphate for replenishing the pool of
reduced nicotinamide adenine dinucleotide phosphate (NADPH). NADPH provides
reducing equivalents for the regeneration of a number of antioxidant proteins including
thioredoxin, glutaredoxin and their respective reductases (Berndt et al., 2007). Thus, by
inhibiting the PPP and subsequently NADPH, asbestos-induced oxidants further tip the
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antioxidant/oxidant scale in favor of oxidants. Asbestos-induced oxidant dependent
destruction can lead to the activation of apoptosis via the tumor suppressor, p53 and protein
kinase C delta (PKCδ) (Shukla et al., 2003d) or via the activation of tumor necrosis factor
alpha (TNFα) (Heintz et al., 2010). Paradoxically, asbestos can cause both cell death and
cell proliferation. The key deciding factor is the dose of asbestos delivered. While the dose
of asbestos reaching lung epithelial or macrophages and mesothelial cells cannot be
determined in real time, it is fair to concede that cells at different locations will receive
different doses of asbestos. Long asbestos fibers have long been known to have a higher
potential for promoting disease and oxidative stress (Donaldson et al., 2010, Murphy et al.,
2011). These fibers cannot pass through the stomata of the pleural mesothelium and thus
get lodged in them, potentially increasing the local concentration of asbestos at such loci
(Murphy et al., 2011, Murphy et al., 2012, Murphy et al., 2013). Macrophages unable to
engulf long asbestos fibers also fuse with other macrophages to engulf the fiber
successfully and this sometimes leads to the aggregation of unsuccessful cells on fibers
(Donaldson et al., 2013). In such situations cell death may ensue not because of a high dose
of asbestos but due to frustrated phagocytosis. So, while some cells may die due to
differences in cell death programs initiated in response to asbestos, areas of cells with lower
levels of asbestos which are still producing lower levels of oxidants can activate mitogenic
pathways that lead to cell survival and proliferation. High asbestos doses on the other hand,
promote the release of large amounts of oxidants that promote glutathione depletion,
necrosis and apoptosis (Shukla et al., 2003a, Liu et al., 2010). The apoptosis observed in
such cases has been attributed to the activation of p53 in response to DNA damage and was
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shown to be attenuated with the introduction of iron chelators and antioxidants (Aljandali
et al., 2001, Broaddus et al., 1996, Shukla et al., 2003b, Panduri et al., 2006).
Asbestos exposure induces chronic inflammation as macrophages and neutrophils attempt
to clear the fibers and die in the process. The death of these cells releases chemokines and
other proinflammatory cytokines into the extracellular milieu thereby attracting more
inflammatory cells, setting up a vicious cycle of death of inflammatory cells and release of
inflammatory molecules and the accompanying release of oxidants that cause DNA
damage. The generation of peroxynitrites in response to asbestos exposure leads to the
formation of 8-nitroguanine adducts (Chao et al., 1996, Fung et al., 1997, Hiraku et al.,
2010, Hiraku et al., 2014). When these adducts are not corrected, DNA replication errors
occur causing mutations as the 8-nitrosoguanine is wrongly paired with adenine and
eventually a guanine to thymine transversion occurs in whichever gene locus affected is
eventually after subsequent rounds of replication. The 8-nitroguanine adduct is actually
used as a marker for chronic inflammation (Wang et al., 2016, Ohshima et al., 2006), which
is one of the predominant effects of asbestos exposure. Oxidative DNA damage induced
by asbestos exposure also affects mitochondrial DNA and this happens at much lower
concentrations of asbestos than is required to cause nuclear DNA damage (Shukla et al.,
2003b). In addition to direct DNA adduct formation, the DNA replication machinery can
also be negatively affected by asbestos-induced oxidant generation and lead to errors in
replication (Huang et al., 2011). Evidence suggests that asbestos exposed individuals have
higher levels of 8-hydroxydeoxyguanosine (8-OHdG) adducts present in their DNA than
non-exposed individuals (Marczynski et al., 2000, Hiraku et al., 2014, Chen et al., 1996)
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providing further proof that asbestos exposure causing oxidative DNA damage that can
lead to the development of mutations in various genes and potentially contribute to the
development of asbestos-induced MM.
Several signaling pathways (apoptosis, inflammatory cytokine secretion and signaling,
proliferation, etc.) impinge on mitogen activated protein kinase (MAPK) activation
(Shukla and Mossman, 2008). Asbestos activates all of these pathways and more
importantly, asbestos activates a number of MAPK proteins (extracellular signal regulated
kinases 1, 2 and 5 (ERK 1, 2 &5) to name a few) (Scapoli et al., 2004, Zanella et al., 1996,
Shukla et al., 2013) and by extension their downstream effectors (Shukla and Mossman,
2008, Heintz et al., 2010). Two transcription factors important in asbestos-induced
pathogenesis, activator protein 1 (AP-1) and nuclear factor kappa B (NFκB) are both redox
sensitive and act downstream of MAPK activation (Heintz et al., 2010). AP-1 and NFκB
both promote inflammation, cell proliferation, transformation and survival, are activated
by asbestos (Flaherty et al., 2002, Janssen et al., 1997), and have been implicated in playing
those roles in the context of asbestos-induced diseases (Heintz et al., 2010).
Several inflammatory processes are activated either directly or indirectly by asbestos
related oxidants. Chrysotile-induced mitochondrial oxidants altered the expression of 178
genes associated with inflammatory cascades at both the transcriptional and effector
protein levels (Huang et al., 2012). Massive parallel sequencing of primary peritoneal and
pleural mesothelial cells exposed to crocidolite asbestos also yielded results indicating that
the greatest change in gene expression was in genes found in inflammatory networks, many
of which have been implicated in some way in MM development (Dragon et al., 2015).
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Several of these genes are regulated by the redox sensitive transcription factors, NFκB and
AP-1. While oxidants generated in response to asbestos activate inflammatory networks,
the nitrative DNA adducts also provide evidence for the generation of oxidants as a result
of chronic inflammation activated in response to the asbestos fibers (Shukla et al., 2003a,
Chen et al., 1996, Fung et al., 1997), thereby perpetuating a never ending vicious cycle of
oxidant activated inflammation and inflammation related oxidant generation and cellular
damage. One other inflammatory cascade that is affected by asbestos-induced oxidant
generation and the antioxidant/oxidant imbalance is the inflammasome (Thompson et al.,
2014a, Zhou et al., 2010). Oxidation of the cellular antioxidant redox protein, thioredoxin
(Trx) leads to the release of its endogenous inhibitor, thioredoxin interacting protein
(TXNIP) from Trx (Thompson et al., 2014a, Nishiyama et al., 1999). Association of
TXNIP with the inflammasome has been shown to be required for inflammasome
activation and important for the pathology of diseases like diabetes (Oslowski et al., 2012)
and atherosclerosis (Byon et al., 2015). The inflammatory responses elicited by asbestos
play an important role in in the development of almost all the asbestos related diseases
(both malignant and non-malignant) and they share the same long latency period albeit
with variations. It is currently not known if MM progresses from pleural fibrosis as some
patients with pleural fibrosis may develop MM but not all fibrosis/asbestosis patients
develop MM.
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1.4 Asbestos-Related Diseases
The commonest asbestos-related diseases are pleural in nature and range from benign
pleural plaques and benign (or sometimes malignant) pleural effusions to pleural fibrosis,
asbestosis, and lung cancer (Manning et al., 2002, Norbet et al., 2015, Prazakova et al.,
2014). The less common diseases include the fatal disease MM (primarily pleural and
peritoneal, and to lesser extent, pericardial mesothelioma) (Mossman et al., 2013), the rare
asbestos-induced IgG-related disease (Onishi et al., 2016), as well as autoimmune diseases
that affect the joints (Pfau et al., 2014). The presentation and outcomes of these diseases
vary. At times, the disease goes undiagnosed and is only observed post-mortem upon
autopsy after death from an unrelated cause.
1.4.1 Pleural Plaques
Pleural plaques, the commonest asbestos-related disease, arises predominantly on the
parietal pleura (O'Reilly et al., 2007). These plaques are distinct areas of fibrosis that can
be found classically on the dome of the diaphragm, on the back wall of the chest between
the seventh and tenth ribs, as well as laterally between the sixth and ninth ribs (Peacock et
al., 2000, Becklake et al., 2007, Norbet et al., 2015). Pleural plaques can be diagnosed
with a chest x-ray depending on the position of the plaque (Peacock et al., 2000). In
addition, examination of such plaques can reveal the presence of asbestos fibers. The
plaques are believed to develop as part of an inflammatory response to asbestos fibers
(Manning et al., 2002). Although calcification of asbestos-induced pleural plaques is
uncommon, there are reports of some calcification in about 10-15% of pleural plaques
(Norbet et al., 2015). Pleural plaques are generally presumed to be benign but some
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patients experience a small reduction in lung function as well as neuropathic pain
(Becklake et al., 2007, Norbet et al., 2015).
1.4.2 Pleural Effusion
The accumulation of fluid in the pleural space of individuals with a history of asbestos
exposure may be a benign or malignant manifestation of asbestos-related disease
(Prazakova et al., 2014, Manning et al., 2002). As with all asbestos-related diseases, there
is a long latency period. Pleural effusions are typically observed within 10-20 years after
initial asbestos exposure (Myers, 2012, O'Reilly et al., 2007). However, since other
conditions can lead to the development of pleural effusions, diagnosis depends heavily on
the exclusion of all other potential causes (O'Reilly et al., 2007). Due to the association of
MM with pleural manifestation, a waiting period of 3 years without the manifestation of a
neoplasm is required before a pleural effusion incident is deemed benign (Peacock et al.,
2000). As such, thorascopic examination of the pleural space and cytological analysis of
the effusion is performed to ascertain the presence of malignant cells and asbestos fibers
(Peacock et al., 2000). Like many other diseases, the level of morbidity associated with
pleural effusions depends on the amount of the effusion and the time it takes to resolve.
1.4.3 Asbestosis
Asbestosis, also known as asbestos-induced pulmonary fibrosis, is an interstitial lung
disease that causes fibrosis of the lung parenchyma and honeycombing (Norbet et al., 2015,
Manning et al., 2002). In some cases, there are calcifications of the lung interstitia.
Asbestosis shares characteristics with idiopathic pulmonary fibrosis and severely
compromises lung function, leading to dyspnea and drastic reduction in lung flow volume
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(Manning et al., 2002, Prazakova et al., 2014). Asbestosis generally occurs within 10 to
30 years after asbestos exposure as a result of unresolved inflammation in response to the
presence of long thin asbestos fibers in the small airways and alveoli (Manning et al., 2002).
The inflammation causes scarring and thickening of the interstitia and subsequent loss of
elasticity of the type II alveoli epithelium, thereby compromising lung function (Norbet et
al., 2015).
1.4.4 Lung Cancer
Inhalation of asbestos can also lead to the development of lung cancer. While the majority
of lung cancers are related to smoking, asbestos exposure accounts for about 3-8% of all
lung cancer cases (Prazakova et al., 2014). Asbestos exposure is believed to increase the
risk of developing lung cancer in smokers by as much as 4- to 9-fold (Ngamwong et al.,
2015, Swiatkowska et al., 2015). Like other asbestos-associated diseases, asbestos-related
lung cancer has a long latency period (20-40 years after asbestos exposure) (Manning et
al., 2002, Ngamwong et al., 2015, Swiatkowska et al., 2015). For a diagnosis of lung
cancer to be attributed to asbestos exposure, however, the patient has usually been heavily
exposed to asbestos with an exposure rate of about 25 fibers/mL per year or more
(Prazakova et al., 2014, Roggli and Sporn, 2016). In addition to the presence of asbestos
fibers in the lung interstitium, presentation with lung cancer must be found to occur more
than 10 years after exposure in order to establish causality (Norbet et al., 2015). In a
number of cases of asbestos-related lung cancer, there is concurrent asbestosis. Asbestosrelated lung cancer cannot be differentiated phenotypically from lung cancer in nonasbestos exposed individuals, but there appears to be a propensity for this type of lung
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cancer to develop in the lower lung compared to non-asbestos related lung cancer (Inamura
et al., 2014, Manning et al., 2002). Studies have shown that cumulative asbestos exposure
is proportionally related to the development of asbestos-related lung cancer (Inamura et al.,
2014).
1.4.5 Malignant Mesothelioma
The deadliest disease attributed to asbestos exposure is MM, which arises in the serosal
lining (mesothelium) of the pleura, peritoneum and sometimes the pericardium (Manning
et al., 2002, Mossman et al., 2013). Even rarer is the occasional incidence of MM in the
tunica vaginalis of the testis (Jankovichova et al., 2015, Trpkov et al., 2011, Chekol and
Sun, 2012). As with all asbestos-related diseases, MM has a long latency period (10-40
years) (Mossman et al., 2013). MM is considered an occult cancer that is difficult to detect
until it is advanced enough to cause appreciable symptoms. Symptoms usually include
chest pain, coughing, dyspnea, pleural effusions (in the case of pleural MM), pain and
discomfort with distention of the abdomen due to ascites build up, and night sweats/fever
(in peritoneal MM) (Moore et al., 2008, Prazakova et al., 2014). Thin and long asbestos
fibers are believed to translocate to the mesothelium outside of the lung, by mechanisms
that are still poorly understood, ultimately causing MM in the pleura or peritoneum
(Mossman et al., 2013, Murphy et al., 2013). In addition to asbestos fibers, erionite–a nonasbestos fiber–has been shown to be more mesotheliomagenic and is responsible for a MM
epidemic in the Cappadocia region in Turkey (Heintz et al., 2010, Dikensoy, 2008).
Erionite has been found in different areas here in the United States and has the potential to
cause cases of MM because of environmental exposure.
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1.5 Mesothelial cells
The mesothelial cell is a unique, squamous epithelial-like cell that is derived from a
mesodermal origin (Mutsaers, 2002). They possess both epithelial and mesenchymal
characteristics; they display apico-basal polarity, express cytokeratins and form cell-cell
junctional complexes (Mutsaers, 2004). Mesothelial cells form a single cell layer known
as the mesothelium with a loose basement layer which covers the internal surfaces of the
body wall (parietal surface) and the external surfaces of all organs in the serosal cavities
(visceral surface) (Mutsaers, 2002). The function of the mesothelium includes the
production of glycosaminoglycans for lubrication to prevent the adhesion of organs;
hyaluronan production for trapping microbes and also preventing adhesion; antigen
presentation for the infiltration of immune cells in the case of infections; cytokine and
chemokine secretion as part of an inflammatory response and for the recruitment of
immune cells (Mutsaers, 2002, Mutsaers, 2004, Mutsaers et al., 2015). The secretion of
extracellular matrix and growth factors by mesothelial cells also aids in their maintenance
of the homeostasis of the serosal cavity (Mutsaers, 2002). The regulation of coagulation,
fibrinolysis and tumor cell adhesion are also an important function of the mesothelium
(Mutsaers et al., 2015). Self-renewal of the mesothelium is a very slow process; at any
given time only 0.16-0.5% of mesothelial cells are undergoing mitosis (Mutsaers, 2004).
Unlike epithelial cells, mesothelial cells tend to overlap with adjacent cells making it
difficult to follow the boundaries of individual cells. On average, a mesothelial cell is about
25 µm in length (Mutsaers, 2002) but only measure about a micron in thickness (Figure
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1.1). The luminal surface of the mesothelium is covered in microvilli (Figure 1.2) that help
trap the glycosaminoglycan and proteins that form the glycocalyx of the mesothelium
[reviewed in (Mutsaers, 2002)]. The function of a mesothelial cell, its state of activation as
well as its location affect the observed phenotype of this cell type (Mutsaers et al., 2015).
For example, activated mesothelial cells can appear raised and elongated (Mutsaers, 2002).
When there is injury to the serosal surface resulting from surgery or denudation of the
mesothelial layer due to other factors, repair of the breach is not simply through growth at
the edge of injury. Mesothelial cells from distant sites can undergo desquamation and these
free floating cells can then migrate to and seed the site of injury and proliferate to repair
the damage in addition to growth at the edge of the wound (Mutsaers, 2002, Mutsaers et
al., 2015, Mutsaers et al., 2016).

Figure 2.1: Scanning electron micrograph of mouse mesothelial cells cultured from mouse
peritoneal wall explants. Small pieces of peritoneal wall were transferred to sterile coverslips
placed in a 12 well dish. Cells were fixed, dehydrated and prepared for SEM imaging after 2
weeks in culture.
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Figure 1.2: Scanning electron micrograph of mouse parietal mesothelium. A section of the
peritoneal wall of wild type mice receiving saline over 8 weeks was oriented mesothelial side up
and fixed for SEM. Samples were sputter coated prior to imaging.

In response to injury mesothelial cells also express elevated levels of tissue factor (TF) and
other procoagulant factors to promote fibrin deposition (Mutsaers et al., 2015). Fibrin
deposition helps in resolution of the injury to the mesothelium but its clearance is required
for proper restoration of serosal homeostasis in order to prevent adhesions. To this end,
mesothelial cells also secrete tissue factor pathway inhibitor (TFPI) to inhibit the formation
of fibrin via the extrinsic coagulation pathway while upregulating the secretion of
fibrinolytic enzymes and their activators such as tissue plasminogen activator,
plasminogen, urokinase (uPA) and its receptor, uPAR. To regulate fibrinolysis, mesothelial
cells also produce plasminogen activator inhibitors, tissue inhibitors of metalloproteinases
(TIMPs) as well as tissue factor pathway inhibitor 2 (TFPI2) (Mutsaers et al., 2015). TFPI2
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indirectly regulates the activity of matrix metalloproteinases by inhibiting the activation of
proteinases such as plasmin and trypsin, among others (Chand et al., 2005, Baker et al.,
2002). Interestingly TFPI2 also promotes activation of pro-MMP2 through an unknown
mechanism and this function of TFPI2 is thought to promote vasculogenic mimicry in nonvascular cells and some tumor cell lines (Ruf et al., 2003). A careful balance between fibrin
deposition and fibrinolysis is maintained by the mesothelium (Mutsaers et al., 2015) and
disruption of this balance has been shown to be important in mesothelioma, fibrosis and
organ adhesion (Williams et al., 2012, Mutsaers et al., 2016). During injury to the serosal
surface, mesothelial cells downregulate TFPI expression in response to thrombin by acting
through NFκB thereby promoting coagulation through the tissue factor pathway (Jeffers et
al., 2015). Conversely, thrombin may upregulate TFPI2 expression to prevent fibrinolysis
through the same pathway as has been observed in macrophages treated with thrombin
(Pou et al., 2011) to inhibit fibrinolysis. Thus, if for any reason fibrinolysis is not initiated
and fibrin deposition continues after resolution of the injury or insult, this imbalance in
fibrinolysis and fibrin deposition may promote fibrosis or organ adhesions at a later stage
(Mutsaers et al., 2016).
Infections, asbestos fibers and high glucose peritoneal dialysis (PD) fluid also elicit an
inflammatory response in the mesothelium (Hillegass et al., 2013, Mutsaers et al., 2015,
Yung and Chan, 2012). Mesothelial cells are phagocytic and take up pathogens for antigen
presentation (Shaw et al., 2016) and also attempt to clear asbestos fibers by phagocytosing
them (Jaurand et al., 1979). The advanced glycation end products formed from the glucose
in the dialysate engage the receptor for advanced glycation end products (RAGE) to
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promote inflammation and peritonitis in patients undergoing PD (Zhou et al., 2016). Thus
mesothelial cells play an active role in maintaining homeostasis in the serosal cavity and
serve as a line of defense against foreign and infectious agents. Disruption of the function
of the mesothelium is deleterious to serosal health and proper organ function.
1.6 Asbestos, Inflammation and Asbestos-Related Diseases
All types of asbestos elicit an immune response in the cells they come into contact with,
either directly or indirectly through the release of danger associated molecular pattern
molecules from cells they encounter (Ballan et al., 2014, Donaldson et al., 2010, Haegens
et al., 2007). The amphibole asbestos fibers are bio-persistent compared to the serpentine
asbestiform, chrysotile, which can be degraded by bodily fluids and cells due to its more
compressible fibril nature and the leaching of magnesium from the fibers (chemical
composition: Mg3Si205(OH)4) (Manning et al., 2002). A recent review by Acencio et al.
(Acencio et al., 2015) clearly summarized the role of inflammatory cytokines in chrysotileand crocidolite-induced mesothelial cell injury leading to diseases. Studies from our group
have also demonstrated that asbestos can cause increased gene expression and protein
levels of various inflammatory cytokines (IL-13, bFGF, VEGF, GSF) from mesothelial
cells (Shukla et al., 2009) and that many of these cytokines are required for MM
development in mice (Hillegass et al., 2010a). Chrysotile asbestos has been shown to elicit
an acute immune response 3 and 9 days post inhalation of this fiber type (Haegens et al.,
2007). In an examination of mice exposed to chrysotile asbestos for 6 hours a day, an
increase in the number of immune cells retrieved from the lungs through bronchoalveolar
lavage showed an increase in infiltrating cells in the asbestos-exposed mice when
22

compared to sham-exposed mice (Haegens et al., 2007). Increases in the number of
infiltrating eosinophils and neutrophils were observed, and the number of lymphocytes
increased after 9 days of exposure (Haegens et al., 2007).
Amphibole asbestos fibers are generally regarded as the main culprits behind
MM, although chrysotile asbestos has also been shown to have mutagenic capabilities and
is linked to MM development (Chew et al., 2014, Chew and Toyokuni, 2015, Kanarek,
2011). Among the amphiboles, crocidolite asbestos is classified as the most carcinogenic
(Dopp et al., 2005, Ballan et al., 2014), and studies into reactive oxygen species (ROS)
production, cell signaling and genotoxicity have generally been carried out using
crocidolite or amosite (Dopp et al., 2005). Crocidolite asbestos elicits an acute immune
response, and because of its biopersistence can cause chronic inflammation by recruiting
inflammatory cells which then die in the process of attempting to clear the asbestos fibers
(Moolgavkar et al., 2001). The death of such immune cells then elicits a new wave of
inflammatory cell influx, thus leading to a never-ending cycle of inflammation in response
to the presence of the fibers. Amphiboles such as amosite and crocidolite also contain iron
in their crystal structures ([(Mg, Fe)7Si8O22(OH)2]n and [NaFe32+Fe23+Si8O22(OH)2]n,
respectively), and the valency state of these iron moieties determines their ability to
participate in Fenton reactions (Dopp et al., 2005). These Fenton reactions promote the
production of reactive species such as the hydroxyl ion (Dopp et al., 2005, Mossman et al.,
2011). Regulators of expression of various cytokines (transcription factors, e.g., NFB
and AP-1) are affected by the redox state of the cell (Shukla et al., 2003c). Raising the
oxidation state or altering the redox balance of the cell can thereby lead to their aberrant
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activation or inhibition, resulting in the production of more inflammatory cytokines in
response to asbestos exposure. Exposure to crocidolite/amosite has been shown to increase
the production and secretion of a number of inflammatory cytokines, including but not
limited to IL-1β, IL-5, IL-6, IL-8, and IL-18 (Haegens et al., 2007, Hillegass et al., 2013).
While tracheal instillation of asbestos into mice has been shown to result in death
of epithelial and mesothelial cells as well as alveolar macrophages, some of these cells
appear to escape such death and survive longer than cells from control animals or cells
unexposed to asbestos (Nishimura et al., 2013). Alveolar macrophages that survive
chrysotile asbestos exposure have been reported to live longer and secrete increased
amounts of the fibrogenic factor TGFβ, leading to the conclusion that such alterations
contribute directly to the fibrosis observed in response to asbestos exposure (Nishimura et
al., 2013, Nishimura et al., 2007, Sullivan et al., 2008). These inflammatory responses to
asbestos have been observed both in vitro and in vivo. Recent studies of patients with
history of asbestos exposure have shown that these patients have elevated levels of IL-8
and other cytokines, as well as their respective receptors (Comar et al., 2016, Comar et al.,
2014). Levels of vascular endothelial growth factor (VEGF), platelet derived growth factor
b (PDGFb) and basic fibroblast growth factor (bFGF) were also significantly increased
upon exposure to asbestos and further increased in some cases with disease (Comar et al.,
2016). VEGF and bFGF are both angiogenic factors that stimulate proliferation of
mesothelial cells (Comar et al., 2016, Strizzi et al., 2001, Van et al., 2012) and alter the
permeability of the mesothelium (VEGF) (Hillegass et al., 2013, Strizzi et al., 2001).
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PDGFb has been shown to promote the growth of fibroblasts and the progression of fibrosis
in lung disease (Safi et al., 1992).
Asbestos fibers can cause systemic changes in inflammatory cytokines (Gavett et
al., 2016, Fukagawa et al., 2008, Dragon et al., 2015), and these changes can lead to the
creation of a pro-tumorigenic environment (Okada, 2014). The initial site of contact for
inhaled fibers is the lung, where alveolar macrophages and epithelial cells encounter the
inhaled asbestos. In as early as 3 days after asbestos exposure, the inflammatory profile in
the lung changes. An increase in the number of infiltrating eosinophils and neutrophils is
observed (Haegens et al., 2007). As cells attempt to clear the foreign objects, the high
aspect ratio of the asbestos fibers leads to frustrated phagocytic events that promote death
of the phagocytic cells. Consequently, greater numbers of inflammatory cells are recruited
to the site of injury. An overproduction of collagen by fibroblasts recruited to these sites
of injury promotes parenchymal fibrosis, because the injury is not resolved due to the
continued presence of the asbestos fibers. As cells attempt to clear asbestos fibers and
resolve the injury, more and more extracellular matrix is deposited and stromal cells are
recruited. These may be the underlying contributing factors to the development of
asbestosis and potentially lung cancer (Heintz et al., 2010).
Asbestos fibers have been found to translocate to the interpleural space by
mechanisms that are still incompletely understood. Studies indicate that asbestos or carbon
nanotubes 10 µm or greater in length cause acute inflammation and fibrosis on the parietal
surface of the pleural mesothelium in a length dependent manner due to an inhibition of
clearance through the pleural stomata (Figure 1.3) (Murphy et al., 2011, Schinwald et al.,

25

2012). It has been proposed that the length of a fraction of the asbestos fibers interferes
with their clearance through the lymphatic drainage, as they cannot go through the pleural
stomata. As a result, fibers within a particular length range accumulate on the parietal
pleura, leading to the formation of pleural plaques and pleural fibrosis by propagating
chronic inflammation and injury to the mesothelium (Donaldson et al., 2010). Recent
studies have shown that asbestos-like fibers such as carbon nanotubes are capable of
eliciting the same kind of inflammatory and fibrotic responses in the pleural mesothelium
as does asbestos (Murphy et al., 2011, Murphy et al., 2012, Nagai and Toyokuni, 2010).
Asbestos bodies are not always associated with pleural plaques, suggesting that an
intermediate inflammatory mediator may be involved. Macrophages, mesothelial cells and
other phagocytic cells undergo frustrated phagocytosis while attempting to clear these high
aspect ratio fibers and secrete a host of inflammatory mediators.

Thus, pleural

macrophages secreting a number of inflammatory cytokines may also play a role in
facilitating inflammation-induced injury and repair in the pleura that could promote
asbestos-related disease formation (Mossman et al., 2011). One study has shown that
supernatants from macrophages exposed to long carbon nanotubes serve as potent
activators of mesothelial cells and significantly increase their secretion of inflammatory
cytokines such as IL-1β and eotaxin (Murphy et al., 2012). This same phenomenon has
been demonstrated for asbestos as well. Studies indicate that one of the inflammatory
cascades activated by asbestos in macrophages and mesothelial cells is the activation of the
inflammasome (Dostert et al., 2008, Hillegass et al., 2013). The inflammasome is a special
component of inflammation, where NOD-like receptor containing pyrin domain 3
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(NLRP3), a cytoplasmic protein complex, senses fibers.

This results in caspase-1

activation and secretion of the pro-inflammatory cytokines IL-1β and IL-18. There are
several NOD-like receptors reported in the literature; however, only activation of the
NLRP3 inflammasome in macrophages and mesothelial cells by asbestos has been
demonstrated to increase secretion of IL-1β, IL-18 and other pro-inflammatory cytokines
as a result of IL-1β signaling (Dostert et al., 2008, Hillegass et al., 2013). Additionally,
asbestos-induced inflammasome activation can lead to the release of a pro-inflammatory
danger-associated molecule, high mobility group box 1 (HMGB1), from mesothelial cells,
which is also a potent inducer of inflammation (Hillegass et al., 2013, Yang et al., 2010,
Carbone and Yang, 2012).
Inflammasome activation induced by asbestos plays an important role in the
development of MM when coupled with genetic predisposition and cumulative exposure
to asbestos (Kadariya et al., 2016b, Hillegass et al., 2010a). In contrast, a recent study of
MM tumor cells and tissue arrays showed attenuated levels of the NLRP3 inflammasome
and caspase-1 activation (Westbom et al., 2015). Treatment of these tumors with cisplatin
caused increased NLRP3 priming and activation. To the contrary, treatment of tumors with
a combination of cisplatin and an IL-1 receptor antagonist resulted in better tumor
reduction as compared to cisplatin alone. These findings again point towards a tumor
promoting role of IL-1β, a pro-inflammatory cytokine (Westbom et al., 2015). Although
there are various ways through which the inflammasome is activated by asbestos, NADPH
oxidase and thioredoxin interacting protein (TXNIP) appear to play prominent roles
(Thompson et al., 2014a, Dostert et al., 2008). This attests to the role of ROS in
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inflammasome regulation. The inflammatory profile of patients with MM has been
recently suggested to offer insights into the interactions between a tumor and its
microenvironment, which promote tumorigenesis (Judge et al., 2016).

Analysis of

peritoneal ascites fluid from patients with peritoneal MM showed localized elevation in a
number of pro-inflammatory cytokines (IL-6, IL-8, MCP-1, MIP-1β, MIP1α, IL-10, VEGF
and TNFα) when compared to serum levels from the same patients (Judge et al., 2016). In
vivo and in vitro studies of the growth of MM from our group have also demonstrated that
inflammation is an active component of MM growth in SCID mice (Hillegass et al., 2010a,
Westbom et al., 2014). The risk of developing MM has been shown to rise with increased
exposure to asbestos (Mossman et al., 2013, Landrigan and Collegium, 2016). In a small
fraction of patients, germline mutations of the BRCA1 associated protein 1 gene (BAP1)
have been shown to increase the risk of developing MM even at lower levels of asbestos
exposure (Napolitano et al., 2016, Ohar et al., 2016, Testa et al., 2011). It is, however,
interesting to note that in a heterozygous BAP1-mutant murine model, exposure to low
doses of asbestos led to a stronger inflammatory response and higher incidence of MM
when compared to their wild type littermates (Napolitano et al., 2016). This suggests that
the higher inflammatory response may play a crucial role in the development of MM in
patients with BAP1 mutations as well, indicating a putative link between the function of
BAP1 and inflammatory responses (Napolitano et al., 2016).
With the postulated hypothesis of how a fraction of longer asbestos fibers are
deposited on the parietal pleura over time, the observation that MM originates from the
parietal pleura before spreading to the visceral pleura is somewhat explained (Donaldson

28

et al., 2010, Murphy et al., 2011). Asbestos activates a number of signaling cascades that
are involved in the regulation of inflammatory responses, and this may play a large role in
the sustained inflammatory response to asbestos fibers that eventually lead to the
development of the various asbestos-related diseases (Shukla et al., 2003c, Nishimura et
al., 2013, Haegens et al., 2007, Heintz et al., 2010). In fact, our next-generation sequencing
studies of primary mesothelial cells indicate that asbestos exposure predominantly
upregulates inflammatory networks (Dragon et al., 2015). Such chronic inflammation
eventually leads to DNA damage and may be responsible for the many deletions and
mutations observed in MM. Inflammation induced by asbestos has been shown to promote
the formation of 8-oxoguanine adducts in nuclear and mitochondrial DNA (Fung et al.,
1997, Okada, 2007). The formation of a number of nitrosylation products, including 8nitroguanine, also results from the generation of ROS as a combined result of Fenton
reactions facilitated by asbestos fibers and the induction of the nitric oxide synthase
enzyme by inflammatory cells (Fung et al., 1997, Okada, 2007, Hiraku et al., 2010). Thus,
not only does asbestos cause mechanical injury to the mesothelium that can lead to aberrant
repair, but its chemical composition also promotes inflammation via the recruitment of
inflammatory cells (Shukla et al., 2003c, Shukla et al., 2007, Okada, 2007). Asbestos
exposure also leads to the activation of cellular pathways that are sensitive to the redox
state of the cell and involved in the regulation of inflammation (Thompson et al., 2014a,
Shukla et al., 2003c).
A recent study of asbestos-exposed workers from an Italian coastal area showed
the presence of elevated chemokines and pro-inflammatory cytokines in serum of asbestos-
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exposed workers as compared to healthy controls (Comar et al., 2016). Inflammatory
parameters have been suggested to have prognostic significance in MM. For example,
lymphocyte-to-monocyte (LMR) ratio (Yamagishi et al., 2015) or neutrophil-tolymphocyte (NLR) ratio along with red cell distribution width (RDW) (Abakay et al., 2014)
could be projected as predictive factors for MM prognosis. Furthermore, inhibition of
inflammation by natural compounds (Benvenuto et al., 2016, Pietrofesa et al., 2016) has
also been shown to inhibit asbestos-induced inflammation and carcinogenesis in animal
models, confirming the role of inflammation in asbestos-induced diseases.

30

Figure 1.3: Inflammation plays a role in asbestos-related diseases. Asbestos fibers first
encounter bronchial epithelial cells when inhaled, and long fibers may become lodged at
bifurcations in the bronchi and lead to chronic inflammation at those sites that recruits
inflammatory cells. Such chronic inflammation can lead to the development of bronchogenic
diseases at those sites. In the lung parenchyma, long and thin asbestos fibers can travel deeper and
interact with alveolar macrophages, which will attempt to clear these fibers. While fibers that are
short enough to be completely engulfed are cleared, longer fibers will cause frustrated attempts of
clearing, leading to more inflammation. The production of various signaling and inflammatory
molecules in response to this assault over time contributes to the interstitial lung diseases observed
in response to asbestos. Longer asbestos fibers have been found to accumulate on the parietal
pleura and are also believed to become lodged in the stomata of the mesothelium at those points
where they may potentiate chronic inflammation that contribute to pleural asbestos diseases. It also
appears that events occurring in the lung may influence or affect disease in the parietal pleura and
vice versa. Taken from Thompson et al. (in press) Springer-Verlag Heidelberg- Book Chapter
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1.6.1 Inflammasomes
Inflammasomes are intracellular molecular multiprotein molecular scaffolds that assemble
in response to various stimuli to promote the autocatalytic cleavage and maturation of the
zymogen, caspase-1 (Martinon and Tschopp, 2007, Lamkanfi et al., 2007). Activation of
caspase-1 leads to its processing of the pro-inflammatory cytokines, IL-1β and IL-18
(Launay et al., 2005, Martinon et al., 2007). Inflammasomes are made up of a pattern
recognition receptor (PRR), an adaptor protein (apoptosis speck-like protein containing a
card domain (ASC)) and the inflammatory caspase, caspase-1 (Martinon and Tschopp,
2007). The name of a given inflammasome is often derived from the PRR that serves as
the scaffold to which ASC and caspase-1 are recruited. There are four different families of
inflammasomes that contain nucleotide oligomerization domain (NOD) – like receptors
(NLRs) as the nucleating PPR on which the inflammasomes assemble. The four family
members, NLR containing a pyrin domain (NALP/NLRP), interlukin-1 converting enzyme
(ICE) protease activating factor (IPAF), NLR apoptosis inhibiting protein (NAIP) and
nucleotide binding oligomerization domain containing protein 2 (NOD2) make up the
subgroups into which the approximately 22 NLR proteins are classified (Martinon et al.,
2007, Benko et al., 2008). The NLRP/NALP family is the largest group with 14 members
and contains the most studied inflammasome to date, the NLRP3 inflammasome. NLRP3
is a unique inflammasome in that it responds to a wide variety of stimuli, unlike the other
inflammasomes that typically respond to one or two types of ligands (Benko et al., 2008,
He et al., 2016). For example, the NLR containing a CARD domain 4 (NLRC4) responds
to pathogen associated molecular patterns (PAMPs) like flagellin, whereas NLRP3 is
capable of responding to a number of PAMPs like lipopolysaccharide (LPS) and muramyl
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peptides as well as endogenous danger associated molecular patterns (DAMPs) like ATP,
in addition to crystalline/fibrous stimuli like uric acid crystals and asbestos (Benko et al.,
2008, Sayan and Mossman, 2016, Martinon and Tschopp, 2007, Dostert and Petrilli, 2008).
The NLRP3 inflammasome requires two signals for activation (Sutterwala et al., 2014, He
et al., 2016). The first signal ‘primes’ the inflammasome by upregulating transcription of
NLRP3 and IL-1β (He et al., 2016, Sutterwala et al., 2014). The second ‘activating’ signal
serves to trigger oligomerization of NLRP3 and assembly of the inflammasome by
recruitment of ASC through its pyrin domain (He et al., 2016, Martinon et al., 2007). ASC
binds homotypically to the pyrin domain of NLRP3 and recruits caspase-1 through its
caspase activating and recruiting domain (CARD) (Martinon et al., 2007). During assembly
of the inflammasome, filaments of ASC also oligomerize (Dick et al., 2016) and recruit
several units of procaspase-1 which then undergoes auto-proteolytic cleavage to become
active. The whole process has been likened to the assembly of the apoptosome and also
resembles a wheel when assembled. This multiprotein scaffold serves to amplify the signal
and cause large quantities of IL-1β and IL-18 to be processed and secreted from activated
immune cells (Dick et al., 2016). The activation of the inflammasome has been studied
predominantly in immune cells, but certain non-immune cells also express inflammasome
components and are capable of assembling an inflammasome in response to the appropriate
stimuli, although they may not yield as much IL-1β or IL-18 as an immune cell.
The NLRP3 inflammasome has been shown to bear mutations that are responsible for
inherited inflammatory diseases like Muckle-Wells syndrome, familial cold autoinflammatory syndrome, and neonatal onset multisystem inflammatory disease (Aganna et
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al., 2002, Dode et al., 2003). NLRP3 has also recently been implicated in inflammatory
bowel disease (Chen and Nunez, 2011, Elia et al., 2015, Zaki et al., 2011). All of these
suggest that aberrant activation of the inflammasome leads to chronic inflammation. Hence
the need for such tight regulation of the activation of the NLRP3 inflammasome.
Chronic inflammation promotes fibrosis by triggering repair mechanisms and activating
resident fibroblasts (Artlett, 2012). Under acute inflammatory conditions and injury, the
activation of fibroblasts and proinflammatory cytokines that promote fibrosis is resolved
upon repair of the injury or resolution of the inflammatory stimulus. When the
inflammation becomes chronic or dysregulated however, the repair process that should
normally allow for normal growth of tissue to replace dead cells or damaged tissue is
corrupted, leading to the development of fibrotic lesions (Artlett, 2012). In non-alcoholic
fatty liver disease activation of the inflammasome is necessary for disease progression and
liver fibrosis (Wree et al., 2014). The inflammasome product, IL-1β, has been implicated
in lung fibrosis as well as the induction of epithelial to mesenchymal transition in different
cell types under chronic and acute conditions (Zhang et al., 1993, Kolb et al., 2001).When
caspase-1 activity was inhibited in a model of systemic sclerosis myofibroblast
differentiation was compromised with lower levels of IL-1β and IL-18, implicating the
inflammasome and especially caspase-1 in the pathogenesis of systemic sclerosis (Artlett
et al., 2011). In kidney tubular epithelial cells, NLRP3 and ASC have been shown to
promote epithelial to mesenchymal transition independent of their inflammasome activity
(Wang et al., 2013). In cardiac fibroblasts, mitochondrial localized NLRP3 promoted ROS
generation and regulated the differentiation of the fibroblasts into myofibroblasts via

34

modulation of R-Smad (Bracey et al., 2014) as seen in kidney epithelial cells where NLRP3
also modulated TGFβ signaling via Smad2 (Wang et al., 2013). Thus, the inflammasome
components individually as well as a part of the inflammasome play a role in driving cell
differentiation and transition from one cell type to the other under varying conditions.
1.7 Mesothelial to Fibroblastic Transition/Epithelial to Mesenchymal Transition
Epithelial to mesenchymal transition, the process by which epithelial cells gain
mesenchymal features and transition into mesenchymal cells is important during
development and necessary for organogenesis. This process is under the control of several
developmental transcriptional factors and genes that are both spatially and temporally
regulated to ensure the proper development of the embryo. From the development of the
hair follicle to the formation of blood vessels and digits, EMT is tightly regulated to ensure
normal development (Botchkarev and Kishimoto, 2003, Reese et al., 2002). A number of
growth factors regulate the process of EMT – transforming growth factor beta family
members (TGFβ) (Wu and Zhou, 2010, Moustakas and Heldin, 2007), insulin growth
factor (IGF) (Kalluri and Neilson, 2003) and epidermal growth factor (EGF) (Kim et al.,
2016) as well as fibroblast growth factor 2 (FGF2) (Kalluri and Neilson, 2003) are among
the growth factors that have been demonstrated to induce EMT. An epithelial cell
undergoing EMT will degrade its junctional complexes and down regulate the expression
of these proteins to enable it to become motile and move to the site where it is needed. The
actin stress fibers in the transition cells will also need to reorganize and switch to more
fibrous actin structures that enable lamellopodia and pseudopodia required for movement
to form and retract in the direction of movement (Kalluri and Neilson, 2003). The
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morphology and repertoire of proteins expressed by cells undergoing EMT changes.
Changes in the expression of some of these have been identified as hallmarks of the EMT
process. For a cell to be considered to be undergoing EMT, it is expected that protein levels
of the adherens junctional protein, E-cadherin, (needed in a complex for adhesion of cells
to each other) will be decreased to none among other junctional proteins. A number of
transcription factors negatively regulate the expression of E-cadherin in addition to
regulating the expression of a host of proteins related to mesenchymal and epithelial
phenotype. Among these transcription factors a handful have been identified as hallmark
EMT factors that are expected to have increased expression in EMT (e.g. ZEB1, Snail,
Slug and TWIST1) (Dohadwala et al., 2010, Wu and Zhou, 2010). While all these
transcription factors exhibit an inverse relationship between their expression and that of Ecadherin during EMT, cell type specific roles determine the important transcription factor
that is upregulated (Kalluri and Neilson, 2003). In some cases, the growth factor or stimulus
initiating EMT determines which transcription factor will be observed to be important for
the process. One of these transcription factors, Snail family of transcription factors, has
been shown to control global epithelial gene expression as well as regulate cell polarity
and survival (Wu and Zhou, 2010). Stationary epithelial cells exhibit an apico-basal
polarity, demonstrate a cuboidal/cobblestone appearance, mesenchymal cells lack polarity,
are loosely arranged in the ECM, tend to have an elongated morphology and do not form
cell-cell attachments and are less susceptible to cell death . As such transitioning epithelial
cells also lose their apico-basal polarity and also start expressing matrix metalloproteinases
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so that they can degrade the basement membrane that hold them in place, appear elongated
and are loosely arranged with minimal to no cell-cell contacts.
EMT can be reactivated to produce fibroblasts in tissue repair after injury. In response to
inflammatory factors that are released from the injured cells and infiltrating immune cells,
fibroblasts may migrate towards the gradient of cytokines and factors released and cells at
the site of injury may also undergo EMT to yield the needed fibroblasts/stromal cells
(Kalluri and Neilson, 2003). Under such conditions however, the EMT program activated
is short lived and reversed once repair is complete or the stimulus is removed (Kalluri and
Weinberg, 2009). Deposited excess extracellular matrix is broken down to allow the tissue
to return to its normal pre-injury state. If for some reason the fibroblast-like cells persist
after repair of the injury they can promote fibrosis (Kalluri and Weinberg, 2009).
Mesothelial cells have been demonstrated to undergo a process similar to EMT during
embryogenesis (Batra and Antony, 2014) and contribute to the generation of cardiac
myocytes and vascular cells as well as parenchymal cells of the developing lung using
lineage tracing studies (Herrick and Mutsaers, 2004, Rinkevich et al., 2012). Because
mesothelial cells are not epithelial in nature, the process has been referred to as mesothelial
to mesenchymal transition (MMT). Mesothelial cells cultured in osteogenic and adipogenic
medium have also been shown to transition into osteoblast and adipocyte-like cells
respectively (Lansley et al., 2011). As such, mesothelial cells may be considered a
multipotent cell type. Another lineage tracing study demonstrated that pleural mesothelial
cells migrated into the lung after bleomycin instillation and transitioned into
myofibroblasts, thus providing evidence that mesothelial cells may contribute to the

37

pathology observed in idiopathic pulmonary fibrosis (Karki et al., 2014). In patients
undergoing continuous ambulatory peritoneal dialysis, the dialysate has been observed to
compromise the permeability of the mesothelium and promote peritonitis over time (Zhou
et al., 2016, Loureiro et al., 2011). In severe cases peritoneal adhesion occurs as the
mesothelium becomes fibrotic. The high glucose content of the dialysate has been shown
to promote inflammation and mesothelial to mesenchymal transition (Choi et al., 2016).
Inflammation and signaling by the receptor for advanced glycation products in the
mesothelial cells have been shown to promote this transition and compromise the
mesothelium (Raby et al., 2016, Yung and Chan, 2009, Schwenger et al., 2006). In
peritoneal dialysis induced fibrosis IL-1β (Strippoli et al., 2008) and TGFβ (Loureiro et al.,
2011) have been found to play important roles. Injury to the mesothelial cells leads to the
secretion of inflammatory cytokines which then promote the infiltration of immune cells
into the peritoneum (Strippoli et al., 2016). Unfortunately, the presence of the immune cells
and their responses to the injury upregulates inflammation further and modulates the
response of the mesothelial cells (Batra and Antony, 2015) leading to the development of
conditions that further promote inflammation and fibrosis. The fibrotic response may start
as a repair mechanism as mesothelial cells transition into a more fibroblastic phenotype
that deposit collagen and extracellular matrix (Zhou et al., 2016). Without resolution this
process continues and fibrosis develops.
Peritoneal dialysis induced peritoneal injury is not the only condition under which IL-1β
has been demonstrated to promote fibrosis or EMT. In a study where IL-1β was transiently
expressed in the lung via adenovirus transduction, IL-1β expression led to acute lung injury
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which progressed to the development of fibrosis after chronic repair (Kolb et al., 2001). In
lung transplant patients there is progressive loss of lung capacity due to the development
of obliterative bronchiolitis in small and mid-sized airways leading to inflammation and
fibrosis of the airways (Borthwick et al., 2010). This loss in lung capacity is believed to be
due to dysregulated repair of injury to the airways after bronchiolitis develops and has been
attributed to the action of pro-inflammatory cytokines released into the airways by
infiltrating macrophages (Borthwick et al., 2010). This was confirmed through a study in
which primary human bronchial epithelial cells were either treated with a combination of
TGFβ and IL-1β or IL-8 or co-cultured with macrophages. This study demonstrated that
TGFβ in conjunction with IL-1β or co-culture with macrophages promoted dysregulated
wound repair with increased cell proliferation and characteristics of EMT (Borthwick et
al., 2010).

In corneal endothelial cells, IL-1β induced endothelial to mesenchymal

transition via FGF2 signaling (Lee et al., 2012, Lee and Heur, 2013) in response to corneal
injury and is believed to be the mechanism that promotes the formation of retro-corneal
fibrous membrane that causes loss of vision (Lee et al., 2012). By this token, the effects of
IL-1β on EMT can be argued to be dependent on the effectors induced by IL-1β
signaling/inflammation. FGF2 is induced through activation of NFκB downstream of IL1β signaling in corneal endothelial cells and the EMT induced was reversed by blocking
the IL-1 receptor (IL-1R) with the IL-R antagonist (Lee and Heur, 2013). Lee et al
demonstrated that IL-1β promoted oral squamous cell carcinoma (OSCC) carcinogenesis
and invasiveness by upregulating oncogenic networks and increasing the proliferation of
dysplastic cells suggesting that inflammasome activation by carcinogens in tobacco were
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important for OSCC development and progression (Lee et al., 2015). In an attempt to
recapitulate the mechanisms that could promote MMT in pleural mesothelial cells as a
possible mechanism for the development of tuberculous pleurisy, Kim et al demonstrated
that TGFβ and/or IL-1β were capable of inducing loss of E-cadherin, as well as increasing
levels of the transcriptional repressor of E-cadherin, Snail (Kim et al., 2011) suggesting
that inflammation in response to Mycobacterium tuberculosis could account for
tuberculous pleurisy seen in some patients.
In cancer, EMT is believed to be reactivated enabling cells that transition to escape the
original tumor and migrate to metastatic sites to establish disease or even invade the
underlying tissue at the original site as the tumor becomes more aggressive (Diepenbruck
and Christofori, 2016). Chronic inflammation plays a role in several cancer types and helps
shape the tumor microenvironment to help promote progression and invasiveness of these
cancers. In head and neck squamous cell carcinomas (HSNCC), the inflammatory
microenvironment is believed to enhance angiogenesis, invasiveness and metastasis
(Dohadwala et al., 2010). IL-1β is one of the pro-inflammatory mediators found in the
microenvironment of HNSCC. Treating HNSCC cells with IL-1β decreased E-cadherin
expression and increased levels of the transcription factors ZEB-1 and Snail, negative
regulators of E-cadherin levels (Dohadwala et al., 2010, St John, 2015). This result
confirmed the role for a pro-inflammatory mediator found in the HNSCC
microenvironment in promoting tumor invasion/metastases through EMT. In addition to
promoting EMT in HNSCC cells upregulation of Snail in these cells made them resistant
to the chemotherapeutic, elortinib (St John, 2015).
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A number of studies have demonstrated that asbestos is capable of inducing EMT in
epithelial cells (Kamp, 2009, Gulino et al., 2016, Tamminen et al., 2012) which provides a
plausible mechanism for how asbestos causes the asbestos related pulmonary fibrosis
referred to as asbestosis. The first cell type to come into contact with inhaled fibers are the
bronchial epithelial cells followed by lung macrophages and alveolar epithelial cells.
Exposure of these cells to asbestos leads to their uptake and attempts by the cells to detoxify
the Fe3+ ions on the fibers leading to an increase in Fenton reactions with the conversion
of Fe3+ to Fe2+. This increase in ROS causes oxidative stress and activates a number of
redox sensitive signaling pathways that all work to promote proliferation and the
development of fibrosis. Signaling pathways like NFκB, EGF signaling HGF/cMET all
respond to oxidation and have been shown to play a role in EMT(Kalluri and Neilson,
2003, Kalluri and Weinberg, 2009, Kamp, 2009). In a bronchial epithelial cell line
(BEAS2B), exposure to chrysotile over a 72 h period resulted in cells attaining a more
fibroblastic appearance while increasing the expression of the mesenchymal markers,
vimentin, fibronectin, alpha smooth muscle actin (αSMA) and the collagenases, matrix
metalloproteinase 2 and 9 (MMP 2&9) at both the protein and transcript level (Gulino et
al., 2016). These cells also had displayed a concomitant decrease in protein and transcript
levels of the epithelial junctional proteins E-cadherin and β-catenin (Gulino et al., 2016).
In these cells asbestos exposure increased ROS levels and signaling via TGFβ, GSKβ and
AKT were implicated in the EMT observed as inhibitors of AKT and GSKβ decreased the
asbestos mediated increase in Snail levels and rescued some E-cadherin expression
although not to basal levels (Gulino et al., 2016). Studies using the lung cancer cell line
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(A549 cells) which exhibit characteristics of alveolar type II cells have also demonstrated
that asbestos can induce EMT in a mitogen activated protein kinase/extracellular regulated
kinase (MAP/ERK) dependent manner (Tamminen et al., 2012). These and other studies
have demonstrated that asbestos can promote EMT in epithelial cells, however the same is
not the case for mesothelial cells from which MM originates. One study has studied
asbestos-induced EMT in MET5A cells (a transformed mesothelial cell line) by looking at
mRNA levels of EMT markers.
1.8 Conclusions
Asbestos-related diseases have a long latency period and are the end result of aberrant
wound healing responses, chronic inflammation, and (in the case of lung cancer and MM)
inflammation-related genetic mutation and deviant gene expression or silencing. The
inflammasome and its products, IL-1β and IL-18, may play an important role in promoting
a myofibroblastic transition in mesothelial cells as well as in activating fibroblasts to create
a microenvironment in which damaged cells survive and go on to acquire mutations and
activate gene programs that enable them to become malignant and clonally expand. More
studies are needed to help uncover the mechanisms involved in the development of these
diseases, as this would lead to discovery of potential biomarkers and therapeutic targets to
aid in early diagnosis and treatment.
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Abstract
Background: Asbestos exposure is related to various diseases including asbestosis and
malignant mesothelioma (MM). Among the pathogenic mechanisms proposed by which
asbestos can cause diseases involving epithelial and mesothelial cells, the most widely
accepted one is the generation of reactive oxygen species and/or depletion of antioxidants
like glutathione. It has also been demonstrated that asbestos can induce inflammation,
perhaps due to activation of inflammasomes.
Methods: The oxidation state of thioredoxin was analyzed by redox Western blot analysis
and ROS generation was assessed spectrophotometrically as a read-out of solubilized
formazan produced by the reduction of nitrotetrazolium blue (NTB) by superoxide.
Quantitative real time PCR was used to assess changes in gene transcription.
Results: Here we demonstrate that asbestos fibers oxidize the pool of the antioxidant,
Thioredoxin-1 (Trx1), which results in release of Thioredoxin Interacting Protein (TXNIP)
and subsequent activation of inflammasomes in human mesothelial cells. Exposure to
asbestos resulted in the depletion of reduced Trx1 in human peritoneal mesothelial
(LP9/hTERT) cells. Pretreatment with the antioxidant dehydroascorbic acid (a reactive
oxygen species (ROS) scavenger) reduced the extent of asbestos-induced Trx1 oxidation
as well as the depletion of reduced Trx1. Increasing Trx1 expression levels using a Trx1
over-expression vector reduced the extent of Trx1 oxidation and generation of ROS by
asbestos, and increased cell survival. In addition, knockdown of TXNIP expression by
siRNA attenuated asbestos-induced activation of the inflammasome.

62

Conclusion: Our novel findings suggest that extensive Trx1 oxidation and TXNIP
dissociation may be one of the mechanisms by which crocidolite asbestos activates the
inflammasome and helps in development of MM.
Key words: Asbestos, Malignant mesothelioma, Thioredoxin, Thioredoxin interacting
protein, Inflammasomes.
Background
Malignant mesothelioma (MM) is a deadly cancer arising from the mesothelium and its
etiology usually involves asbestos exposure (1). MM is a very invasive and aggressive
disease that is chemo-resistant to most of the standard chemotherapeutic agents. Patients
with MM typically have a poor prognosis with a life expectancy of about 8-12 months after
diagnosis (2). Efforts at understanding how asbestos exposure leads to the development of
MM and other malignancies have not definitively determined how exposure leads to the
formation and progression of this unusual neoplasm. Studies have, however, shown that
apoptosis followed by compensatory proliferation and chronic inflammation induced by
asbestos fibers play a major role in disease progression (3-6). Chronic inflammation
induced by asbestos exposure is believed to be involved in the pathogenic process that
leads to asbestos related diseases like MM (7, 8). Recent work from our group has
demonstrated that asbestos-induced inflammation in mesothelial cells and macrophages
could, in part, be mediated by activation of the inflammasome, a protein complex involved
in the processing of cytokines (9). The exact mechanism by which asbestos activates the
inflammasome is not completely understood, but reactive oxygen species (ROS) are
believed to play a role (6). It has also been reported that a redox-regulated protein,
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thioredoxin interacting protein (TXNIP) can bind and activate the Nod-like receptor family
pyrin domain containing 3 (NLRP3) inflammasome (10). ROS induced in response to
asbestos exposure have been shown to initially deplete intracellular levels of reduced
glutathione (11, 12), but the effect of asbestos on another major cellular antioxidant,
thioredoxin (Trx1) is unknown.
Thioredoxin is a small ubiquitously expressed redox active protein that is important for
maintaining the reducing milieu of the cell, in part by reducing protein disulfide bonds that
occur in response to oxidative processes. During reduction of disulfide bonds Trx1 itself
becomes oxidized and in turn reduced by thioredoxin reductase (TR) using electrons from
reduced nicotinamide adenine dinucleotide phosphate (NADPH) (13). Trx1 is inhibited by
thioredoxin interacting protein (TXNIP) via a redox-dependent interaction (14, 15). TXNIP
is only capable of binding to and inhibiting Trx1 in its reduced state (10, 15). In response
to oxidative insults, TXNIP has been shown to bind to and activate the NLRP3
inflammasome (10). Based on these observations and the capacity for asbestos fibers to
generate ROS intra- and extracellularly, we hypothesized that asbestos-induced ROS
generation will oxidize Trx1 causing its dissociation from TXNIP. As a result of this
dissociation, TXNIP would be free to bind to, and activate, the NLRP3 inflammasome.
Here, we show for the first time, that asbestos exposure leads to the irreversible oxidation
of Trx1 and depletes reduced Trx1 levels in LP9/hTERT cells. We also show that overexpression of Trx1 reduces levels of asbestos-induced ROS. Our results indicate that
oxidation of Trx1 by asbestos results in dissociation of TXNIP and subsequent activation
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of inflammasomes, as knockdown of TXNIP by siRNA partially reduced asbestos-induced
inflammasome activation as indicated by a reduction in caspase-1 activation.

Materials and Methods
Human LP9 mesothelial cells, an hTERT-immortalized cell line that phenotypically and
functionally resembles normal human mesothelial cells, were obtained from Dr. James
Rheinwald (Brigham and Women’s Hospital, Harvard University, Boston, MA). All cells
were incubated at 37°C in 5% CO2 and grown to 80–90% confluency as described
previously (16). The physical and chemical characterization of the National Institute on
Environmental Health Sciences (NIEHS) reference sample of crocidolite asbestos has been
reported previously (17). The NIEHS chrysotile reference sample was used for asbestos
fiber comparisons. After sterilization under UV light overnight, particulates were
suspended in Hank’s balanced salt solution (HBSS) at 1 mg/ml, sonicated for 15 min in a
water bath sonicator, and triturated five to ten times through a 22-gauge needle. A volume
of this suspension was added to cells in medium to achieve the desired final concentration
of 75 x 106 µm2/cm2 dish surface area, a concentration known to cause apoptosis and
compensatory proliferation of surrounding rat pleural mesothelial and murine alveolar type
II epithelial cells (3)(18). Glass beads (Polysciences Inc, Warrington, PA) were used as a
non-pathogenic particle control. Dehydroascorbic acid (DHA) and 2,4-Dinitro-1chlorobenzene (DNCB) were purchased from Sigma (St. Louis, MO). Trx1 expression
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vector (pCMV-SPORT6) and pcDNA (empty vector control) used for over-expression
studies were obtained from Dr. Nicholas Heintz..
Western blot analyses:
Cells grown in 60 mm culture dishes were washed 3x with ice-cold phosphate bufferedsaline (PBS), collected in lysis buffer (20 mM Tris pH 7.6, 1% Triton X-100, 137 mM
NaCl, 2 mM EDTA, 1 mM Na3O4V, 10 mM NaF, 1 mM DTT, 1 mM phenylmethylsulfonyl
fluoride, 10 µg/ml leupeptin, and 10 µg/ml aprotinin) and incubated on ice for 30 min.
Lysates were centrifuged at 14,000 rpm for 15 min at 4°C. Supernatants were collected,
and protein concentrations were determined using the Bradford assay (Bio-Rad, Richmond,
CA). Cell lysates (40 µg per lane) were resolved by one-dimensional SDS-PAGE and
transferred to nitrocellulose membranes according to standard procedures. Equal loading
of protein was verified by β-actin (Abcam, Cambridge, MA). Membranes were washed in
Tris-buffered saline (TBS), and blocked for 2 h with TBS-Tween (TBST) containing 10%
nonfat milk, then incubated with rabbit anti-human Trx1 antibody (Abcam, Cambridge,
MA) at 1:5000 dilution in TBST containing 5% nonfat milk and 0.01% sodium azide
overnight at 4°C. Membranes were washed four times with TBST for 15 min each time
prior to incubation with secondary antibody. Western blots shown are representative blots
with their accompanying densitometric analysis.
Determination of the redox state of thioredoxin:
The redox state of thioredoxin in response to crocidolite exposure was determined using
the redox Western blot method as previously described (19). Briefly, cells were lysed in 6
M guanidine HCl buffer (6 M Guanidine HCl; 50 mM Tris/Cl pH 8.3; 3 mM EDTA, 0.5%
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TritonX – 100; 10 µg/ml aprotonin and 10 µg/ml leupeptin) containing 50 mM iodoacetic
acid (IAA) for alkylation of the thiol groups of thioredoxin. Cells were incubated in lysis
buffer at 37°C for 30 min in the dark. Excess IAA was removed by spinning lysates on
Amicon centrifugal concentrating columns with a 10,000 nominal molecular weight limit
(NMWL) (EMD Millipore, Billerica, MA). In order to exchange the IAA containing buffer,
the lysates were washed 3 times with a HEPES buffer at pH 7.4 and the concentrated lysates
were collected in fresh collection tubes by inverting the columns in the tubes. After protein
determination by the Bradford method (Bio-Rad, Richmond CA), 40 µg of protein was
loaded onto a 15% non–reducing native polyacrylamide gel using a 1X Tris Glycine (pH
8.8) running buffer. The electrophoresis was carried out at 75V for approximately 3.5 h.
The redox gel was then washed in 50 mM Tris (pH 8.3) for 5 min and then equilibrated in
1X transfer buffer by washing in buffer 3 times for 5 min each. Thereafter, the proteins
were transferred onto a nitrocellulose membrane by wet transfer at 100V for 2 h. The
nitrocellulose membrane was then blocked with 10% milk in 1X Tris buffered saline with
Tween 20 (TBS-T) for 6 h at room temperature (RT) and incubated in anti-Trx1 primary
antibody (1:5000 in 5% milk/TBS-T, Abcam, Cambridge, MA) overnight at 4°C. Goat
anti–rabbit secondary antibody conjugated to horseradish peroxidase (1:2000 in 1X TBST, Jackson ImmunoResearch Laboratories Inc. West Grove, PA) was used and
visualization was done by enhanced chemiluminescence reagents (Amersham Pharmacia
Biotech, Piscataway, NJ) on X-ray film. Blots were quantified using Quantity One software
(Bio-Rad, Richmond, CA). Distribution of redox states of Trx1 was determined as band
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intensity of reduced or oxidized Trx/ (reduced+semi-oxidized+fully oxidized) as described
by Watson et al., (2003) (19).
Real-Time Quantitative PCR (qRT-PCR):
Total RNA was prepared using an RNeasy plus mini kit according to the manufacturer’s
protocol (Qiagen, Valencia, CA) as described previously (16). Total RNA (1 µg) was
reverse-transcribed with random primers using the Promega AMV Reverse Transcriptase
kit (Promega, Madison, WI) according to the recommendations of the manufacturer. To
quantify gene expression, the cDNA was amplified by TaqMan Real Time Q-PCR using
the 7900HT SequencePrism Detector (Applied Biosystems, Foster City, CA). Duplicate
assays were performed with RNA samples isolated from at least four independent
experiments. Fold changes in gene expression were calculated using the delta-delta Ct
method. The values obtained from cDNA and hypoxanthine phosphoribosyl transferase
(HPRT) controls helped determine relative gene expression levels for the gene locus
investigated. The Assay on Demand primers and probes used were purchased from Applied
Biosystems.
Since exposure of cells to chrysotile asbestos had no effect on the oxidation state of Trx1,
all subsequent experiments were performed using crocidolite asbestos. All references to
asbestos relate to crocidolite asbestos unless otherwise specified.
Dehydroascorbic acid (DHA) pretreatment:
In order to investigate whether the ROS generated by crocidolite exposure was responsible
for the extensive oxidation of thioredoxin, cells where pretreated with the ROS quencher,
dehydroascorbic acid (1 mM) for 1 h before exposure to crocidolite for 8 h.
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Antioxidant pretreatment of cells by N-acetylcysteine (NAC):
To investigate the role of the asbestos-induced ROS on inflammasome activation, cells
were pretreated with 2 mM NAC for 20 h as previously described (Shukla et al., 2004).
Briefly, cells were grown to 90% confluency in 60 mm dishes and serum starved by
replacing complete medium with 0.5% fetal bovine serum (FBS) supplemented medium
for 6 h prior to addition of NAC diluted in HBSS at pH 7.4 (cells were maintained in
reducing medium for the entire duration of NAC pretreatment). After pretreatment with
NAC, cells were exposed to crocidolite asbestos for 48 h. Thereafter, inflammasome
priming was assessed by qRT-PCR of NLRP3 transcript levels while activation was
analyzed by Western blot analysis of caspase-1, p20 fragment.
Treatment with 2,4-Dinitro-1-chlorobenzene DNCB:
To obtain a final concentration of 10 µM in culture, 2,4-Dinitro-1-chlorobenzene (DNCB)
(an irreversible alkylating inhibitor of TR) was dissolved in DMSO with a final DMSO
content of 0.2% which was determined to be non-cytotoxic in previous experiments. For
all experiments, cells were pretreated with DNCB for 1 h prior to exposure to crocidolite.
Lactate dehydrogenase (LDH) activity assay:
To determine the cytotoxic effects of DNCB and asbestos exposure on LP9 cells, an LDH
assay was performed using the LDH kit from Promega (Madison, WI) according to the
manufacturer’s direction. Briefly, 50 µl of media were collected from each dish in triplicate
into a 96 well plate using cells lysed by the addition of 0.9% Triton X-100 as a positive
control. To each of these wells, 50µl of LDH substrate buffer was added and the reaction
was incubated on a rotary shaker at room temperature for 30 min in the dark. Thereafter,
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the reaction was terminated by the addition of 50 µl stop buffer to each well. Any bubbles
present were broken with a hypodermic needle and the plate was

read

spectrophotometrically at 490 nm in a 96 well plate reader. Cytotoxicity was expressed as
a percentage of LDH released relative to the lysis control.
Detection and quantitation of apoptosis:
To determine whether modulation of Trx1 protein levels and oxidation state altered cell
death in human mesothelial cells, detection of apoptosis was performed using the ApoStain
technique asdescribed previously (Shukla et al., 2003). In brief, cells were grown on glass
cover slips and exposed to asbestos with or without DNCB (10 µM) for 8 h. The cover
slips were then processed to determine the numbers of apoptotic cells and total cell
numbers per field. Five random fields were evaluated at a magnification of 400X on each
cover slip.
Assessment of pyroptosis by asbestos
Since asbestos causes inflammasome activation, as measured by caspase-1 activation (4),
we were interested in learning if asbestos-induced cell death may be due in part to
pyroptosis (caspase-1 dependent cell death) or not. For this purpose we pretreated LP9 cells
with a specific caspase-1 inhibitor (40 µM Caspase-1 inhibitor VI (zYVADfmk), EMD
Biosciences, Billerica, CA) for 1 h and subsequently with asbestos for 24 h. The number
of viable cells was determined after trypsinization and counting of cells on a
hemocytometer at the end of the experiment. Media supernatants were also analyzed for
the levels of the p20 subunit of active caspase 1 by Western blot analysis.
Transfection procedures:
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Trx1 Over- expression
Cells at 90% confluence were transfected with pcDNA (empty vector control, 4 µg DNA
per 60 mm dish) and human Trx1 over expression vector (pCMV-SPORT6, 4 µg DNA
per 60 mm dish) using Lipofectamine 2000 (10 µl) (Life Technologies, Grand Island, NY),
following the manufacturer’s protocol. The efficiency of Trx1 protein over expression was
determined by qRT-PCR after 48 and 72 h.
Knockdown of TXNIP
LP9 cells that were 90% confluent were transfected with either ON-TARGET plus smart
pool human TXNIP siRNA (siTXNIP) or ON-TARGET plus non-targeting siRNA
(siControl) from Dharmacon (Fisher Scientific, Pittsburgh, PA) using Lipofectamine 2000
(Life Technologies, Grand Island, NY) diluted in a final volume of 500 µl Optimem
medium (Life Technologies, Grand Island, NY), as previously described (16). All siRNA
were reconstituted to 20 µM before transfection and stored at -20 °C until use. The
magnitude of TXNIP knockdown was assessed by qRT-PCR.
To confirm observations of the role of TXNIP in inflammasome activation, a human
mesothelioma cell line (HMESO) in which the extracellular signal regulated kinase 2 had
been stably knocked down (shERK2) was used. These cells have been previously reported
(GSE21750) to have down-regulated expression of TXNIP (several fold). To activate the
inflammasome, shERK2 HMESO cells and corresponding control cells stably transfected
with non-targeting shRNA (shCon) were treated with 5 µM doxorubicin (Dox) as
previously described (20). After 48 h of treatment the shERK2 and shCon HMESO cells,
treated with or without Dox, medium supernatants were harvested by centrifuging medium
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at 300 x g for 7 min in the cold (4° C) to remove cellular debris. The resulting supernatants,
stored in 1 ml aliquots, were concentrated using Amicon centrifugal concentrating columns
with a 10,000 nominal molecular weight limit (NMWL) (EMD Millipore, Billerica, MA).
4X sample buffer was added to the concentrated supernatant to a final concentration of 1X
before being electrophoresed at 100V for 2 h on a 15% SDS PAGE gel. Immunobloting
was performed as described above with capase-1 p20 antibody (Cell Signaling, Danvers
MA) to detect caspase-1 activation.
Statistical Analysis
All data were analyzed by one-way ANOVA compared with the respective control group
and a Neuman-Keuls posttest for multiple comparisons or the student t-test. Results are
presented as the mean ± SEM. All experiments were repeated at least twice. Comparisons
with a p value less than 0.05 were considered statistically significant. Statistical analyses
were conducted using Graph Pad Prism v6 software.

Results
The effects of crocidolite exposure on thioredoxin 1 (Trx1) expression in human
mesothelial cells: To determine the effect of crocidolite exposure on the expression levels
of Trx1, LP9/h-TERT cells were exposed to 75 x 106 µm2/cm2 crocidolite for 8 and 24 h
and RNA was extracted. Analysis of fold changes in mRNA levels for Trx1 by qRT-PCR
revealed a 1.6 fold increase in Trx1 mRNA levels after 24 h of crocidolite exposure as
compared to controls (*p<0.05) (Figure 1a). An assessment of the total Trx1 protein levels
after crocidolite exposure showed a decrease in protein levels after 24 h (Figure 1b & c).
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In contrast, glass beads (which were used as a negative control) and crocidolite at surface
area coverage of 15 x 106µm2/cm2 did not cause a significant increase in mRNA levels at
24 h as compared to untreated controls.
The oxidation state of thioredoxin 1 (Trx1) after crocidolite exposure: LP9 cells exposed
to 75 x 106 µm2/cm2 crocidolite for 8 and 24 h showed a decrease in the proportion of
reduced Trx1 as assessed by redox Western analysis as compared to untreated controls
(Figure 2a). This decrease in the level of reduced thioredoxin was not observed in cells
treated with sodium arsenite, which has been shown previously to oxidize Trx1 in a
different cell type (21). In addition, the total amounts of Trx1 observed in crocidolite
exposed cells appeared to be lower than the levels in the other treatment groups. A third
band that represented fully oxidized thioredoxin was present in cells exposed to either
crocidolite or arsenite, but was not observed in lysates from the untreated controls. To
determine whether the oxidation of thioredoxin by crocidolite was specific to crocidolite
alone, LP9 cells were also exposed to chrysotile asbestos and glass beads. As assessed by
redox Westerns, oxidation of thioredoxin was specific to the higher concentration (75 x 106
µm2/cm2) of crocidolite alone (Figure 2c). Levels of reduced and semi-oxidized Trx1
remained the same at 8 and 24 h in response to chrysotile and glass bead exposure.
Inhibition of thioredoxin reductase (TR) by dinitrochlorobenzene (DNCB) and
pretreatment with dehydroascobic acid: To determine whether inhibition of TR by DNCB
would increase asbestos-induced oxidation of Trx1, LP9 cells were pretreated with 10 µM
DNCB and exposed to 75 x 106 µm2/cm2 crocidolite for 8 and 24 h. A lactate
dehydrogenase (LDH) assay performed on the medium from exposed cells showed that
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LDH levels were reduced in cells pretreated with DNCB when compared with cells
exposed to asbestos alone (Figure 3a). In addition, redox Western blot analysis of cell
lysates indicated that the oxidation of Trx1 by asbestos was ameliorated when cells were
pretreated with DNCB before exposure to crocidolite asbestos (Fig. 3b). On the contrary,
cells exposed to chrysotile asbestos with and without DNCB showed no changes in the
redox states of Trx1 when compared to controls (Figure 3c). An Apostain assay to detect
chromatin condensation and single strand breaks in nuclear DNA as a measure of early
apoptotic events was also conducted to determine the effects of pretreatment with DNCB
on asbestos-induced apoptosis. Apostain revealed that cells pretreated with DNCB were
protected from apoptosis after 8 h of exposure to crocidolite asbestos (Figure 3d). On the
other hand, pretreatment of LP9 cells with DHA before exposure to asbestos slightly
increased the amount of reduced thioredoxin in cells compared to asbestos exposure alone
(Figure 3e). However, there was no significant increase when compared to control or
asbestos exposure alone.
ROS generation in response to asbestos is modulated by Trx1 in LP9 cells: To assess ROS
generation after exposure to asbestos, 90% confluent LP9 cells were exposed to 75 x 106
µm2/cm2 asbestos for 24 h and incubated with NBT as described in the methods.
Spectrophotometric assessment of the solubilized formazan revealed a significant increase
in ROS levels when compared to controls (Figure 4a). Quantitative RT-PCR performed on
cDNA from Trx1 over-expressing cells and their respective controls indicated a 4 fold
increase in Trx1 levels after 48 h of transfection and this was reduced by approximately
50% 72 h post-transfection (Figure 4b). The effect of Trx1 over-expression on asbestos74

induced ROS generation and cell survival was assessed by exposing 90% confluent LP9
cells transfected with a Trx1 over-expression vector (pCMV-SPORT6) and empty vector
transfected controls (pcDNA) to 75 x 106 µm2/cm2 crocidolite asbestos for 2 h. The levels
of ROS generated in response to asbestos exposure were then measured as described
previously. Cells over-expressing Trx1 were found to exhibit a trend of reduced ROS levels
compared to the null controls exposed to asbestos (Figure 4c). It is to be noted here that the
amount of ROS generated by asbestos after 2 h of exposure is significantly lower in
magnitude than 24 h after asbestos exposure (Figure 4a). An assessment of the redox state
of Trx1 in Trx1 over-expressing cells after asbestos exposure indicated that levels of
reduced Trx1 were rescued in over-expressing cells as compared to control cells transfected
with empty vector (EV) alone (Figure 4d). Additionally, cells over-expressing Trx1 also
had increased cell survival after exposure to crocidolite (Figure 4e).
Effect of N-acetyl-cysteine (NAC) on asbestos-induced inflammasome activation:
Asbestos exposure results in the generation of ROS in LP9 cells, and ROS has been
reported to be one of the activators of the NLRP3 inflammasome (6). To determine whether
asbestos-induced ROS plays a role in inflammasome activation, LP9 cells were pretreated
with NAC and analyzed for inflammasome priming and activation by qRT-PCR and
Western blot analysis. A decrease in steady-state NLRP3 transcript levels was observed
in cells pretreated with NAC prior to asbestos exposure when compared to cells exposed
to asbestos alone (Figure 5a). Concurrently, levels of active caspase 1 secreted into the
medium after exposure of LP9 cells to asbestos were also significantly reduced after
pretreatment with NAC (Figure 5b).
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Validation of the knockdown of TXNIP expression by siTXNIP was determined by qRTPCR and showed that an approximately 50% reduction in TXNIP mRNA levels was
achieved after 48 h of transfection (Figure 6a). Western blot analysis of the cell medium
after exposure to asbestos for 48 h indicated that active caspase 1 levels (caspase1-p20)
were reduced after knockdown of TXNIP when compared to siControl transfected cells
(Figure 6b).
In mesothelioma cell lines with a stable knockdown of extracellular signal regulated kinase
2 (shERK 2), the expression of TXNIP was found to be down-regulated 4-fold (Figure 6c).
Activation of the NLRP3 inflammasome by doxorubicin treatment of shERK2 HMESO
cells indicated that caspase 1 activation was drastically reduced as compared to control
cells stably transfected with non-targeting shRNA (shCon) (Figure 6d) and there was no
priming of NLRP3 as measured by mRNA levels of NLRP3 using qRT-PCR (Figure 6c).
Caspase-1 dependent cell death (pyroptosis), which may occur in response to
inflammasome activation, may contribute to asbestos-induced cell death in addition to
asbestos-induced apoptosis and lytic cell death. Therefore, we sought to determine whether
pyroptotic cell death occurred in response to asbestos-induced inflammasome activation.
To do so, LP9 cells were pretreated with 40 µM Caspase-1 inhibitor VI (zYVAD-FMK)
before exposure to asbestos. When compared to cells exposed to asbestos alone, there was
an 18% increase in cell viability, suggesting this fraction of cells may have undergone
pyroptotic cell death upon exposure to asbestos (Figure 6e). Immunoblotting for Cas-1 p20
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in concentrated medium supernatants also confirmed that the inhibitor attenuated activation
of the caspase-1 as expected (Figure 6f).

Discussion
Reactive oxygen species generated in response to asbestos exposure have been shown to
have deleterious effects in different cell types. Asbestos-induced ROS generation has been
shown to cause oxidative damage to mitochondrial and genomic DNA (22, 23) and may
modulate the activity/function of various signaling molecules, transcription factors and
enzymes that are redox sensitive (11), (22, 24). The high iron content as well as the valency
state of iron on crocidolite asbestos fibers has been shown to facilitate Fenton reactions
both intracellularly and extracellulary (25, 26). Mitochondrial generated superoxide can
react with Fe3+ ions on asbestos fibers to reduce it to Fe2+ (26). Unfortunately, this enables
the Fe2+ to react with any H2O2 present in the cell to produce hydroxyl radicals. This can
lead to a cycle of oxidation and reduction of Fe3+ to produce more ROS. Additionally, the
high aspect ratio of the crocidolite fibers leads to frustrated phagocytosis as mesothelial
cells try to unsuccessfully phagocytose the fibers (6). Frustrated phagocytosis promotes a
sustained production of superoxide through the activity of membrane bound NADPH
oxidases that are activated during the repeated phagocytosis attempts (27). Asbestos
exposure has been shown to cause a depletion of reduced glutathione levels in vitro (11,
12), but its effects on Trx, another major antioxidant of the cell, is unknown. The ability of
asbestos fibers to activate the inflammasome in macrophages and mesothelial cells (4, 6)
and the involvement of the endogenous inhibitor of Trx, TXNIP, in activation of the
NLRP3 inflammasome (10) led us to hypothesize that oxidation of Trx by asbestos-induced
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ROS may cause the dissociation of TXNIP from Trx and lead to activation of the
inflammasome. Here we show for the first time that asbestos exposure of human
mesothelial cells leads to oxidation of Trx and a compensatory increase in Trx1 transcript
levels. We also report that TXNIP is involved in asbestos mediated activation of the
inflammasome which may be as a result of the oxidation of Trx1 by asbestos-induced ROS
generation.

Quantitative real time PCR showed that asbestos exposure increased the steady-state RNA
levels of Trx1 by approximately 1.6 fold after 24 h. The promoter of the Trx gene (TXN)
contains an antioxidant response element (ARE) (28). It is therefore likely that ROS
generated in response to asbestos exposure led to an increase in Trx1 expression as a
compensatory mechanism by activating ARE-dependent gene expression. It has been
reported by our group that cells exposed to asbestos show increased expression of the
mitochondrial manganese superoxide dismutase (MnSOD) (12). Studies also show that
increases in expression of cellular antioxidant proteins (MnSOD and Trx1) occur in
response to oxidative stress (11, 12). Exogenous thioredoxin as well as endogenously overexpressed Trx has also been shown to increase MnSOD levels in a redox dependent manner
(29). As such, increases in ROS generation in LP9 cells exposed to asbestos coupled with
the oxidation of Trx1 and increased transcription of Trx1 could be considered an indication
of asbestos-induced oxidative stress. To the contrary, the total intracelluar protein levels of
Trx1 were reduced by about 67% in response to asbestos exposure after 24 h (Figure 1b,
c). This suggests that, ROS generation by asbestos exposure may lead to an increased
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oxidation and removal of Trx1 protein as a conjugate, and the cells may increase
transcription as a compensatory mechanism. However, Trx1 is secreted into the culture
medium in response to many stimuli – it may not be degraded (30, 31). Similarly, we have
demonstrated previously that asbestos exposure depletes glutathione from cells while
increasing the steady-state RNA levels of γ-glutamylcysteine synthetase (a rate limiting
enzyme for glutathione synthesis) at the same time (11).

To determine if asbestos exposure causes changes in the antioxidant capacity of Trx1, the
oxidation state of Trx1 was assessed by redox Western blot analysis after exposure of LP9
cells to asbestos. The analysis of the oxidation states of Trx1 after asbestos exposure
showed that Trx1 became irreversibly oxidized and levels of reduced Trx1 were drastically
decreased compared to control cells. The diminution in the levels of reduced Trx1 may be
due to the oxidation of the structural cysteine residues (Cys 62, 69 and 73). Oxidation of
these structural cysteines can lead to disulfide bond formation between Cys 62 and 69
which has been shown to reduce the use of Trx1 as a substrate for TR (19). As a result,
Trx1 cannot be reduced to its active form. The formation of disulfide bonds between Cys
73 of two adjacent Trx1 molecules leading to their dimerization has also been shown to
occur under extremely oxidizing conditions (32). This dimerization may lead to
conformational changes in the active site of Trx1 which will make the active site Cys
residues inaccessible to TR for reduction. Other studies have shown that strong oxidants
can cause the oxidation of Trx1 producing a mixture of Trx1 monomers, dimers and
oligomers with no free sulfhydryl groups (33). These findings support the possibility that
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asbestos-induced ROS may be involved in directly or indirectly altering the oxidation state
of Trx1.

Maintenance of the reducing milieu of the cell is also important for cell survival; thus,
imbalances in the ratio of cellular antioxidants and oxidants could lead to deleterious or
lethal effects on the cell. To investigate what role perturbations in the redox state of the
thioredoxin system plays in asbestos-induced cell death, LP9 cells were pretreated with
dinitrochlorobenzne (DNCB), an irreversible alkylating inhibitor of TR (34) and assessed
for cell death in response to asbestos exposure. An LDH assay as well as the Apostain
assay showed that pretreatment with DNCB protected cells from asbestos induced cell
death contrary to all reports in the literature in which treatment of cells with DNCB resulted
in cell death (35-37). Recent studies have conversely shown that inhibition of TR leads to
increases in GSH levels and a reduction of Trx1 and Trx2 by glutaredoxin in the absence
of a functional TR enzyme (38, 39). It is therefore likely that the protection of human
mesothelial cells from asbestos-induced cell death after pretreatment with DNCB may be
due to increases in GSH and levels of reduced Trx1.

Levels of intracellular GSH are sensitive to ROS levels (40) and are modulated upon
exposure of cells to asbestos (11, 12). Reactive oxygen species have also been shown to
play a role in the activation of the NLRP3 inflammasome after asbestos exposure (6) and
may be linked to the effects of GSH levels on Trx1 oxidation state and the availability of
TXNIP to bind to and activate the inflammasome. To test the effect of increased GSH or
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reduced ROS levels on inflammasome activation, LP9 cells were incubated with 2 mM
NAC for 20 h prior to asbestos exposure and this led to a significant decrease in
inflammasome activation, as well as a reduction in priming. This suggests that high GSH
levels may buffer reduced Trx1 levels (39) and prevent the dissociation of TXNIP from
Trx1. As such, TXNIP is unable to bind to and activate the inflammasome leading to
reduced levels of Caspase-1 p20 peptides in the medium supernatant. The reduction in
priming of the NLRP3 may also be due to the decrease in ROS levels as GSH levels
increased to buffer cells from the ROS generated in response to asbestos exposure since
transcription of NLRP3 is under the control of NFκB (a redox sensitive transcription factor)
(41-43) . Exposure of LP9 cells to NAC also attenuated the increase in Trx1 mRNA
induced by asbestos as there was no significant increase when compared to control (data
not shown). This implies that the oxidative stress induced by asbestos exposure is
ameliorated by NAC.

We have demonstrated previously that crocidolite asbestos causes cell death and
compensatory proliferation (3), which may be a required step for crocidolite asbestosinduced cell transformation and MM development. Our results here, indicate that a fraction
of total cell death by asbestos is caused by pyroptosis (caspase-1 dependent cell death,
Figure 6), a process known to be regulated in part by TXNIP. However, this observation
needs to be confirmed using siRNA mediated knockdown of caspase-1 in future studies.
We suspect that pyroptosis is prevented by over-expression of Trx1 (Figure 4) which
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renders TXNIP unavailable to subsequently induce inflammasome assembly and thus,
caspase-1 activation.

Assessment of the effects of Trx1 over-expression on asbestos-induced ROS generation
revealed that LP9 cells over-expressing Trx1 had lower levels of ROS after asbestos
exposure when compared to vector transfected cells. Although asbestos induced a
significant increase in ROS generation in LP9 cells after 24 h, the trend of reduction in
ROS levels with Trx1 over-expression at an earlier time point (2 h) were not statistically
significant, but reproducible. The reduction in asbestos-induced ROS generation in LP9s
over-expressing Trx1 also corresponded to a moderate increase in cell survival which also
exhibited a trend. Cells undergoing oxidative stress up-regulate the expression of
antioxidant proteins like thioredoxin and MnSOD as well as the antioxidant peptide
glutathione to counter the increase in oxidant levels (11, 12, 44). As such, the reduction in
asbestos-induced ROS levels upon over-expression of Trx suggests that the increase in
Trx1 levels after asbestos exposure may be a compensatory mechanism to restore the
antioxidant-oxidant balance that is disrupted by asbestos (22).

Our study also showed that the redox-dependent Trx-TXNIP interaction is involved in
asbestos-induced inflammasome activation. When TXNIP, the negative regulator of Trx1
reductase activity, was knocked down in LP9 cells, inflammasome activation was reduced.
Cells transfected with siTXNIP had decreased amounts of active Caspase-1 subunit p20 in
the medium after exposure to asbestos when compared to control. Additionally, activation
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of the inflammasome by the chemotherapeutic doxorubicin in shERK2 HMESO cells,
which have a four-fold lower expression of TXNIP, was attenuated, confirming that
TXNIP is required for inflammasome activation. In support of our data Zhou et al. (10)
demonstrated that knockdown of TXNIP by siRNA in beta islet cells, reduced activation
of the NLRP3 inflammasome. Thus our findings corroborate the role of TXNIP in
inflammasome activation by asbestos, and relate inflammasome activation via TXNIP to
ROS levels in the cell (Figure 7).

Conclusion
This study has demonstrated that activation of the inflammasome by asbestos is mediated
in part by TXNIP as a consequence of alterations in the redox state of Trx1 in the cytosol.
Further studies are in progress to offer an understanding of how asbestos-induced
activation of the inflammasome and subsequent generation of biomolecules (IL-1β, IL-18,
HMGB1 etc.) may lead to mesothelial cell transformation events and mesothelioma
development.
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Quantitative real time PCR
Reactive oxygen species
Short hairpin RNA against ERK2
Short hairpin RNA non-targeting
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
TBS-Tween
Thioredoxin 1
Thioredoxin Interacting Protein
Thioredoxin reductase
Tris-buffered saline
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TPA
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HEPES
ARE
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Dox
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IAA
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SDS PAGE
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Figures

Figure 2.1: Crocidolite asbestos exposure modulates Trx1 levels in mesothelial cells. (A) LP9
cells were exposed to crocidolite asbestos at 75 x 106 µm2/cm2 for 8 and 24 h. Glass beads (GB) at
the same surface area concentration were used as an inert particulate control. RNA was extracted
from the samples and used to prepare cDNA, which was quantified by qRT-PCR (*p< 0.05
compared to untreated controls (NC)). (B) Western blot analysis of LP9 cells for total thioredoxin
protein after exposure to crocidolite asbestos, β-actin was used as a loading control. (C)
Densitometric analysis of (B) using Quantity One software (n =2 per group).
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Figure 2.2: Crocidolite asbestos exposure causes oxidation of Trx1 in human mesothelial cells.
(A) LP9/h-TERT cells were exposed to crocidolite at 75 x 106 µm2/cm2 for 8 and 24 h and 40 µg
of protein was run on a 15% native gel and a redox Western blot analysis was performed as
described in the Methods section on the immobilized proteins. (B) Quantitation of the blot in (A).
(C) Cells were exposed to two concentrations of crocidolite asbestos (15 x 106 µm2/cm2 and 75 x
106 µm2/cm2), as well as chrysotile asbestos (75 x 106 µm2/cm2) and a redox Western analysis was
performed on the lysates [* p< 0.05 compared to null controls (n = 2 per group)].
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Figure 2.3: Inhibition of thioredoxin reductase by DNCB and pretreatment of cells with DHA
rescues asbestos-induced oxidation of Trx1. (A) LDH assay to assess lytic cell death after
pretreatment of LP9 cells with DNCB and exposure to asbestos (data is presented as a percentage
of the lytic control). (B) Effect of DNCB on asbestos-induced Trx1 oxidation. Cells were pretreated
with 10 µM DNCB for an hour and then exposed to asbestos for 8 h. Cell lysates were then
derivatized with IAA and analyzed for oxidation of Trx1 by redox Western blot and densitometry
of redox Western analysis of Trx1 oxidation state was performed. (C) Effect of DNCB pretreatment
on chrysotile asbestos-induced oxidation of TRX1 (D) Analysis of apoptosis in response to DNCB
pretreatment and asbestos exposure for 8 h as measured by Apostain technique. (E) LP9 cells were
pretreated with 1mM DHA for an hour and exposed to asbestos for 8h. Thereafter, the oxidation
state of Trx1 was assessed by redox Western blot analysis (* p< 0.05 compared to null controls;
†p<0.05 compared to crocidolite asbestos exposure alone (Croc 75) n = 2 per group).
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Figure 2.4: Over-expression of Trx1 increases cell survival and ameliorates asbestos-

induced ROS generation in LP9 cells. (A) LP9 cells were exposed to two doses of
crocidolite asbestos (15 x 106 µm2/cm2 and 75 x 106 µm2/cm2) for 24 h and incubated with
NBT for 45 min at 37°C. The absorbance of the solubilized formazan formed after
incubation with NBT was then read at 630 nm to determine ROS levels after asbestos
exposure. (B) Over-expression of Trx1 in LP9 cells using the pCMV-SPORT6 plasmid
was confirmed by qRT-PCR 48 and 72 h after transfection. (C) Trx1 transfected cells were
exposed to crocidolite asbestos for 2 h and incubated with NBT for 45 min to determine
ROS levels. Solubilized formazan was measured spetrophotometrically at 630 nm on a
plate reader. (D) Analysis of the oxidation state of Trx1 after asbestos exposure of Trx1
over-expressing LP9 cells was determined by redox Western blot analysis and
densitometry of the blot was performed (n = 2 per group). (E) LP9 cells transfected with
the Trx1 over-expressing plasmid, pCMV-SPORT6 were exposed to crocidolite asbestos
for the times indicated. Cells were then trypsinized and counted to estimate cell survival
(*p < 0.05 compared to control; †p < 0.05 compared to Trx1 OE). Cell survival and NTB
graphs are the average results of 3 experiments.
Figure 2.5: Asbestos-induced inflammasome priming and activation is attenuated by

NAC. (A) LP9 cells pretreated with 2 mM NAC were exposed to 5ug/cm2 asbestos for 48
h and changes in NLRP3 mRNA levels were assessed by qRT-PCR. (B) Inflammasome
activation was assessed by Western blot analysis of the media supernatants from cells
exposed to asbestos with and without pretreatment with NAC. Immobilized proteins on the
nitrocellulose membrane were probed for the presence of active caspase-1 (p20 fragment)
(*p< 0.05 compared to null control; † compared to Croc 75 alone; n = 2 per group).
Figure 2.6: Knockdown of TXNIP decreases inflammasome activation. (A) LP9/hTERT

cells (90% confluent) were transiently transfected with siTXNIP or siControl siRNA for
48h and knockdown of TXNIP expression was assessed by qRT-PCR. (*p< 0.05 compared
to siControl) (B) siControl and siTXNIP transfected cells were exposed to crocidolite
asbestos for 48 h and the medium were collected, concentrated and analyzed for the
presence of caspase-1 (p20) by Western blot analysis. (C) The transcript levels of ERK 1/2
as well as TXNIP were verified in shERK2 HMESO cells by qRT-PCR in the presence and
absence of 5 µM Dox along with priming of the inflammasome (*p<0.05 compared to
shCon alone; †p<0.05 compared to shCon + Dox; n = 2 per group). (D) Inflammasome
activation was assessed by Western blot analysis for the p20 fragment of caspase-1 in the
media supernatants after treatment with Dox (*p<0.05 compared to shCon alone; †p<0.05
compared to shCon + Dox; n = 2 per group). (E) LP9 cells were pretreated with 40 µM of
the caspase-1 inhibitor VI (cas-1 inh) prior to exposure to asbestos for 48 h and cells were
counted to determine survival (*p<0.05 compared to control; †p<0.05 compared to Croc
75 alone). (F) Western blot analysis for Cas-1 p20 fragment in medium supernatant from
LP9 cells pretreated with the caspase-1 inhibitor prior to exposure to asbestos (n = 2 per
group).
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Figure 2.7: Role of ROS and antioxidants in asbestos-induced activation of the NLRP3

inflammasome. A simplified schema showing how increased ROS or decreased GSH as a
result of asbestos exposure can cause oxidation of Trx1 and release of TXNIP. TXNIP thus
released binds to NLRP3 and activates it as represented by caspase-1 activation. NAC on
the other hand reduces ROS and elevates GSH levels resulting in inhibition of activation
of NLRP3.
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Abstract
Despite the causal relationship established between malignant mesothelioma (MM) and
asbestos exposure, the exact mechanism by which asbestos induces this neoplasm and other
asbestos-related diseases is still not well understood. MM is characterized by chronic
inflammation which is believed to play an intrinsic role in the etiology of this disease. We
have recently shown that asbestos activates the nod-like receptor family member
containing a pyrin domain 3 (NLRP3) inflammasome in a protracted manner leading to an
up-regulation of IL-1β and IL-18 production in human mesothelial cells. Combined with
bio-persistence of asbestos fibers we hypothesize that this creates an environment of
chronic IL-1β signaling in human mesothelial cells which may promote mesothelial to
fibroblastic transition (MFT) in an NLRP3 dependent manner. Using a series of
experiments, we show that asbestos induces a fibroblastic transition of mesothelial cells
with a gain of mesenchymal markers (vimentin and N-cadherin) while epithelial markers
like E-cadherin are down-regulated. Use of small interfering RNA against NLRP3,
recombinant IL-1β and IL-1 receptor antagonist confirmed the role of NLRP3
inflammasome dependent IL-1β in the process. In vivo studies using wild type and various
inflammasome component knockout mice also demonstrated the process of asbestosinduced MFT and its amelioration in caspase-1 knockout mice. Taken together, our data
are the first to suggest that asbestos induces MFT in an inflammasome dependent manner.
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Introduction
Malignant mesothelioma (MM) is a fatal cancer of the pleural or peritoneal mesothelium.
MM has been causally related to asbestos exposure for over 50 years 1 yet the mechanisms
involved in the development of the disease are still poorly understood. With a latency
period of 10-40 years and a propensity towards resistance and recurrence, MM is in dire
need of new drug targets for combination therapy as well as biomarkers for early detection.
Chronic inflammation has been implicated in the development and progression of MM
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and prevalently high circulating cytokines which are incidentally associated with fibrosis
(interleukin 6 (IL-6), Platelet Derived Growth Factor and IL-8) have been used as
prognosticators of survival for MM patients 3, 4. A recent massive parallel sequencing study
of immortalized and primary mesothelial cells after asbestos exposure has shown that the
most highly upregulated genes after asbestos exposure belong to inflammatory networks 5,
further implicating inflammation as an important factor in the development of asbestosrelated diseases.
We have previously shown that asbestos activates the nod-like receptor containing a pyrin
domain 3 (NLRP3) inflammasome, leading to the secretion of mature IL-1β and IL-18 in
human mesothelial cells (HMCs)6. In these cells however, the activation of the
inflammasome is protracted leading to the accumulation of IL-1β and IL-186. IL-1β
signaling has been shown to upregulate the secretion of the cytokines, IL-6 and IL-8 which
have been demonstrated to play a major role in lung fibrosis7. In addition to promoting
fibrosis, IL-1β has been shown to induce epithelial to mesenchymal transition (EMT) in
corneal endothelial cells as well as inducing stemness in colon cancer cells through the
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activation of transcription factors that regulate the mesenchymal phenotype8, 9. On the other
hand, NLRP3 and apoptosis speck-like protein containing a CARD domain (ASC) (an
adaptor protein for the assembly of the inflammasome) have both been shown to play a
role in transforming growth factor beta (TGFβ) signaling independent of their
inflammasome activity in tubular epithelial cells10. We therefore hypothesized that the
NLRP3 inflammasome and its products facilitate mesothelial to fibroblastic transition
(MFT) of human mesothelial cells in response to asbestos exposure. As such, asbestosinduced MFT may serve as the initial step in MM tumorigenesis. In this study we
investigate the process of MFT in response to asbestos exposure at the transcriptional and
translational levels as well as the role of the NLRP3 inflammasome components in the
process, using in vitro and in vivo models. We show for the first time that asbestos induced
inflammasome activation results in IL-1β secretion, which promotes MFT through the
signaling cascades elicited by IL-8 and IL-6 which may involve tissue factor pathway
inhibitor 2 (TFPI2), and fibroblast growth factor 2 (FGF2).

Materials and Methods
Cell Culture
Immortalized human peritoneal (LP9/hTERT (LP9)), primary human pleural (HPM-3) and
peritoneal (HM3) mesothelial cells were purchased from Brigham and Women’s Hospital
(Boston, MA) and were cultured as previously described6. All cells were grown to 90-95%
confluency. All experiments were repeated at least two or more times.
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Asbestos fiber preparation for exposure
NIEHS reference samples of crocidolite asbestos have been previously characterized 11.
Fibers were sterilized and suspended as previously described6.

Cell treatments with asbestos/IL-1β/IL-1 receptor antagonist
To assess the response of human mesothelial cells to long term asbestos exposure, cells
were exposed to two pulses of 1(15x10-6 um2/cm2; surface area equivalent) (LP9 and HM3)
or 5 (75x10-6 um2/cm2; surface area equivalent) (HPM3, as these cells were less sensitive
to asbestos) μg/cm2 crocidolite asbestos 48 h apart. Medium was refreshed every 48 h (until
cells were harvested) to ensure that cells were not nutrient starved; thus, it was imperative
to replace any asbestos fibers lost in the process of switching out media. LP9 and HM3
cells displayed a permanently altered cell shape 10-14 days after the initial asbestos
exposure. For HPM3 cells, duration to transition was much shorter (1 week post addition
of first asbestos pulse). Thus, cells were maintained in fresh medium for the last 72 h with
no ill effects prior to termination of the experiment. A schematic representation of asbestos
pulses and medium changes is depicted in Figure 1A. In experiments where the effect of
asbestos-induced IL-1β signaling on MFT was being assessed, recombinant IL-1β
(Peprotech, Rocky Hill, NJ) or its receptor antagonist (IL-1Ra) (Insight Genomics, Sterling
VA) were also replaced during the first 48 hour medium change. HPM3 or LP9 cells were
pretreated with two pulses of either 1 ng/mL IL-1β or 150 ng/mL IL-1Ra respectively one
hour before asbestos exposure. Both agents were stored in 0.1% BSA solutions and as such,
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control cells received equal amounts of 0.1% BSA for the same duration as a vehicle
control. Cells receiving both IL-1Ra and IL-1β were pretreated with the antagonist one
hour prior to treatment with IL-1β. Effect of asbestos exposure on viability of different
human mesothelial cells showed that peritoneal cells are more sensitive to asbestos
exposure than pleural mesothelial cells12, 13. Precisely, we observed 35-40% cell death in
peritoneal mesothelial cells (LP9 and HM3) in response to asbestos exposure as compared
to 15-20% cell death in pleural mesothelial cells (HPM3 and HPM4)12. Glass beads (GB)
were used as negative control at equal particle surface area concentration and showed no
significant effect on viability and other parameters 6, 13.

Assessment of cell morphology
Cells were inspected visually for changes in morphology (acquisition of a spindle-like
shape and reorientation/alignment of cells into a whorl) and imaged 48 h after each pulse
and at time of harvest using an Olympus IX70 inverted light microscope (Olympus
America Inc. Center Valley, PA) in phase contrast with a 20X objective. Cells were also
followed visually with each media change to ascertain whether transition in cell
morphology remained stable and to determine when transition in shape became more
uniform.

Quantitation of cell morphology
The effects of asbestos exposure on the morphology of cells was assessed using the
integrated morphology analysis module in the MetaMorph Image Analysis software
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(Molecular Devices, Sunnyvale, CA). A total of thirty cells per dish were outlined in
MetaMorph to obtain a measure of their perimeters and total area which was then used to
determine the shape factor for each cell (Shape factor =

4𝜋𝐴
𝑃2

A= area; P= perimeter). The

shape factor is a value that ranges from 0 to 1 as a measure of how circular an object is (0
represents a flattened non circular object whereas 1 represents a perfect circle). The change
in length of the cells was also determined using the region measurements tool to measure
the longest axis (longest chord through the cell) of each of the cells as well. Data obtained
from a total of sixty cells per group were then pasted into Graph Pad Prism v 6.0 to yield a
min to max plot for each condition and for statistical analysis of the resulting distribution.

Cell transformation assay
To determine whether LP9 cells that had undergone MFT were capable of anchorage
independent growth, cells were trypsinized at the end of the MFT experiment and used for
a CytoSelectTM 96-well cell transformation assay (Cell Biolabs Inc. San Diego, CA) per
the manufacturer’s protocol. Wells were monitored for colony formation after 1 week in
culture and imaged in phase contrast on the Olympus IX70 microscope each week.

PCR Array
To determine whether the transcripts of genes involved in the EMT pathway were altered
in response to asbestos exposure, LP9 and HPM3 cells were exposed to asbestos (5 µg/cm2)
for 48 h or 1 week (HPM3 only). As a positive control, LP9 cells were treated with 10
ng/ml TGFβ for 48 h to induce MFT. Cells were then lysed for total RNA extraction using
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the Qiagen RNeasy Plus Mini kit as per the manufacturer’s directions. After ensuring the
integrity of the RNA samples, 500 ng of RNA was used for cDNA synthesis to be utilized
in the Human EMT pathway RT2 Profiler PCR Array as described previously14. Data
obtained were then analyzed using the online SA Biosciences data analysis template.

Transfection experiments
The role of the inflammasome in asbestos-induced MFT was examined in mesothelial cells
using siRNA approaches. Ninety percent confluent LP9 cells were transiently transfected
with On-Target Smart Pool© siNLRP3 (ThermoScientific (Life Technologies), Grand
Island, NY) or non-targeted control (siControl) constructs 32 h prior to asbestos exposure
to study the effects of reduced NLRP3 protein levels on MFT as described before14.
Additional experiments were performed with 4 single siNLRP3 and non-target controls
(ThermoScientific (Life Technologies), Grand Island, NY) as described above.

Western Blot Analysis
Cells were lysed in 4x sample buffer and boiled at 95°C for 15 minutes as previously
described15. For analysis of EMT parameters, 40 μg of protein was loaded on 15, 10 or 7.5
% SDS PAGE gels to resolve proteins. Immunoblotting for EMT markers was performed
on transferred proteins using E-cadherin, Snail, Slug, N-cadherin, Vimentin and ZO-1 (Cell
Signaling Technology, Danvers, MA). Western blot analysis was performed on media
supernatants or peritoneal lavage fluid (PLF) after concentration. Equal volumes of media
supernatants or PLF were concentrated using StrataClean resin beads (Agilent
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Technologies, Santa Clara, CA) as previously reported16. An equal volume of 4X sample
buffer was added to beads after media had been aspirated and boiled for 5 min at 95°C.
Thereafter 10-15 μL of each sample was resolved on a 15 % SDS PAGE for subsequent
immunoblotting for pro-inflammatory cytokines IL-6, IL-8, FGF2, TFPI2 and the danger
associated molecule HMGB1 (Abcam, Cambridge, MA).

ELISA for IL-18 and IL-1β
Media supernatants from in vitro experiments or PLF from in vivo experiments were
concentrated in Amicon centrifugal filtration units with a molecular weight limit of 10 kDa
(Millipore, Billerica MA) as described previously6. The levels of IL-1β and IL-18 secreted
in response to asbestos exposure were then measured using the Human Quantikine IL1β/IL-1f2 Immunoassay (R&D Systems, Minneapolis, MN) and Human IL-18 ELISA kits
(MBL, Woburn, MA) respectively following the manufacturer’s directions. Values are
expressed as pg (IL-1β /IL-18)/ mL of total culture supernatant initially collected.

Mouse models of asbestos exposure
To study in vivo effect of asbestos on mesothelial cell transition we selected intraperitoneal
injection model of asbestos exposure developed by Goodlick et al17 and recently used by
various groups18,19. All these studies demonstrated the development of early
inflammation18, peritoneal fibrosis and eventually MM in mice17, 19 in response to asbestos.
Inhalation or aspiration models were not considered for this study as asbestos exposure by
either model has not been shown to cause peritoneal fibrosis or MM in mice. Age (8-10
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weeks) and sex matched NLRP3 -/- 20 and Cas-1 -/- mice21 (C57/BL/6 background, obtained
from Dr. Matthew Poynter (UVM) and bred in our facility) as well as their wild type
C57BL/6 (Charles River Laboratory) counterparts were housed in isolators with ad libitum
access to food and water according to the University of Vermont Institutional Animal Care
and Use Committee guidelines (#12-004). Mice (6-8 mice per group) received either 500
μL of 0.9% sterile saline or 500 μL of 200 μg/mL crocidolite asbestos ip once a week over
the course of 8 weeks as previously described17. As a negative control, mice were injected
with glass beads (GB, Polysciences Inc., Warrington, PA) at an equal surface area
concentration (500 µL of 1.076 mg/mL). Mice were euthanized with an overdose of sodium
pentobarbital after which the peritoneal walls and diaphragms were harvested, fixed in 4%
PFA with a specific orientation of mesothelial lining facing outward. Cross sections of
paraffin embedded peritoneal walls were made, hematoxylin and eosin (H&E) stained and
examined histologically as demonstrated previously by Donaldson et al.

22

. Images were

obtained using an Olympus BX50 with a Retiga Magnafire 2000R camera (Olympus
America Inc., Center Valley, PA) (20X objective). Peritoneal wall sections were also
stained for collagen (Col 1α1) (PhophoSolutions, Aurora CO), pan-cytokeratin
(Antibodies-online.com, Atlanta, GA), alpha smooth muscle actin (αSMA) (Sigma
Aldrich, St Louis, MO) and vimentin (Vim) (Cell Signaling Technologies, Danvers, MA).
Immunofluorescently stained sections were imaged on a Zeiss LSM 510 META confocal
laser scanning microscope (Zeiss, Peabody, MA). All mice were confirmed for their
genotype at the beginning and end of the experiment.
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MetaMorph Analysis for quantitation of thickening of peritoneum
Thickening of the parietal submesothelium after asbestos exposure was determined as
follows: Images of peritoneal wall sections obtained with an Olympus BX50 light
microscope and imported into the offline version of the MetaMorph imaging analysis
software (Molecular Devices, Sunnyvale, CA) and calibrated for measurements. Using the
line tool, the distance from the edge of the mesothelium to the border between the muscle
cells underneath was measured and exported into Excel. Five measurements were taken for
each of the five images taken per sample and the average ±SEM of the 25 measurements
were used to plot a graph of the increase in thickness of the parietal mesothelium in
response to asbestos exposure.

PLF collection and analysis for total cell counts, differentials and cytokines
At the time of harvest, peritoneal lavage fluid (PLF) was collected from each animal as
previously described 23. The resultant lavage fluid was drawn out for the measurement of
cytokines [by ELISA (IL-1β and IL-18) and Western blot analysis (FGF2, IL-6 and
TFPI2)] and identification of inflammatory cell infiltrating the peritoneum after asbestos
exposure. Cells collected from PLF were used for cytospin preparation for differential cell
counts after determination of total cell numbers as previously described 23.

Immunohistochemistry and Immunocytochemistry
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To assess EMT marker expression in response to asbestos exposure, formalin fixed paraffin
embedded sections of peritoneal walls were deparaffinized with xylene and rehydrated in
decreasing concentrations of ethanol. Thereafter samples were immunofluorescently
stained as previously described24. Peritoneal wall sections were stained for pan-cytokeratin
(AE1+AE3) (Antibodies-online.com, Atlanta, GA), vimentin, αSMA and Col1α1. Primary
antibodies were used at a ratio of 1:100 or the recommended dilution from the
manufacturer. The appropriate secondary antibody conjugated to Alexa fluor 647 (goat anti
rabbit) or Alexa fluor 588 (goat anti mouse) were employed at a dilution of 1:400.

Statistical Analysis
All experiments were performed in duplicate or triplicate and repeated at least twice. A
one-way analysis of variance (ANOVA) followed by a Newman-Keuls procedure for
adjustment of multiple pairwise comparisons or the Student t-test was applied to all data
points to establish the significance of observed differences between the various
experimental groups. A p value ≤0.05 was considered to be significant. All statistical
analyses were performed using the GraphPad v 6.0 software program.
Results
Asbestos exposure induces MFT in mesothelial cells as depicted by changes in gene
profile:
To determine whether asbestos was capable of inducing a mesothelial to fibroblastic
transition, LP9 and HPM3 were exposed to asbestos for 48 h or 1 wk with TGFβ as a
positive control and an EMT PCR Array was performed. Expression levels of genes related
to an epithelial phenotype like E-cadherin (CDH1), keratin 19 (KRT19), keratin 7 (KRT7),
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macrophage stimulating 1 receptor (MST1R) which is usually expressed on ciliated
epithelial cells and F11R, a regulator of tight junction assembly were reduced after asbestos
exposure in both cell lines. Changes in the transcript levels of genes related to fibroblastic
phenotype were different in magnitude between the two cell types in response to asbestos.
For instance, while SNAI1 was downregulated at 24 and 48 h in LP9 cells after asbestos
exposure there was a two-fold increase seen in HPM3 cells after one week of asbestos
exposure (Table 1). TIMP1 was upregulated by as much as 36-fold in the LP9s (after 24 h)
but did not make the two-fold cutoff in HPM3 cells after asbestos exposure (supplemental
tables 1 and 2). TFPI2 levels however, increased in both cell types (Table 1) but to a greater
magnitude in LP9 cells (52-fold in LP9s and 13-fold in HPM3). TGF family member, bone
morphogenic protein 2 (BMP2) was upregulated to the same extent in both cell lines in
response to asbestos (Table 1).

Asbestos exposure causes morphological changes in mesothelial cells:
Exposure of LP9 and HM3 cells to asbestos for 2 weeks with fresh medium every 48 h
resulted in a change in morphology of the cells to a fibroblastic cell type (Figure 1B). While
exposure to 1 μg/cm2 asbestos had no effect on HPM3 cells (data not shown), exposure to
5 μg/cm2 asbestos resulted in morphological changes over the course of one week (Figure
1B). In a colony forming transformation assay only asbestos-exposed LP9 cells which
appeared fibroblastic formed colonies after two to six weeks on soft agar and some colonies
were still associated with asbestos fibers (Figure 1C). Morphometric analysis of LP9 and
HPM3 cells in figure 1B showed that the length of LP9 cells did not change significantly
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with exposure to asbestos (Figure 1D). However, there was a significant decrease in the
circularity of these cells upon exposure to asbestos (Figure 1D) (* p<0.05 compared to
control). For HPM3 cells, the length of the cells increased with exposure to asbestos in a
dose dependent manner and the circularity (shape factor) of the cells decreased with
exposure to the higher dose of asbestos alone (Figure 1 E) (* p< 0.05 compared to control).

Asbestos exposure causes changes in epithelial and mesenchymal markers in human
mesothelial cells:
Assessment of the expression levels of epithelial and mesenchymal markers after asbestos
exposure revealed a marked reduction in the expression levels of E-cadherin in both LP9
and HPM3 cells (Figure 2A and 2C respectively). The transcription factors Snail and Slug,
both down-regulators of E-cadherin expression, were upregulated in response to asbestos
exposure in LP9 cells (Figure 2A). The mesenchymal markers, vimentin and N-cadherin
were upregulated in LP9 cells (Figure 2C) while HPM3 only exhibited an increase in
vimentin protein levels (Figures 2A). No significant changes in snail or slug protein levels
were observed in HPM3 cells. IL-6, IL-8, FGF2 and TFPI2 levels were also markedly
elevated in media after 96 h of asbestos exposure as determined by Western blot analysis
of media supernatants pooled from both pulses of asbestos exposure (Figure 2B and D).
Increases in IL-8 and IL-6 levels in HPM3 cells were however not significant after 96 h
(Figure 2B). Beta-actin (Figure 2A) or α-tubulin (Figure 2D) was used as a loading control
for lysate samples. For medium samples, Ponceau stain was used to confirm equal loading
due to unavailability of an appropriate loading control (data not shown). Assessment of
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mRNA levels for E-cadherin (CDH1), N-cadherin (CDH2), IL-8, IL-6, SNAI1 (snail) and
SNAI2 (slug) by qPCR at 48 h and 5 days show that asbestos exposure decreases the
transcript levels of E-cadherin as early as 48 h after exposure (Figure 2E). N-cadherin
(which is constitutively expressed by mesothelial cells) levels were surprisingly decreased
after 48 h as well, and exhibited a decrease in transcript levels over time in moderate but
significant amounts which were not affected by asbestos exposure after 5 days (Figure 2E).
Transcript levels of IL-8 increase initially after 48 h of exposure but decrease over time
with or without asbestos exposure (Figure 2E). IL-6 transcript levels also increase
significantly with asbestos exposure but only after the first 48 h (Figure 2E). While SNAI1
levels decrease with asbestos exposure and with time, asbestos exposure significantly
increased SNAI2 transcript levels at both time points (Figure 2E). Levels of IL-1β and IL18 were also found to be increased in supernatant of HPM3 cells when measured by ELISA
(Figure 2F and 2G). Similar results were obtained from LP9 cells published previously6.

The NLRP3 inflammasome augments asbestos-induced MFT:
In assessing the role of NLRP3 in the asbestos-induced MFT observed, the levels of FGF2,
IL-8, IL-6 and TFPI2 were all found to be decreased in medium in response to asbestos
exposure in siNLRP3 transfected cells when compared to control transfected cells (Figure
3A). The loss of E-cadherin in response to asbestos exposure was not reversed significantly
by inhibition of NLRP3 expression by siRNA. (Figure 3B). Lack of sample material
prevented us from measuring IL-1β and IL-18 in this experiment. These results
demonstrate a partial role of NLRP3 in asbestos-induced MFT. No significant effect on
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morphology change could be demonstrated as that is a long term experiment whereas
transient transfection effects last only for a short duration. The reduction of asbestosinduced NLRP3 activation in LP9 cells after siRNA treatment was confirmed by qRTPCR
and showed a significant decrease in NLRP3 transcript levels (priming) in response to
asbestos exposure after knockdown by siRNA 72 h post transfection (Figure 3C).
We also used four single siNLRP3 constructs [siNLRP3(05-08)] and siNLRP3(06) showed
most remarkable effect on NLRP3 mRNA levels (Figure 3C). Of the 4 constructs, only
siNLRP3(06) had an appreciable effect on attenuation of IL-6 and IL-8 levels. TFPI2 and
FGF2 levels were only slightly decreased in response to asbestos exposure in cells
transfected with siNLRP3(06) (Figure 3D) as compared to controls. The effect with the
pool of 4 siNLRP3 was certainly more remarkable than single siNLRP3, suggesting that
the use of pool of siRNA may be a more effective approach.

IL-1β signaling regulates asbestos-induced MFT:
As asbestos activates the NLRP3 inflammasome with a concomitant release of IL-1β in
human mesothelial cells6, the next step was to demonstrate the role of this cytokine in
asbestos-induced MFT. Pretreatment of HMCs (HPM3 and LP9) with the IL-1 receptor
antagonist, IL-1Ra (150 ng/ml), prior to asbestos exposure resulted in a delay in the
transition of the morphology of HPM3 cells to a more fibroblastic appearance (Figure 4A,
Figure S1A (LP9 cells)). Cells exposed to asbestos were generally more elongated and
narrower in width than control cells (mean shape factor of ~ 0.4 and median length of about
60 microns) , and blocking IL-1R delayed this process at 48 h, as fewer cells were long
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and narrow as determined using the morphometric analysis (Figure 4A). Additionally,
blocking of the IL-1 receptor resulted in a significant decrease in the levels of IL-6, IL-8
and TFPI2 while increasing the levels of FGF2 secreted in response to asbestos exposure
(Figure 4B). Furthermore, pretreatment of cells with IL-1Ra also reduced levels of IL-18
in response to asbestos exposure (Figure 4C). In LP9 cells, pretreatment with IL-1Ra
reduced IL-8 and FGF2 levels noticeably while only slight reductions in IL-6 and TFPI2
were observed (Figure S1B). To further confirm the role of IL-1β signaling in asbestosinduced MFT, HPM3 and LP9 cells were treated with two pulses of recombinant IL-1β
(0.5, 1, 5 or 10 ng/mL). The greatest change in morphology was observed in the group
exposed to 1 ng/mL IL-1β (Figure 4D,S1C and S1D); cells in this group were the most
elongated and least circular (Figure 4D and S1D graphs). The change in morphology
observed with 0.5 ng/mL was no different from that observed with 1 ng but was
inconsistent (not shown). Western blot analysis of media supernatants from cells treated
with 2 doses of IL-1β indicated that treatment with the lower dose of IL-1β (1 ng/mL) led
to activation of caspase-1 as measured by levels of the p20 subunit of active Cas-1 in the
supernatant. Additionally, IL-6 levels were increased by treatment with the lower
concentration of IL-1β, but had a minimal effect on TFPI2 secretion. Unlike asbestos
exposure, treatment with either concentration of IL-1β failed to increase levels of the
danger associated molecule, HMGB1 (Figure 4E). The increase in IL-6, IL-8 and FGF2
induced by IL-1β was attenuated by pretreatment of HPM3 cells with IL-1Ra (150 ng/mL).
However, this concentration of IL-1Ra failed to block the transition of HPM3 cells to a
more fibroblastic phenotype in response to IL-1β (data not shown). IL-1β treatment also
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caused a decrease in E-cadherin and upon pretreatment of cells with a higher dose of IL1Ra (1 μg/mL), a small increase in E-cadherin was observed (Figure 4F). FGF2 and IL-8
levels were drastically reduced by the 1 µg/mL as well (Figure 4F). The expected blockage
of IL-1β-induced MFT was also observed morphologically in LP9 cells pretreated with IL1Ra (Figure S1E and S1F), suggesting that the previous dose was too low to effectively
block all the IL-1 receptors available. Unlike HPM3 cells however, treatment of LP9 cells
with IL-1β caused a slight increase in E-cadherin levels but no change in N-cadherin,
whereas pretreatment with IL-1Ra restored E-cadherin levels and decreased N-cadherin
levels slightly (Figure S1F, lower panel).
Asbestos exposure causes MFT in mice that is dependent on inflammasome activation:
Having made these observations in vitro, in vivo asbestos exposure experiments were
conducted to confirm whether asbestos had the same effect in C57BL/6 mice. Asbestos
exposure caused a significant increase in the thickness of the peritoneal submesothelium
when compared to controls at 8 weeks (Figure 5A). Glass beads (which are non-fibrous
silicates) were used as a negative control. For asbestos exposed samples, five random fields
spanning the thickened sections of the peritoneal walls were imaged. Five random fields of
control samples were also imaged to ensure there was no bias in variation of
submesothelium thickness within and between samples. An increase in total number of
cells infiltrating the peritoneal cavity was observed at early time points in the PLF with a
peak on day 9 (Figure 5B). The neutrophil numbers however, dipped after day 3 and peaked
again on day 28 (Figure 5C). IL-1β and IL-18 levels peaked on day 3 and progressively
declined over the course of the experiment but rose again after 8 weeks (Figure 5D and
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5E). Immunohistochemical analysis of the peritoneal wall cross-sections for the expression
levels of vimentin, alpha smooth muscle actin (αSMA), collagen 1α1 (Col1α1) and
cytokeratin 18 showed increases in expression levels of these proteins after asbestos
exposure (Figure 5F).

Chrysotile asbestos also caused a significant increase in the

thickness of the peritoneal wall, whereas, glass beads (GB) did not cause thickness
increases, but occasional sites of GB surrounded by inflammatory cells were observed
(6A).
Asbestos-induced thickening of the peritoneal wall is caspase-1 dependent:
The peritoneal walls of inflammasome component knock out mice (NLRP3-/-, ASC-/- and
Cas-1-/- respectively) were assessed for asbestos-induced thickening of the submesothelium
after H&E staining as described above. NLRP3-/- mice showed decreased thickening of
their peritoneal walls when compared to their wild type counterparts; however, it was not
significant. On the other hand, Cas-1-/- mice exposed to asbestos had significantly less
thickening in the submesothelium (Figure 6A-6C). Glass beads, which were used as a
particulate negative control did not cause thickening of the sub-mesothelium (Figure 6A).
No significant difference in thickening was observed with ASC-/- mice (data not shown).
No significant changes were observed in total cell counts (Figure 6D), but infiltrating
neutrophil levels (Figure 6E) were lower in Cas-1-/- mice when compared to WT mice
exposed to asbestos. While IL-1β levels in the PLF of Cas-1-/- mice were not significantly
different from that in WT mice (Figure 6F), a significant reduction in IL-18 levels was
observed in Cas-1 -/- after asbestos exposure (Figure 6G). Additionally, the assessment of
FGF2 and TFPI2 by Western blot analysis showed drastic reduction in the levels of these
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two proteins in response to asbestos exposure in the Cas-1 -/- mice (Figure 6H). However,
IL-6 levels were higher in exposed mice as compared to their saline controls but were
inconclusive (Figure 6H).

Discussion
The mechanisms involved in asbestos-induced MM are less understood. Chronic
inflammation is believed to play an important role in the etiology of this deadly disease4,
23

. Recently, we have demonstrated that asbestos can prime and activate the NLRP3

inflammasome in mesothelial cells 6 resulting in the release of pro-inflammatory cytokines,
IL-1β and IL-18. IL-1β has been shown to promote EMT and cancer cell stemness in a
number of cell types8, 9. Cell type specific studies on the importance of the inflammasome
for cancers with an inflammatory signature have indicated that the inflammasome is a key
player in the etiology of these cancers25-28. These studies, combined with our own
observations suggest that the inflammasome may be a key potentiator of asbestos-induced
MFT and MM. We therefore hypothesized that activation of the inflammasome in response
to asbestos exposure facilitates MFT which may be the earliest event in the process of MM
development. Transcript levels of the EMT related genes from PCR Array revealed
changes in expression in mesothelial cells that did not exactly mimic changes produced by
TGFβ, the positive control (Table 1). These results suggested that asbestos-induced MFT
occurred through pathways which may not be directly downstream of TGFβ (like BMP2)
signaling but involved some of the same players. Although asbestos exposure led to a 12fold decrease in Snai1 mRNA levels over a 48 h period in LP9/hTERT cells, increased
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protein levels of Snai1 were observed at later time point in HPM3. These gene changes
were accompanied by changes in morphology of mesothelial cells to a more fibroblastic
type. The differences observed in the gene expression between the two cell types may be
due to the differential susceptibility of the peritoneal and pleural mesothelial cells to
asbestos-induced regulation of genes as observed in a recent NGS study by our group

12

.

For in vivo studies we selected a mouse model of asbestos exposure where inflammation,
fibrosis and MM development have been demonstrated. In vivo studies of asbestos
exposure also showed that asbestos causes a significant increase in the thickness of the
parietal peritoneal sub-mesotheilium which is accompanied by increased collagen
deposition as well as increased vimentin and αSMA expression in the same region.
Additionally, cytokeratin expression is maintained in the mesothelium with and without
asbestos exposure which suggests that the cells in the submesothelium are mesothelial in
origin. A study of the changes observed in the peritoneal wall of continuous ambulatory
peritoneal dialysis (CAPD) patients also revealed similar changes in the submesothelium
29

as were observed in the peritoneal walls of mice exposed to asbestos.

We are the first to report that asbestos exposure upregulates FGF2 and TFPI2 secretion
both in vitro and in vivo, and may play an important role in the transition from mesothelial
to fibroblastic/myofibroblastic phenotype. Support of our findings is derived from other
reports that FGF2 in concert with IL-1β promotes EMT in corneal endothelial cells 9, while
FGF2 alone is capable of inducing EMT in HERS cells during cementum formation in
tooth development

30

. Another report has shown that MCF-7 cells undergoing EMT

upregulate TFPI2 gene expression in excess of 300-fold
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, which corroborates our

findings. TFPI2 inhibits fibrinolysis, an important function of the mesothelium that
prevents adhesion of organs

32

. Fibrin has also been shown to promote EMT in a study

where mesothelial cells in culture were overlaid with fibrin resulting in a fibroblastic
transition of the mesothelial cells

33

. Consequently, over-expression of this protein in

response to asbestos exposure could lead to fibrin deposition thereby facilitating the MFT
observed in our study. Further studies are underway to determine the exact role these
proteins play and the mechanisms they utilize in asbestos-induced MFT. As asbestos
exposure also induces the secretion of IL-1β and IL-18 under both in vitro and in vivo
conditions by activating the NLRP3 inflammasome 6 or by other mechanisms, it is likely
that the phenomenon of MFT observed in response to extended asbestos exposure is due
to IL-1β signaling. This was confirmed by using IL-1Ra prior to asbestos exposure, which
delayed the onset of MFT compared to cells exposed to asbestos alone. However, there
was a greater loss of cells after transitioning into a fibroblastic phenotype in IL-1Ra
pretreated cells suggesting that IL-1β acts as a pro-survival signal caused by asbestos
exposure and may be considered as an early asbestos-exposure biomarker for asbestos
related diseases. Secretion of the pro-inflammatory cytokines, IL-8 and IL-6 (both
implicated in fibrogenesis) in response to asbestos was significantly reduced by the
blockade of the IL-1 receptor suggesting that they are directly or indirectly regulated by
IL-1β signaling. Secretion of TFPI2 was also decreased by blockade of IL-1R and this may
be an indirect response caused by the reduction in IL-6 signaling. IL-6 signaling has been
shown to regulate the expression of TFPI2 34; thus, a decrease in IL-6 levels would explain
the decrease in TFPI2 levels in the presence of IL-1Ra after asbestos exposure. Unlike the
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other cytokines, FGF2, which is secreted in a non-classical secretion pathway dependent
on caspase-1, was upregulated in response to asbestos after pretreatment with IL-1Ra.
Since FGF2 can initiate EMT in CECs as well as HERS cells 9, 30, it may explain why the
mesothelial cells eventually undergo MFT after the delay imposed by the antagonist. It is
a possibility that both FGF2 and IL-1β play pivotal roles in asbestos-induced MFT. In fact,
IL-1β has been shown to induce FGF2 secretion in human mesothelial cells as well as
corneal endothelial cells 35, 36. The dose of IL-Ra used in these experiments can be said to
be the limiting factor as the use of an approximately 7-fold higher concentration (1 μg/mL)
led to a complete blockage of MFT, with a slight reduction in FGF2 secretion (greatest
reduction was observed in the lower molecular weight isoforms). Since cells were only
exposed to IL-1Ra at this dose for 72 h with and without asbestos exposure, further studies
are needed to ascertain the mechanism by which IL-1β initiates/induces MFT in
mesothelial cells. The role of IL-1β in asbestos-induced MFT was further confirmed by
recombinant IL-1β. Low concentration of IL-1β (1ng/mL) caused MFT, whereas high
concentrations were ineffective. This observation and other published reports
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supports

our finding that low concentrations of IL-1β secreted in response to asbestos exposure is
enough to cause MFT, potentially, in association with other molecules.
As IL-1β can be secreted in response to non-canonical inflammasome activation as well as
by other sources including caspase 8 activation

38

, there was a need to confirm that the

asbestos-induced MFT observed was indeed dependent on regulation of the NLRP3
inflammasome. To demonstrate this, NLRP3 was knocked down in LP9/hTERT cells by
siNLRP3. Exposure of these NLRP3 inhibited cells to asbestos resulted in a reduction in
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TFPI2, IL-6 and FGF2 secretion in the culture supernatant as well as a partial rescue of the
loss of E-cadherin expression as compared to control cells exposed to asbestos. NLRP3
and ASC have been reported to promote EMT independently of their inflammasome
functions 10; thus, ASC may play a similar role in our system accounting for the incomplete
rescue of E-cadherin expression in response to asbestos after NLRP3 knock down. Since
these experiments show a partial role of NLRP3 in asbestos-induced MFT, a stably NLRP3
inhibited cell line or recently discovered inhibitors

39, 40

are required to confirm these

effects.
To confirm the role of inflammasomes in MFT in an in vivo model, we used inflammasome
component KO mice. Although ASC and NLRP3 KO mice did not show any significant
difference in asbestos-induced peritoneal wall thickening as compared to their WT counter
parts, caspase-1 KO mice had significantly attenuated submesothelial thickening after 8
weeks of asbestos exposure when compared to their saline counterparts and WT controls.
This implies that caspase-1 is required for asbestos-induced thickening of the parietal
mesothelium. Caspases including caspase-1 have been shown to be involved in
injury/remodeling/fibrosis in various models

41-45

, however, we are first to report the

involvement of caspase-1 in asbestos-induced MFT. Caspase-1 deficiency caused
diminished levels of asbestos-induced IL-18 in the PLF, however, IL-1β levels were not
affected. As IL-1β can be derived from sources 46 other than the inflammasome, it is not a
surprising observation. In addition, IL-1β regulates its own function by regulating IL-1Ra
levels. Our microarray data show that asbestos inhalation results in 4-fold increased IL1Ra mRNA levels in lungs at 9 days (unpublished data). The initial increase, followed by
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decline and then recovery of IL-1β levels in our in vivo model could be explained by the
regulation of IL-1β by IL-1Ra. To understand the role of IL-1β in MFT, currently we are
using Anakinra and a specific NLRP3 inhibitor and plan to use IL-1R KO mice in the
future. Furthermore, assessment of IL-1Ra and IL-1R expression is also underway as both
of these can play important roles in IL-1β biology. NLRP3 inflammasome has also been
shown to be involved in the process of fibrosis in various models

47-50

. In support of our

observations, a Finnish study has recently identified a polymorphism in NLRP3 with
increased risk of asbestos-related interstitial lung fibrosis and a CARD8 polymorphism
associated with development or calcification of pleural thickening

51

. These SNPs have

been linked to enhanced IL-1β production and severe inflammation. No significant effect
seen in our NLRP3 KO model could be attributed to global knockdown of NLRP3 gene.
As has been reported earlier

52, 53

, NLRP3/ASC deletion from different cell types could

have different consequences. To pinpoint the role of mesothelial cell NLRP3/ASC in
asbestos-induced MFT, mesothelial cell specific targeted knockdown is required.
Taken together our data suggests that asbestos-induced MFT in mesothelial cells is
regulated in part by the inflammasome via IL-1β/IL-18 in conjunction with TFPI2 and
FGF2. Further studies are needed to dissect the roles played by the different proteins
involved and this will help provide a basis for determining the mechanism and identifying
biomarkers by which asbestos promotes cell survival that can lead to the development of
malignancies like MM.
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Table 3-1
EMT related gene expression changes in mesothelial cells in response to asbestos
exposure. LP9 and HPM3 cells were exposed to asbestos (5 μg/cm2) for the indicated
times and whole RNA extracted from these cells was analyzed for gene expression levels
of EMT pathway proteins in an EMT PCR array. TGFβ (10 ng/ml) was used as a
positive control.

Gene ID
BMP2
CDH1
COL1A2
COL3A1
F11R
GNG11
KRT19
KRT7
MST1R
NODAL
PDGFRB
SNAI1
SPARC
STEAP1
TFPI2
TGFB2

LP9 (24h)
3.765
-6.6193
-4.3086
-2.2648
-2.3134
3.842
-7.8025
-3.121
-2.6243
2.916
-6.3478
-4.2379
-2.888
1.6883
52.4955
-2.1052

LP9 (48h)
3.6387
-5.5775
-4.8255
-3.5446
-3.9013
4.4137
-7.2188
-5.5928
-4.0842
-1.4034
-5.982
-12.1875
-4.2795
2.4375
51.2382
-2.2664

HPM3 (48h)
3.7264
-12.3847
-6.3425
-7.5456
-1.9703
2.6357
-11.0012
-2.9612
-4.2371
3.2188
-2.6859
-1.3492
-6.402
2.3314
13.0143
3.1156
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HPM3 (1wk)
4.3582
1.5624
-2.7621
-1.415
-2.1186
3.1512
-1.7105
-1.7818
-2.7908
6.2224
-1.8618
2.147
-3.1342
3.5186
10.8795
1.5631

TGFβ
-1.3692
-2.3526
6.0221
1.1224
-1.1799
1.9597
-13.8892
-3.3246
-8.288
1.6575
1.4718
3.1556
1.8388
-1.3104
4.1882
1.6297

Figures
Figure 3.1: Asbestos exposure induces a morphological change in human mesothelial cells. A.
Schematic representation of asbestos exposure schedule for induction MFT. B. Exposure of LP9,
HM3 (peritoneal) and HPM3 (pleural) cells to asbestos [1 (peritoneal cells) (15x10-6 µm2/cm2 (Asb
15)) and 5 μg/cm2 (75x10-6 µm2/cm2 (Asb 75)) (pleural cells)] for 2 and 1 week respectively resulted
in morphological changes to the cells over the duration of exposure. C. Fibroblastic looking LP9
cells from B were grown on soft agar to determine whether the cells were transformed and capable
of forming colonies. All micrographs imaged on Olympus IX70 inverted microscope (scale bar =
50 µm). D and E. Quantitative depiction of changes in morphology of LP9 (D) and HPM3 (E) cells
as determined using the MetaMorph image analysis software. The integrated morphology and
regional measurement tools were used to determine the shape factor (circularity) and longest axis
(length) of cells respectively (* p < 0.05 compared to control).
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Figure 3.2: Asbestos alters markers of a mesothelial to fibroblastic transition in HMCs. A.
Western blot analysis performed on cell lysates from HPM3 exposed to asbestos one week after
the first dose (Asb 75 (5 µg/cm2 asbestos)). B. Western blot analysis of pooled culture supernatants
from HPM3 cells in A. 96 h after the first asbestos pulse (48 h after second pulse). C. Western blot
of LP9 cell lysates two weeks after the first asbestos pulse (Asb 15 (1 µg/cm2)). D. Western blot
analysis of pooled culture supernatants from LP9 cells in C. 96 h after the first asbestos pulse. E.
Fold change of CDH1 (E-cadherin), CDH2 (N-cadherin), IL-8, IL-6, SNAI1 (Snail) and SNAI2
(Slug) transcripts in HPM3 cells exposed to asbestos (5 µg/cm2) for 48 h or 5 days (5d) as
determined by qRTPCR (*p < 0.05 compared to 48 h control; † p < 0.05 compared to 48 h asbestos
exposure; ‡ p < 0.05 compared to 5 d control). F. IL-1β and G. IL-18 cytokine levels in pooled
culture supernatants from A 48 h after first asbestos pulse (* p< 0.05 as compared to control).
(Control = 0)
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Figure 3.3: Asbestos-induced MFT is partially dependent on NLRP3. A. Western blot analysis
of culture supernatants from siNLRP3 (and scrambled controls) transfected LP9 cells 48 h after
asbestos exposure (5 µg/cm2). B. Western blot analysis of E-cadherin levels 10 days after asbestos
exposure. α-Tubulin was used as a loading control. C. NLRP3 transcript level fold changes 72 h
after transfection of LP9 cells with scrambled control (siControl) or a pool of siNRLP3 constructs.
D&E. NLRP3 transcript level fold change after transfection of LP9 cells with individual siNLRP3
constructs (05-08). Transfected cells were exposed to 5 µg/cm2 asbestos (for 48 h) prior to RNA
extraction (* p < 0.05 compared to control; †p<0.05 as compared to siControl-Asb). F. Western
blot analysis of culture supernatant from LP9 cells transfected with siNLRP3(06) and scrambled
control 48 h after asbestos exposure.
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Figure 3.4: IL-1β signaling regulates asbestos-induced MFT. A. Phase contrast micrograph of
HPM3 cells pretreated with 150 ng/mL IL-1Ra 1 h prior to asbestos exposure. Images were
obtained at 20X, 48 h after initial asbestos pulse (scale bar = 50 µm); changes in morphology were
also quantified using MetaMorph image analysis software as described in Figure 1 (* p < 0.05
compared to control; † p < 0.05 compared to asbestos alone). B. Western blot analysis of cytokines
(FGF2, IL-6 and IL-8) and TFPI2 levels in pooled culture supernatants 96 h after initial asbestos
pulse and densitometric analysis of blots (* p< 0.05 compared to control; † p < 0.05 compared to
asbestos alone). C. IL-18 levels measured by ELISA 96 h after first asbestos pulse with and without
IL-1ra. D. Phase contrast micrographs of dose dependent MFT in HPM3 cells exposed to IL-1β at
indicated concentrations (imaged at 20X on Olympus IX70 inverted microscope, scale bar = 50
µm) and morphometric analysis using the MetaMorph image analysis software as described in
Figure 1 (* p <0.05 compared to control). E. Western blot analysis of TFPI2, IL-6, Caspase-1 and
HMGB1 levels 96 h after HPM3 cells were treated with 1 or 5 ng/mL IL-1β. F. Western blot
analysis of FGF2 and IL-8 levels in concentrated media supernatant, and immunoblots of Ecadherin and N-cadherin expression in cell lysates from HPM3 cells pretreated with 150 ng/ml or
1µg/ml IL-1Ra with and without IL-1β (1 ng/ml) treatment (β-actin was used as a loading control
for cell lysates).
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Figure 3.5: Asbestos exposure induces mesothelial to fibroblastic transition in the parietal
peritoneal mesothelium in vivo. A. Wild type C57/BL6 mice were exposed to 500 μL of 200
μg/mL asbestos in saline or saline alone for 3, 7, 14, 28 or 56 days (8 weeks). Cross sections of
peritoneal walls were stained by hematoxylin and eosin (H&E) for histological analysis of the
submesothelial layer. Peritoneal wall sections were imaged on the Olympus BX50 inverted
microscope at a magnification of 20X (Scale bar = 50 μm). Single cell layer of parietal mesothelium
(arrow), thickened peritoneal wall after asbestos exposure (double headed arrow). B. Total and C.
Differential cell counts in PLF showing the relative proportions of immune cells infiltrating the
peritoneal cavity in response to asbestos exposure at 3, 9, and 14 days, 4 and 8 wks. D. IL-1β and
E. IL-18 levels in the PLF of asbestos exposed mice over the course of time as measured by ELISA.
Cytokine levels reported as pg/mL of PLF collected. (* p ≤0.05 compared to saline controls). F.
Peritoneal wall sections from animals exposed to asbestos for 8 weeks were immuno-fluorescently
stained to ascertain levels of cytokeratin (green), vimentin, collagen (Col1α1) (red) and alpha
smooth muscle actin (αSMA) after asbestos exposure [nuclei were stained with DAPI (blue)].
Smaller panels to the right are individual fluorescent channels. Sections were imaged on the Zeiss
LSM 510 META confocal laser scanning microscope at a magnification of 100X (scale bar = 50
µm).
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Figure 3.6: Caspase-1 is important for asbestos-induced mesothelium thickening in mice. A.
Micrographs of peritoneal wall sections from C57/BL6 wild type and NLRP3-/- and Cas-1-/- mice
after 8 weeks of asbestos exposure (100 µg weekly) stained with hematoxylin and eosin for
histological analysis. Glass beads (GB) at an equal surface area (538 µg weekly) were used as a
negative control for particulate exposure. Single cell layer of parietal mesothelium (arrow),
thickened peritoneal wall after asbestos exposure (double headed arrow). Images were obtained on
Olympus BX50 as indicated above (scale bar = 50 µm). B. and C. Graphical representation of
peritoneal wall thickness in asbestos exposed versus saline controls for wild type and knockout
(NLRP3-/- and Cas-1-/-) mice. (* p ≤0.05 compared to saline controls, † p ≤0.05 compared to wild
type asbestos). D. Total cell counts per mL of PLF retrieved from wild type, NLRP3-/- and Cas-1-/saline and asbestos exposed mice. E. Differential cell counts of cells in PLF of Cas-1-/- and wild
type mice after 8 weeks of asbestos exposure. (* p ≤0.05 compared to saline controls, † p ≤0.05
compared to wildtype asbestos). F. IL-1β and G. IL-18 levels in PLF of wild type and Cas-1-/- mice
as measured by ELISA. (* p ≤0.05 compared to saline controls, † p ≤0.05 compared to wild type
asbestos). H. Western blot analysis of TFPI2, FGF2 and IL-6 in saline and asbestos exposed Cas-1
-/-mice.
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Figure 3.S 1: Regulation of asbestos-induced MFT by IL-1β signaling in LP9 cells. A. Phase
contrast micrograph of LP9 cells pretreated with 1 µg/mL IL-1Ra 1 h prior to asbestos exposure (1
µg/cm2). Images were obtained at 20X, 9 days after initial asbestos pulse (scale bar = 50 µm). B.
(top) changes in morphology were also quantified using MetaMorph image analysis software as
described in Figure 1 (* p < 0.05 compared to control; † p < 0.05 compared to asbestos alone);
(bottom) Western blot analysis of TFPI2, IL-6, FGF2 and IL-8 in concentrated culture supernatant
96 h after asbestos exposure (48 h after 2nd pulse). C. Phase contrast micrographs of dose dependent
MFT in LP9 cells exposed to IL-1β at indicated concentrations (imaged at 20X on Olympus IX70
inverted microscope, scale bar = 50 µm). D. Morphometric analysis using the MetaMorph image
analysis software as described in Figure 1 (* p <0.05 compared to control). E. Phase contrast
micrographs of LP9 cells on day 7 pretreated with two pulses of 1 µg/mL IL-1Ra 1 h prior to each
treatment with IL-1β (1 ng/ml). F. (top) Morphometric analysis using the MetaMorph image
analysis software as described in Figure 1 (* p <0.05 compared to control); (bottom) immunoblots
of E-cadherin and N-cadherin expression in cell lysates from LP9 cells pretreated with 1µg/ml IL1Ra with and without IL-1β (1 ng/ml) treatment (β-actin was used as a loading control for cell
lysates).
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Supplemental Tables
Table S3 1: Supplementary Table 1: HPM3 Up-Down Regulation (comparing to control
group). EMT PCR Array showing changes in epithelial and mesenchymal gene transcript levels
in response to asbestos exposure at the indicated time points.
Gene Symbol Asbestos 48 h
Control 1 week
Asbestos 1 week
AHNAK
AKT1
BMP1
BMP2
BMP7
CALD1
CAMK2N1
CAV2
CDH1
CDH2
COL1A2
COL3A1
COL5A2
CTNNB1
DSC2
DSP
EGFR
ERBB3
ESR1
F11R
FGFBP1
FN1
FOXC2
FZD7
GNG11
GSC
GSK3B
IGFBP4
IL1RN
ILK
ITGA5
ITGAV
ITGB1
JAG1
KRT14
KRT19
KRT7
MAP1B
MMP2
MMP3

1.5792
1.0624
-1.6117
3.7264
-1.0635
-1.3216
2.4273
-1.1282
-12.3847
1.2953
-6.3425
-7.5456
-1.856
1.1627
-1.2754
1.3114
1.4506
-2.2666
1.7174
-1.9703
-3.3992
1.5069
1.4026
-1.3295
2.6357
-1.0635
1.6402
-1.3322
-1.0635
1.1208
1.3369
-1.0283
-1.5339
2.2522
1.5939
-11.0012
-2.9612
-1.3576
-1.0059
1.0699

1.0132
-1.2511
-1.12
1.5373
-1.0279
1.3617
-1
-1.0972
5.7653
-1.1278
2.0146
1.1109
-1.0525
-1.1365
1.8084
2.1798
1.0717
-1.0798
2.1959
-1.2619
-2.3197
-1.8364
-1.6568
1.5607
-1.4636
-1.0279
1.2334
-1.1695
1.1799
1.0401
-1.0353
1.0364
-1.5047
1.3536
1.0912
-1.2177
-1.3399
-1.1685
1.4789
-1.0279
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1.3926
1.0568
-1.8291
4.3582
-1.09
-1.0053
1.5624
1.2291
-2.7621
1.167
-1.415
-5.0961
-1.6874
1.2778
-1.5851
-1.7285
-1.1281
-4.1619
2.0227
-2.1186
-3.0557
1.2277
2.4985
-1.2541
3.1512
-1.09
1.1082
1.07
-1.09
-1.0137
1.6001
-1.0322
-1.4487
1.3233
1.9662
-1.7105
-1.7818
1.0577
-1.7502
1.4705

MMP9
MSN
MST1R
NODAL
NOTCH1
NUDT13
OCLN
PDGFRB
PLEK2
PPPDE2
PTK2
PTP4A1
RAC1
RGS2
SERPINE1
SIP1
SMAD2
SNAI1
SNAI2
SNAI3
SOX10
SPARC
SPP1
STAT3
STEAP1
TCF3
TCF4
TFPI2
TGFB1
TGFB2
TGFB3
TIMP1
TMEFF1
TMEM132A
TSPAN13
TWIST1
VCAN
VIM
VPS13A
WNT11
WNT5A
WNT5B
ZEB1
ZEB2
ACTB
B2M

-1.0522
1.382
-4.2371
3.2188
1.0345
1.1392
-1.1743
-2.6859
-1.298
1.2698
1.2451
1.8772
1.2452
3.1374
3.0997
1.3777
1.2976
-1.3492
1.9274
-1.9488
1.0262
-6.402
3.5223
1.0186
2.3314
1.7196
1.2603
13.0143
1.0335
3.1156
-5.2243
1.5955
-1.1269
-2.1067
-1.3839
1.4826
3.8325
1.3418
-1.1293
1.1955
-1.2688
-1.0243
1.1674
1.5983
-2.0322
-1.2127

-1.0279
1.1578
1.3598
2.1623
-1.4809
-1.3118
1.2795
-1.3118
-1.5209
-1.3331
1.1926
1.3644
1.0557
1.3999
-1.117
-1.0826
-1.1437
-1.1151
1.0146
-1.1838
-1.0939
1.0251
2.4378
1.2058
1.4721
1.1663
1.2199
-1.4212
-1.2209
-1.1308
1.271
-1.523
1.1634
-1.0577
1.1379
1.1296
1.143
1.5525
1.4439
1.4304
-1.2563
1.4264
-1.1896
-1.29
-1.2044
1.011
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-1.09
1.5725
-2.7908
6.2224
-1.1599
1.445
-1.6622
-1.8618
-1.9483
1.334
1.084
1.5303
1.0652
2.3974
2.7995
1.0584
-1.0305
2.147
1.1812
-1.3848
1.4733
-3.1342
4.2056
-1.2245
3.5186
1.1024
1.1914
10.8795
1.003
1.5631
-4.6528
1.955
-1.3052
-3.3933
1.0424
1.3555
4.7097
1.8283
1.1343
1.4199
1.0331
1.2817
1.3607
1.0463
-1.3493
-1.8523

GAPDH
HPRT1
RPLP0
HGDC
RTC
RTC
RTC
PPC
PPC
PPC

1.2384
1.3576
1.4662
-1.0635
-1.2568
-1.215
-1.5071
-1.3561
-1.2333
-1.188

-1.0255
1.1446
-1.0726
-1.0279
1.0414
1.0112
-1.2591
-1.2543
-1.1293
-1.2576

2.0503
1.7733
1.5403
-1.09
1.3972
1.292
1.0636
-1.3495
-1.244
-1.1863

Table S3 2: Supplementary Table 2: LP9 Up-Down Regulation (comparing to control
group). EMT PCR Array showing changes in epithelial and mesenchymal gene transcript levels
in response to asbestos exposure at the indicated time points.
TGFβ
GeneSymbol
Asbestos 24 h
Control 48 h
Asbestos 48 h
AHNAK
AKT1
BMP1
BMP2
BMP7
CALD1
CAMK2N1
CAV2
CDH1
CDH2
COL1A2
COL3A1
COL5A2
CTNNB1
DSC2
DSP
EGFR
ERBB3
ESR1
F11R
FGFBP1
FN1
FOXC2
FZD7
GNG11
GSC
GSK3B
IGFBP4

1.412
1.0571
-1.3557
3.765
1.2948
-3.2483
1.8551
1.0156
-6.6193
-1.5621
-4.3086
-2.2648
-1.6882
1.1409
-1.4808
1.2973
1.8205
1.0801
2.8133
-2.3134
-1.2347
-1.7323
1.528
-1.3662
3.842
1.0427
-1.1654
1.5353

-1.1431
-1.2555
-1.0045
-1.251
1.0283
1.193
-1.2446
-1.3133
1.1599
-1.1625
1.0861
1.0705
-1.1137
-1.1617
-1.2077
1.04
-1.1691
1.0616
3.3194
-1.0611
-1.8485
1.1357
-1.4986
1.0976
-1.0795
1.0283
1.1173
-1.2743

146

1.0302
-1.1862
-2.0368
3.6387
-1.0992
-3.5801
1.8534
-1.1017
-5.5775
-2.7896
-4.8255
-3.5446
-2.1739
-1.2253
-2.7121
1.7848
1.1592
-1.8804
3.5933
-3.9013
1.6232
-1.5942
1.2792
-1.8204
4.4137
-1.0992
-1.4549
1.44

-1.0782
1.0374
1.7251
-1.3692
1.0679
-1.0772
-1.2037
-1.1491
-2.3526
1.8825
6.0221
1.1224
1.4059
1.0228
-1.2013
2.1121
-1.1622
-4.0811
3.7041
-1.1799
-3.1715
4.065
1.8721
-1.3546
1.9597
1.0679
-1.067
-1.3229

IL1RN
ILK
ITGA5
ITGAV
ITGB1
JAG1
KRT14
KRT19
KRT7
MAP1B
MMP2
MMP3
MMP9
MSN
MST1R
NODAL
NOTCH1
NUDT13
OCLN
PDGFRB
PLEK2
PPPDE2
PTK2
PTP4A1
RAC1
RGS2
SERPINE1
SIP1
SMAD2
SNAI1
SNAI2
SNAI3
SOX10
SPARC
SPP1
STAT3
STEAP1
TCF3
TCF4
TFPI2
TGFB1
TGFB2
TGFB3
TIMP1
TMEFF1
TMEM132A

1.6471
-1.3073
1.0516
-1.7505
-1.1982
1.8205
1.3607
-7.8025
-3.121
1.1177
-1.8321
4.2878
1.1912
-1.1326
-2.6243
2.916
-1.072
1.0175
1.6554
-6.3478
2.81
1.1455
1.014
2.3209
1.1061
2.7271
1.6015
1.2045
1.3662
-4.2379
2.0924
-2.5851
1.5011
-2.888
1.9207
-1.279
1.6883
1.2018
-1.5009
52.4955
1.1249
-2.1052
-1.6938
36.1243
1.3669
1.0985

1.0283
-1.1002
-1.0669
-1.1326
-1.0222
1.2691
2.4327
-1.374
-1.708
1.0898
1.2051
1.2777
1.0283
-1.0219
-1.5062
-1.0869
1.0421
-1.084
1.1171
1.1841
-1.714
-1.0005
-1.2169
1.0404
-1.1616
-1.099
-1.5197
-1.0089
-1.1158
1.048
1.2
1.4717
-1.2409
1.0561
1.5386
1.1537
-1.0822
-1.1182
1.1335
-1.3626
-1.2205
-1.1589
1.2194
19.1314
1.0204
-1.3936
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1.9763
-1.5853
-1.0028
-2.7578
-1.5358
1.0372
2.9076
-7.2188
-5.5928
-1.413
-2.4643
4.4816
-1.0992
-1.1102
-4.0842
-1.4034
-1.5011
-1.1328
-1.4503
-5.982
2.3003
-1.1121
-1.5792
1.294
-1.1934
1.7296
1.7627
-1.3726
-1.1219
-12.1875
2.0274
-1.6555
-1.1834
-4.2795
-1.0112
-1.624
2.4375
-1.2633
-1.2522
51.2382
-1.1655
-2.2664
-1.7508
64.8636
-1.5051
-1.6818

1.0679
-1.0848
2.8733
1.7883
1.1725
1.6461
3.2998
-13.8892
-3.3246
1.1865
1.8809
11.1963
1.0679
1.2978
-8.288
1.6575
-1.5346
-1.142
-1.5645
1.4718
2.1136
1.0909
-1.167
1.2631
-1.1277
1.4981
2.322
-6.8141
-1.153
3.1556
1.7828
1.4634
-1.0269
1.8388
6.4474
-1.0473
-1.3104
-1.0994
1.7189
4.1882
1.9178
1.6297
1.0311
75.3638
-1.0997
1.0211

TSPAN13
TWIST1
VCAN
VIM
VPS13A
WNT11
WNT5A
WNT5B
ZEB1
ZEB2
ACTB
B2M
GAPDH
HPRT1
RPLP0
HGDC
RTC
RTC
RTC
PPC
PPC
PPC

-1.6774
1.4506
1.5508
1.2573
-1.1681
1.5422
2.2184
1.3825
1.2768
1.8423
-1.7516
1.3732
1.0182
1.2338
1.0154
1.0427
1.0964
1.0064
1.0634
1.0279
1.0541
1.0759

-1.3458
1.1641
1.1248
-1.1142
1.0955
1.7348
-1.5289
1.0354
1.2007
-1.0668
1.0211
1.1931
-1.346
1.0256
1.0773
1.0283
1.1341
1.0385
1.2117
-1.0312
1.1202
1.0353
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-1.8577
1.2522
1.2662
1.1711
-1.7278
3.1581
2.5263
1.6819
-1.0134
1.0903
-1.317
-1.0173
1.035
1.3652
-1.0547
-1.0992
1.0469
-1.1128
-1.1182
-1.1185
-1.1327
-1.0811

2.5372
1.1122
28.942
1.0778
-1.0446
6.7123
-1.0319
2.4091
-1.0749
-1.0106
1.003
1.0823
-1.06
-1.0404
1.016
1.0679
1.318
1.1225
1.2977
1.031
1.0184
-1.0255

CHAPTER FOUR: INVESTIGATING THE ROLE OF IL-1 RECEPTOR
ANTAGONIST AND INFLAMMASOME INHIBITOR (CRID3) IN ASBESTOSINDUCED MFT IN VIVO AND POTENTIAL ROLES FOR TFPI2 AND FGF2 IN
VITRO

Introduction
The inflammasome has been implicated in the development and progression of
epithelial to mesenchymal transition (EMT/MFT) and fibrosis either through signaling by
the components or the products of the inflammasome (NLRP3, ASC and mature IL-1β)
(Ludwig-Portugall et al., 2016, Perez et al., 2016, Lee et al., 2012) (Thompson et al. Am J
Pathol, in press). The NLRP3 protein has been shown to augment TGFβ signaling
independent of its inflammasome function in tubular epithelial cells (Wang et al., 2013).
In colitis-associated colon cancer, NLRP3 protein levels were observed to be high in cells
with a mesenchymal phenotype which was reversed by knockdown of NLRP3 expression
(Wang et al., 2016). This knockdown also corresponded to downregulation of the EMT
associated transcription factor Snail levels and was independent of inflammasome
activation (Wang et al., 2016). In corneal endothelial cells, IL-1β has been shown to induce
EMT via FGF2 signaling as result of corneal injury (Lee et al., 2012). Under inflammatory
conditions, IL-1β was shown to act synergistically with TGFβ2 to induce endothelial to
mesenchymal transition in human umbilical vein endothelial cells (HUVECs) and cardiac
endothelial cells (Maleszewska et al., 2013). In both cell types, endothelial markers were
lost and an increase in vimentin and other mesenchymal markers was reported over time
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(Maleszewska et al., 2013). In another study adenoviral mediated transient expression of
IL-1β in the lungs of experimental animals resulted in long term tissue repair and the
development of pulmonary fibrosis even after the IL-1β had ended (Kolb et al., 2001).
Inflammation plays an important role in the development and progression of
several cancers and the inflammasome has been shown to either promote or curtail
tumorigenesis depending on the cell type in which it is activated (Zitvogel et al., 2012,
Yazdi

and

Drexler,

2015,

Pertilli,

2017).

In

mesothelioma,

chronic

inflammation/inflammasome modulation is believed to play a pivotal role in the
development and progression as well as chemoresistance of the disease (Westbom et al.,
2014, Westbom et al., 2015, Mossman et al., 2013, Hillegass et al., 2010). Asbestos has
been shown to activate the inflammasome in a protracted manner, thus chronic activation
of the inflammasome by biopersistent asbestos fibers can potentially promote the
development of mesothelioma (Hillegass et al., 2013). The mechanism(s) by which
asbestos causes MM is currently unknown and the fact that products and/or components of
the inflammasome are capable of inducing or augmenting EMT provides a plausible
mechanism by which asbestos exposure would provide the right environment for the
development of this deadly disease. A recent study has shown that the inflammasome and
IL-1β signaling are important for MM initiation and progression (Kadariya et al., 2016).
Other studies exploring modulation of inflammasome activation as a target for drug
develop and to aid in investigating the regulation of the inflammasome in cancer and
inflammatory diseases have developed and/or tested a number of small molecule inhibitors
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and naturally occurring metabolites as inhibitors of the inflammasome (Coll et al., 2015,
Ludwig-Portugall et al., 2016, Misawa et al., 2015, Qiu et al., 2016).
In Chapter 3 we show that the inflammasome plays a role in asbestos induced
mesothelial to fibroblastic transition with a potential role for TFPI2 and FGF2. To
investigate the role of the inflammasome in the MFT process and how TFPI2 and FGF2
facilitated this process we turned to our in vitro and in vivo models of asbestos-induced
MFT. We hypothesized that modulation of inflammasome activation or IL-1β signaling in
vivo would ameliorate asbestos induced thickening of the parietal mesothelium in vivo. We
also hypothesized that manipulating TFPI2 levels using an siRNA approach or inhibiting
FGF2 signaling by blocking all the FGF receptors would attenuate asbestos-induced MFT
in vitro. To this end we investigated the effect of inhibiting the inflammasome using the
small molecule NLRP3 inflammasome inhibitor, MCC950/CRID3 (Primiano et al., 2016)
as well as recombinant IL-1Ra to block IL-1β signaling in vivo prior to asbestos exposure.
In vitro, we either pretreated primary mesothelial cells with the pan FGFR small molecule
inhibitor BGJ8-98 or we knocked down TFPI2 expression with a pool of siRNA constructs
against TFPI2 prior to asbestos exposure to investigate the role of FGF2 and TFPI2 in
asbestos-induced MFT. While we did not observe any significant effects on asbestosinduced sub-mesothelium thickening in vivo, preliminary data obtained from our in vitro
studies indicate that FGF2 signaling and TFPI2 play important roles in asbestos-induced
MFT and warrant further studies to elucidate their exact role to determine whether targeting
these two pathways would be an effective mode of therapy for MM treatment or biomarkers
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for assessing therapy effectiveness or disease progression or even as serum markers for
early detection of MM.
Materials and Methods
Experimental Animals
Age (8 weeks old) and sex matched C57BL/6 mice were purchased from Charles
River Laboratory and housed in microisolators with ad libitum access to food and water.
Animals were handled in accordance with the institutional animal care and use committee
(IACUC) guidelines (#12-004) of the University of Vermont. Animals received either 50
µL, MCC950/CRID3 (TOCRIS Bioscience (Bio-Techne), Minneapolis, MN) (50 mg/kg)
(Coll et al., 2015), Anakinra® (IL-1Ra) (Kineret®, SOBI Inc. Waltham, MA) or sterile
saline intraperitoneally 24 hr prior to the start of the experiment. Animals were then
randomly grouped (6 animals per group) to receive asbestos (500 µL of crocidolite asbestos
200 µg/mL in sterile saline) or sterile saline the following day. All animals in the respective
groups received 50 uL CRID3, Anakinra or saline 1x daily, five times a week not including
the day of asbestos injections for 8 weeks. Asbestos was administered once a week for 8
weeks. Mice were euthanized with an overdose of Beuthansia drug at the end of the
experiment and peritoneal lavage fluid (PLF), diaphragms (peritoneal side up) and
peritoneal walls (mesothelial side up) were collected for analysis of inflammatory cell
infiltration/cytokine analysis and sub-mesothelium thickening respectively. Peritoneal
walls and diaphragms were fixed in 4% paraformaldehyde and embedded in paraffin before
sectioning.
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Asbestos fibers
Prior to injections, NIEHS crocidolite fibers were sterilized overnight by UV
irradiation and suspended in sterile saline to yield a 200 µg/mL suspension. Asbestos fibers
were then sonicated for 15 minutes in a water bath sonicator and triturated 10 times through
a 22 gauge needle to obtain a homogenized suspension. Fiber suspension was vortexed
between injections to maintain homogeneity of suspension. Each animal received either
500 µL of sterile saline or asbestos on day 0 of the experiment and once weekly thereafter
for the duration of the study. For in vitro experiments, a 1 mg/mL suspension of UV
irradiated crocidolite was prepared as previously described (Hillegass et al., 2013) and cells
were exposed to 1 µg/cm2 asbestos per surface per area of the culture dish.
Analysis of PLF
PLF was collected from each animal immediately after euthanasia and processed
for total number of infiltrating inflammatory cells and cytokines as previously described
(Hillegass et al., 2010). Cytokine levels were assessed in concentrated PLF samples by
ELISA (IL-1β and IL-18) as previously described (Westbom et al., 2015).
Cell Culture
Primary human pleural mesothelial (HPM3) and immortalized human peritoneal
mesothelial cells [LP9/hTERT (LP9)] were cultured at 37°C, 0.5 % CO2 in a humidified
incubator as previously described (Hillegass et al., 2013). Cells were grown to 90%
confluency before being subjected to overnight serum starvation (Medium+ 0.5% serum
and appropriate supplements) prior to treatment.
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siRNA Transfections
To investigate the role of TFPI2 in asbestos-induced MFT, 90% confluent LP9
cells were transfected with either a pool of 4 siTFPI2 constructs (siTFPI2), On-Target
Smart Pool© siTFPI2, [ThermoScientific (Life Technologies), Grand Island, NY] or
scrambled siRNA constructs (siControl) [ThermoScientific (Life Technologies), Grand
Island, NY] following the manufacturer’s protocol. Lipofectamine 2000® [ThermoFisher
Scientific (Invitrogen), Carlsbad, CA] was used as the transfection agent.
Quantitative Real-Time PCR
To assess mRNA transcript level changes in genes related to inflammasome
activation as well as TFPI2 transcript levels in response to siRNA mediated gene
knockdown and asbestos exposure, cells were lysed for RNA extraction using the RNeasy
Plus kit (Qiagen, Valencia, CA) as per the manufacturer’s instructions. One microgram of
RNA was used for synthesis of cDNA following the manufacturer’s protocol for the
Promega RT-PCR kit (Promega, Madison, WI). Samples were then submitted for
quantitative real-time PCR (qPCR) to ascertain fold changes in mRNA transcript levels for
IL-1B, NLRP3, PYCARD, E-cadherin, SNAI1 and TFPI2.
Western Blot Analysis
Western blot analyses were conducted on the culture supernatants to determine
the effects of TFPI2 knockdown and FGF2 inhibition on the asbestos-induced upregulation
of the secretion of IL-6, IL-8, TFPI2, FGF2 as well as inflammasome activation (indirectly
through the secretion of the p20 subunit of caspase-1 into the culture medium) as well as
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levels of the DAMP, HMGB1 which is secreted into the culture medium in response to
asbestos exposure and inflammasome activation.
Equal volumes of culture supernatant were first concentrated using StrataClean®
resin beads (Agilent Technologies, Santa Clara, CA) as previously described (Westbom et
al., 2015). Equal volumes (10 µL) of the concentrated supernatant were then loaded onto
15% SDS PAGE gels to resolve constituent proteins after which proteins were transferred
onto a nitrocellulose membrane and immunoblotted with the appropriate primary and
secondary antibodies [IL-6, IL-8, FGF2, TFPI2 and HMGB1; rabbit polyclonal antibodies
from (Abcam, Cambridge, MA) and caspase-1 (Cell Signaling Technology, Danvers, MA)
used at 1:500 dilution; secondary antibody – goat anti rabbit conjugated to hydrogen
peroxidase (1:5000), (Jackson ImmunoResearch Laboratories Inc. West Grove, PA)].
Quantitation of Submesothelium Thickening
Cross-sections of the peritoneal walls of mice exposed to asbestos with and
without treatment with CRDI3 or Anakinra and their respective controls were stained with
hematoxylin and eosin to enable histological assessment of changes to thickness of the
submesothelium. Five images spanning the length of each section were captured with a
Retiga Magnafire camera on a BX50 Olympus light microscope (Olympus America Inc.,
Center Valley, PA) utilizing the 20X objective. Images were then imported into
MetaMorph Image Analysis Software to measure the thickness of the submesothelium as
previously described (Thompson et al. Am J Pathol, in press).
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ELISAs for IL-1β and IL-18
Culture supernatants and PLF samples were concentrated using the Amicon
centrifugal filtration units (10K molecular weight limit) (Millipore, Billerica, MA) as
previously described (Westbom et al., 2015). Levels of IL-18 and IL-1β were measured
using IL-18 ELISA kits (MBL, Woburn, MA) and Quantikine IL-1β/IL-1f2 Immunoassay
(R&D Systems, Minneapolis, MN) respectively as per the manufacturer’s instructions.
Human and mouse kits for the two cytokines were used for the culture supernatant and PLF
samples respectively. Cytokine levels are reported as pg IL-1β/IL-18 per mL of starting
material.
Results
Effects of modulating inflammasome activity and IL-1 signaling on asbestosinduced submesothelial thickening: Assessment of the thickness of the submesothelium in
response to asbestos exposure with and without the inflammasome inhibitor,
CRID3/MCC950 or the IL-1 receptor antagonist, Anakinra did not yield any significant
differences in thickness (Figure 1 A and B). Neither drug was successful in reducing the
total number of cells infiltrating the peritoneal cavity in response to asbestos exposure
(Figure 1C) and no significant changes in the profile of the cells infiltrating the cavity were
observed (Figure 1D). As was expected in response to blocking signaling through the IL-1
receptor however, IL-1β levels significantly increased in response to the administration of
Anakinra upon exposure of animals to asbestos, but this was not the case in CRID3 treated
animals (Figure 1E). CRID3 treatment failed to modulate the effect of asbestos exposure
on IL-1β levels altogether (Figure 1E). The same trend was observed for IL-18 as seen for
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IL-1β for both drugs (Figure 1F). Although IL-18 signals through its own receptor, (IL18R), treatment of animals with Anakinra also increased asbestos-induced IL-18 secretion
significantly. All IL-1 members require their respective receptors and the IL-1 receptor
accessory protein (IL-1RAcp) for signaling upon ligand binding. It is this interaction
between IL-1R1 and IL-1RAcp that IL-1Ra/Anakinra disrupts to prevent signaling.
Role of TFPI2 in asbestos-induced MFT: Transfection of LP9 cells with siRNA
targeting effectively downregulated TFPI2 transcript (approximately 21 fold decrease) and
protein levels (Figure 2A). Although asbestos-induced induction of IL-1β secretion was
slightly reduced in cells with inhibited TFPI2, the decrease was not significant (Figure 2B).
Interestingly, in the presence of reduced asbestos-induced TFPI2 levels, levels of active
caspase-1 were also reduced (Figure 2C). TFPI2 inhibition also caused a slight decrease in
IL-8 levels in response to asbestos exposure, while HMGB1, IL-6 and FGF2 levels
remained unaffected (Figure 2C). Morphologically, reduced levels of TFPI2 delayed
transition of LP9 cells to a more fibroblastic phenotype during the first 48 h of asbestos
exposure (Figure 2D). After 96 h of asbestos exposure however, cells had started appearing
more fibroblastic (Figure 2D).
Role of FGF2 in asbestos-induced MFT: Inhibition of FGFR1-4 with BGJ-398
caused a dose dependent decrease in IL-1B transcript levels after asbestos exposure in
HPM3 cells (Figure 3A). No effect was observed on NLRP3, PYCARD transcript levels in
response to FGFR inhibition or asbestos exposure or the combination thereof after (Figure
3A). By itself, BGJ-398 dose dependently reduced E-cadherin (CDH1) transcript levels but
decreased SNAI1 levels independent of dose (Figure 3A). Asbestos exposure also
157

decreased both of these genes, but pretreatment of the cells with the inhibitor did not result
in further decreases in expression beyond the effects of the inhibitor for SNAI1 whereas
CDH1 levels were just slightly higher in asbestos exposed pretreated cells than inhibitor or
asbestos alone (Figure 3A). However, none of these changes were significant. Upon
analysis of cytokine release in response to asbestos exposure by Western blot analysis,
TFPI2 levels were found to be slightly decreased in the asbestos group that was treated
with 5 µM BGJ-398 (Figure 3B). Analysis of secreted IL-1β levels by ELISA 48 h after
asbestos exposure showed that 5µM BGJ-398 slightly ameliorated asbestos-induced IL-1β
(Figure 3C). By itself, BGJ-398 at this concentration (5µM) had no significant effect on
secreted IL-1β levels, unlike the 2 and 10 µM doses (Figure 3C).
Discussion
Malignant mesothelioma has a long latency period ranging from 10-60 years after
asbestos exposure (Bianchi and Bianchi, 2007, Thompson et al., 2014). It is a deadly
disease that is refractory to all current therapeutic modalities approved for its treatment. To
compound matters, MM is difficult to diagnose and most cases present in the later stages
of the disease (Rodriguez Panadero, 2015) therefore limiting the ability to obtain positive
results. As per our knowledge no biomarkers exist that allow for early diagnosis in at risk
populations. Epithelial to mesenchymal transition (EMT) has been implicated in tumor
development and progression (Lee et al., 2006, Diepenbruck and Christofori, 2016) and its
prevention can help stop the dissemination of late stage disease to metastatic sites.
Although asbestos exposure has been causatively linked to MM, the mechanisms involved
in the development of and progression of this disease remain a mystery. It is essential to
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determine which pathways and crucial players drive MM development and progression in
order to develop multi-target treatment modalities that will counteract the chemoresistant
nature of the disease. In most cases of MM, there is recurrence of the disease even after
aggressive treatment involving pleural decortication and removal of the affected lung in
eligible patients even though these patients receive chemotherapy and sometimes radiation
therapy after surgery (Taioli et al., 2015, Beebe-Dimmer et al., 2016). A biomarker that
would allow the effectiveness of therapeutic regimens to be determined before
resistance/recurrence would help improve survival beyond the current median of 8-12
months.
Chronic inflammation induced by the mechanical damage caused by asbestos as
well as the ROS generated in response to asbestos fibers and the myriad signaling networks
activated by asbestos exposure all play a role in the development of this deadly disease
(Donaldson et al., 2010, Shukla and Mossman, 2005, Shukla et al., 2003). However, studies
on MM samples/patients from all stages of MM are not available to enable an in-depth
study of the progression of this fatal disease. Our in vitro and in vivo asbestos exposure
models allow for the role of some of these inflammatory networks, such as the
inflammasome to be investigated. The inflammasome plays both sides of the field with
respect to promoting tumorigenesis or enhancing tumor clearance (Zitvogel et al., 2012,
Petrilli, 2017). By understanding which role the inflammasome plays in MM, we will be
able to determine how that can be exploited for the detriment of disease progression. Recent
studies have confirmed the role of the inflammasome in MM initiation and our lab has also
demonstrated that the inflammasome plays a role in asbestos-induced MFT which may
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serve as a point of initiation for MM development (Kadariya et al., 2016) (Thompson et al.
Am J Pathol, in press). In the current study, we attempted to define the exact role of IL-1β
signaling in MFT but our model failed to recapitulate the delay we saw in vitro when we
treated animals with the IL-1 receptor antagonist, Anakinra. Anakinra has a half-life of 46 h in vivo (Calabrese, 2002) and would require several doses to maintain the appropriate
ratio of IL-1β to IL-1Ra required to block IL-1β signaling in vivo. Our animals were dosed
once daily and we observed increases in IL-1β secretion in animals receiving the antagonist
and asbestos compared to those exposed to asbestos only. In our in vitro studies we needed
a thousand fold more IL-1Ra than IL-1β to inhibit asbestos and IL-1β mediated MFT
(Thompson et al. Am J Pathol, in press). In vivo, where there are many different types of
cells expressing the IL-1 receptor and a biologic with a short half-life, it is more difficult
to determine the exact dose that would help maintain the proposed >100-fold IL-1Ra/IL1β ratio to ensure inhibition of IL-1β signaling (Arend, 2002, Arend et al., 1990). IL-1α
also uses the same receptor as IL1β and its role in asbestos-induced MFT and inflammation
has not been explored. These two IL-1 family members sometimes have opposing functions
under inflammatory conditions (Voronov et al., 2013), thus, any regulatory functions of
IL-1α that would help balance IL-1β action is also lost when the receptor is blocked. Future
studies, employing IL-1β and IL-1Ra deficient mice will have to be conducted to pinpoint
the role of IL-1β and the exact stage at which the course towards malignancy is set and
cannot be corrected.
We also used an NLRP3 inflammasome specific inhibitor to test the role of
NLRP3 pharmacologically but the use of MCC950/CRID3 did not yield encouraging
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results. The mechanism by which MCC950 inhibits the inflammasome has yet to be
determined although it has been reported to reduce IL-1β levels in vivo and in vitro
(Primiano et al., 2016, Coll et al., 2015). Utilizing a house dust mite model of airway
inflammation in mice, as well as a skin inflammation model in which imiquimod cream
was applied behind the ear of test mice, Primiano et al., were able to demonstrate that
CRID3 administered orally (200 mg/kg; 2x daily) reduced IL-1β levels in the
bronchoalveolar lavage fluid and ear swelling in the skin inflammation model (Primiano et
al., 2016). In vitro, IL-1β were reduced when human monocytes treated with imiquimod
were pretreated with CRID3 (Primiano et al., 2016). We found no effect of CRID3 on
asbestos-induced IL-1β levels in vitro (data not shown) or in vivo (Figure 1D). This
suggests that MCC950 was ineffective or failed to block asbestos-induced activation of the
inflammasome in our experimental set up. Other small molecule inhibitors (e.g.
sulforaphane) are being developed and tested for their inflammasome modulating activity
(Yang et al., 2016). In addition, a number of naturally occurring compounds/metabolites
(e.g. resveratrol) are also being tested for their ability to modulate inflammasome activity
(Jiang et al., 2016, Miller et al., 2014, Qiu et al., 2016). Thus, future studies using any of
these pharmacological agents are needed to ascertain whether they can be used as
prophylactic treatment for individuals exposed to asbestos or considered at risk of
developing mesothelioma. Such agents may also be used in conjunction with conventional
chemotherapeutics for MM like cisplatin to reduce the detrimental effects of
inflammasome activation by cisplatin. The inflammasome promotes or hinders cancer
progression depending on the cell type in which it is activated (Zitvogel et al., 2012, Kolb
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et al., 2014, Yazdi and Drexler, 2015), therefore it is important to understand the cell types
important for inflammasome mediated regulation of asbestos-induced MFT and MM
progression. By so doing, therapies targeting inflammasome activity in those cells can be
developed by immunotherapy and chemotherapy for delivery of inflammasome modulators
to specific cells.
Recent studies have shown that FGF signaling is an attractive target. FGF2,
FGF18 and FGFR1 have been found to be overexpressed by mesotheliomas (Marek et al.,
2014, Schelch et al., 2014) and recent studies using FGF-ligand trap have shown promise
in preclinical studies where it reduced tumor growth (Blackwell et al., 2016). In another
study, the use of an FGFR neutralizing antibody used in conjunction with radiotherapy
improved the effectiveness of the radiotherapy treatment of the MM (Schelch et al., 2014).
FGF2 is a mitogen for mesothelial cells and is secreted in response to injury to the
mesothelium (Mutsaers, 2002, Fujikawa et al., 2003). Its secretion from mesothelial cells
has also been shown to be induced by IL-1β (Cronauer et al., 1999). Our preliminary
studies with the pan FGFR inhibitor, BGJ-398 suggests an interplay between asbestosinduced IL-1β upregulation and FGF signaling. This calls for further study to ascertain the
exact role of FGF2 in the process of asbestos-induced MFT and the implications of this
role for the treatment and monitoring of MM. Since we see an upregulation of FGF2 levels
both in vitro and in vivo after asbestos exposure and it is overexpressed in MM it bears
promise as a marker of asbestos exposure and MM progression in conjunction with other
markers in order to ensure disambiguation. Further studies are required before the
candidacy for FGF2 as an MM biomarker can be confirmed but for now, it shows promise.
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Fibrin turnover is an important function of the normal mesothelium (Mutsaers et
al., 2016, Mutsaers et al., 2015) and imbalances in fibrinolysis and fibrin deposition have
been shown to be important for MFT (Fang et al., 2012, Batra and Antony, 2015) and
mesothelioma growth (Williams et al., 2012). The overlay of mesothelial cells with fibrin
caused them to down regulate the junctional protein, E-cadherin and induce MFT in human
mesothelial cells in vitro (Fang et al., 2012). Another study has demonstrated that reexpression of TFPI in a mesothelioma cell line inhibited growth of the cells (Williams et
al., 2012). In our studies on asbestos induced MFT, we see elevated levels of TFPI2 which
are downregulated upon blockage of the IL-1 receptor or knockdown of the NLRP3 protein
(Thompson et al., Am J Pathol, in press). Our preliminary data indicate that knockdown of
TFPI2 in LP9 cells delays asbestos MFT in a manner reminiscent of blocking the IL-1
receptor. TFPI2 has been shown to regulate the activity of matrix metalloproteinase 2
(MMP2) which may play a role in the clearance of fibrin (Ruf et al., 2003). Although TFPI2
does not inhibit plasminogen activators, it inhibits the activity of plasmin (Chand et al.,
2005, Puttabyatappa et al., 2016) thus, indirectly affecting fibrin turnover and promoting
MFT. TFPI2 inhibits the activity of MMP2 and MMP9 and in so doing is involved in
regulating extracellular matrix remodeling (Chand et al., 2005). Our studies also showed
a reduction in caspase-1 activation in the absence of TFPI2. At this time the mechanisms
and players involved in how TFPI2 influences asbestos-induced MFT remain to be
elucidated. Further studies are required to determine where in the signal cascade TFPI2
functions to promote MFT and whether it can be utilized as a reliable biomarker for disease
progression and therapy effectiveness. TFPI2 is considered a tumor suppressor gene and
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its promoter is often methylated in a number of cancers. However its role as a potential
driver of MFT has yet to be explored.
Altogether, data from this study identify many players for asbestos-induced MM
pathogenesis, but, also points to the need for more work to be done to elucidate the
importance of these players to be used as biomarkers or drug targets.
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Figures
Figure 4.1: Modulating IL-1β signaling does not attenuate asbestos-induced
submesothelium thickening. (A) H&E stains of cross sections through mouse peritoneal
walls eight weeks after asbestos exposure. Mice received 50 µL of sterile saline, Anakinra
(100 mg/kg) or CRID3 (10 mg/kg) 5x weekly with or without asbestos exposure (1x week)
(scale bar = 50 µm). (B) Quantitation of submesothelial thickening by MetaMorph software
analysis. (C) Total cell counts per mL of PLF collected (* p<0.05 compared to control).
(D) Differential cell counts as a percentage of total number of cells counted from PLF).
(E&F) IL-1β and IL-18 levels measured in concentrated PLF as determined by ELISA.
Values reported as pg IL-1β or IL-18 per mL of PLF (* p<0.05 compared to control; †
p<0.05 compared to asbestos alone).

Figure 4.2: Knockdown of TFPI2 attenuates asbestos-induced MFT. (A) Immortalized
peritoneal mesothelial cells (LP9/hTERT) were transfected with control non-targeting
siRNA (siCon) or siTFPI2 and exposed to 3 µg/cm2 asbestos for 48 h, 32 h post
transfection. TFPI2 transcript levels were assessed by qPCR. Protein levels of TFPI2 in
control and siTFPI2 transfected cells were also determined by Western blot analysis of
culture medium 48 h after exposure to 1 µg/cm2 asbestos. (B) The levels of IL-1β secreted
into the culture medium 48 h after exposure to 3 µg/cm2 asbestos was determined by
ELISA. (C) Western blot analysis of concentrated culture medium supernatants to
determine the effect of TFPI2 loss on caspase-1, IL-6, HMGB1, FGF2 and IL-8 levels 48
h after exposure to indicated amounts of asbestos. (D) Phase contrast micrographs of
transfected cells to assess morphological changes in response to asbestos exposure.
(Images obtained with 20X objective). ** p< 0.05 compared to siCon.

Figure 4.3: FGF2 signaling regulates IL-1β and TFPI2 levels in response to asbestos
exposure. (A) HPM3 cells were pretreated with increasing doses of the pan FGFR

2

inhibitor, BGJ-398 (2, 5 and 10 µM) 1 hour before two pulses of exposure to 5 µg/cm
asbestos 48 h apart. Transcript levels of EMT, and inflammasome components as well as
TFPI2 were then analyzed 1 week after the first asbestos pulse when cells possessed a
stable fibroblastic morphology. (B) Western blot analysis of FGF2, IL-6 and TFPI2 levels
secreted into the culture medium 48 h after the second asbestos pulse. * p < 0.05 compared
to control, † p < 0.0001 compared to asbestos alone, ‡ p < 0.0001 compared BGJ [2]. (C)
IL-1β levels in culture supernatant 48 h after asbestos exposure as determined by ELISA.
* p<0.05 compared to control; † p< 0.05 compared to the respective concentration of drug
alone; ‡ p<0.05 compared to asbestos alone.
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CHAPTER FIVE: CONCLUSION AND FUTURE DIRECTIONS
Through the studies described herein, we have attempted to understand
one of the previously unknown inflammatory mechanisms activated by asbestos
in mesothelial cells both in vitro and within the context of the peritoneum of the
whole animal. Asbestos-related diseases and in particular, MM, have a long
latency period during which inflammation and mechanical damage from the
fibers promote a chronic cycle of injury and repair of cells in contact with the
asbestos fibers (Miller and Shukla, 2012, Murphy et al., 2011). While chronic
inflammation has long been proposed to play a major role in the development of
MM (Hillegass et al., 2010a, Shukla et al., 2003, Linton et al., 2012, Carbone and
Yang, 2012), the exact mechanisms employed by asbestos to induce/foster the
growth of this lethal neoplasm remain elusive. MM is difficult to diagnose
because of its occult site of origin as well as the fact that its symptoms are shared
with a number of maladies (Henderson et al., 2013) leading to misdiagnoses in
areas where MM is not often encountered by medical practitioners. It requires
both a differential diagnosis and imaging techniques as well as a large panel of
differential markers being tested on biopsied tissue to reach a diagnosis
(Henderson et al., 2013, Chapman et al., 2012, Rodriguez Panadero, 2015). MM
patients are typically diagnosed in the late stages of the disease as the disease
does not typically present with overt symptoms until the tumor is large enough or
causing pleural effusions to compromise breathing (pleural MM), cause pain
(pleural and peritoneal) or distention of the abdomen from the tumor mass or the
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buildup of ascetic fluid (Mitsui et al., 2015, Mossman et al., 2013, Neumann et
al., 2013). No progress has been made in the last twenty years to improve the
prognosis of MM (Rodriguez Panadero, 2015, Kao et al., 2010). In addition to
being refractory to all current modes of therapy, there are no biomarkers that
allow for early detection. A wide array of genes are upregulated or downregulated
in response to asbestos exposure and the largest network of genes affected by
asbestos exposure belong to inflammatory cascades (Hillegass et al., 2010b,
Dragon et al., 2015). One such inflammatory cascade activated by asbestos in
mesothelial cells is the inflammasome. Asbestos activates the NLRP3
inflammasome in a prolonged manner, leading to the secretion of IL-1β and IL18 (Hillegass et al., 2013). Both IL-1β and IL-18 have been implicated to play
roles in the development, progression and maintenance of inflammation driven
cancers (Kolb et al., 2014, Muzes and Sipos, 2015). Through our studies we are
the first to show that activation of the inflammasome by asbestos in mesothelial
cells is partially modulated by the redox state of the cellular redox protein, Trx1
via its interaction with TXNIP which has been shown to be involved in
inflammasome activation. Reactive oxygen species generation in response to
asbestos exposure upsets the redox balance of cells exposed to asbestos and
increases expression of thioredoxin as well as the proportion of semi-oxidized
Trx1 in mesothelial cells. This increase in the Trx1 oxidized state led to a
dissociation of Trx1 from its negative regulator, TXNIP and promoted
inflammasome activation. By knocking down the expression levels of TXNIP
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using siRNA, we were able to ameliorate the extent of asbestos induced
inflammasome activation. The treatment of shERK2 bearing Hmeso cells that
exhibited a 4-fold reduction in TXNIP levels with inflammasome inducing
doxorubicin confirmed the role of TXNIP in asbestos-induced inflammasome
activation. As inflammasome activation was significantly reduced in these cells
after treatment with doxorubicin.
With the increasing evidence that the inflammasome or its individual
components were involved in epithelial to mesenchymal transition (Wang et al.,
2016, Wang et al., 2013, Lee et al., 2015, Lee et al., 2012), and evidence
indicating that asbestos as well as chemotherapeutics used for the treatment of
MM both activate the inflammasome (Zitvogel et al., 2012, Westbom et al., 2015,
Bruchard et al., 2013), it became imperative to investigate the role of asbestosinduced inflammasome activation in the role of MM development. MM cell lines
and tumors both exhibit lower inflammasome activity than normal mesothelial
cells. While prolonged asbestos exposure at sub-toxic levels promotes an EMTlike transition in mesothelial cells, our studies demonstrated for the first time that
this MFT we observed was in part dependent on asbestos-induced activation of
the inflammasome both in vitro and in vivo. In fact, inhibition of IL-1β signaling
delayed the transition of mesothelial cells into a fibroblastic phenotype. The
treatment of mesothelial cells also recapitulated several of the MFT features
observed in response to asbestos and could be inhibited by pretreatment of cells
with IL-1Ra. The pretreatment of cells with IL-1β prior to asbestos exposure
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however, failed to induce EMT earlier in mesothelial cells, suggesting that other
signaling cascades or factors regulating MFT were activated by asbestos in
addition to the effects of IL-1β signaling.
Our studies narrowed down a few potential candidates for further study in
the asbestos-induced mechanisms controlling MFT and may control MM
development and progress. TFPI2, a regulator of fibrinolysis and FGF2, an EMT
inducing growth factor and pro-inflammatory cytokine were significantly
upregulated in response to asbestos exposure and their levels appear to be
regulated in part by inflammasome activity. In response to knocking down
NLRP3 levels by siRNA, decreases in levels of IL-6, IL-8, FGF2 and TFPI2 were
observed. In vivo studies also revealed a potential role for IL-18 and Cas-1 in
asbestos-induced thickening of the submesothelium.
TFPI2 is considered a tumor suppressor gene and its promoter has been
demonstrated to be hypermethylated in a number of cancers (e.g. metastatic
melanoma, gastric and colorectal cancer) (Ribarska et al., 2010, Hibi et al., 2011a,
Takada et al., 2010, Sun et al., 2016). Serum levels of methylated TFPI2 have
also been detected in advanced gastric cancer (Hibi et al., 2011b) and
hepatocellular carcinoma patients (Sun et al., 2013), and is being considered as a
biomarker for metastatic melanoma and a potential prognostic marker for
hepatocellular cancer advancement (Lo Nigro et al., 2013, Sun et al., 2016). In
contrast to the role of TFPI2 as a tumor suppressor, elevated serum levels have
been reported in ovarian clear cell cancer (OCCC) patients and is now being
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validated as a biomarker for OCCC (Arakawa et al., 2013, Arakawa et al., 2016).
In uveal melanoma, Ruf et al. demonstrated that TFPI2 was important for
vascular mimicry and invasiveness of the uveal melanoma cell line MUM-2B
compared to its less invasive counterpart MUM-2C (Ruf et al., 2003).
TGFβ2 has been shown to upregulate TFPI2 levels in human trabecular
meshwork cells as part of an alteration in turnover of the ECM by these cells as
they undergo EMT (Fuchshofer et al., 2009). The growth of the non-invasive
breast cancer cell line (MCF-7) in a 3-D scaffold consisting of an artificial ECM
oriented in different directions verified the role of the ECM in EMT as these cells
displayed changes in morphology and protein expression consistent with EMT
(Foroni et al., 2013). These cells expressed increased amounts of TGFβ2 and
TFPI2 which potentially facilitated the transition of these cells into a more
mesenchymal phenotype (Foroni et al., 2013).
A number of studies have demonstrated that FGF2 induces EMT in
different cell types (Lee et al., 2012, Chen et al., 2014, Strutz et al., 2002).
Additionally, FGF has been shown to promote the proliferation of mesothelial
cells and is overexpressed in mesothelioma (Mutsaers et al., 1997, Marek et al.,
2014). Recent studies have also revealed FGF2 as an attractive drug target for
reducing MM growth (Schelch et al., 2014, Blackwell et al., 2016) which has the
potential of improving the prognosis of MM when combined with the current
approved therapeutic modalities. Our studies show that asbestos induces FGF2
expression and secretion. The transcription factor NFκB, which is redox sensitive
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and activated by asbestos (Janssen et al., 1995), has been shown to regulate FGF2
expression in endothelial cells (Lee and Kay, 2012) and the same may hold true
for mesothelial cells. It is therefore possible that FGF2 may be an early marker
of asbestos exposure and further investigation of FGF2 serum levels in asbestos
exposed individuals and patients with various asbestos related diseases and MM
will be needed to confirm whether FGF2 is a good biomarker of MM
development.
Further studies are required to determine the exact roles of TFPI2, Cas-1,
FGF2 and IL-18 in MM development and MFT. The use of TFPI2, IL-18, IL-1β
and IL-1Ra knock out mice will be required to tease out the roles of these
molecules and their respective pathways in MM development. Since the
inflammasome exerts cell type specific roles in either promoting or inhibiting
tumorigenesis (Yazdi and Drexler, 2015, Allen et al., 2010, Kolb et al., 2014),
mesothelial cell and immune cells specific knockout mice will need to be
developed to aid in these studies as well. New studies suggest that FGF receptor
1 is important for the growth of MM and the use of an FGF-ligand trap has shown
promise in restricting MM growth in pre-clinical studies (Marek et al., 2014,
Blackwell et al., 2016). This gives further credence to the need to investigate the
role of FGF2 in asbestos-induced MFT. By extension, the roles of both FGF2 and
TFPI2 in MM resistance as a result of activation of the inflammasome by
chemotherapeutics will have to be investigated. If these two factors do indeed
function downstream of IL-1β signaling to promote MFT, it will be imperative to
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potentially include an FGF2 neutralizing antibody to treatment modalities
involving chemotherapeutics and IL-1Ra in order to circumvent any deleterious
effects of Il-1β signaling while promoting pyroptosis. Additionally, serum FGF2
and TFPI2 levels could be monitored during MM treatment as a measure of
treatment efficacy and as predictors of recurrence after treatment. Both of these
will need to be further studied for candidacy as part of a panel of serum or plasma
markers for early MM detection in at risk groups.

180

References
ALLEN, I. C., TEKIPPE, E. M., WOODFORD, R. M., URONIS, J. M., HOLL, E. K.,
ROGERS, A. B., HERFARTH, H. H., JOBIN, C. & TING, J. P. 2010. The NLRP3
inflammasome functions as a negative regulator of tumorigenesis during colitisassociated cancer. J Exp Med, 207, 1045-56.
ARAKAWA, N., KOBAYASHI, H., YONEMOTO, N., MASUISHI, Y., INO, Y.,
SHIGETOMI, H., FURUKAWA, N., OHTAKE, N., MIYAGI, Y., HIRAHARA,
F., HIRANO, H. & MIYAGI, E. 2016. Clinical Significance of Tissue Factor
Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell
Carcinoma. PLoS One, 11, e0165609.
ARAKAWA, N., MIYAGI, E., NOMURA, A., MORITA, E., INO, Y., OHTAKE, N.,
MIYAGI, Y., HIRAHARA, F. & HIRANO, H. 2013. Secretome-based
identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell
adenocarcinoma. J Proteome Res, 12, 4340-50.
BLACKWELL, C., SHERK, C., FRICKO, M., GANJI, G., BARNETTE, M., HOANG,
B., TUNSTEAD, J., SKEDZIELEWSKI, T., ALSAID, H., JUCKER, B. M.,
MINTHORN, E., KUMAR, R. & DEYOUNG, M. P. 2016. Inhibition of
FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP1039/GSK3052230. Oncotarget, 7, 39861-39871.
BRUCHARD, M., MIGNOT, G., DERANGERE, V., CHALMIN, F., CHEVRIAUX, A.,
VEGRAN, F., BOIREAU, W., SIMON, B., RYFFEL, B., CONNAT, J. L.,
KANELLOPOULOS, J., MARTIN, F., REBE, C., APETOH, L. &
GHIRINGHELLI, F. 2013. Chemotherapy-triggered cathepsin B release in
myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes
tumor growth. Nat Med, 19, 57-64.
CARBONE, M. & YANG, H. 2012. Molecular pathways: targeting mechanisms of
asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res, 18, 598604.
CHAPMAN, E. A., THOMAS, P. S., STONE, E., LEWIS, C. & YATES, D. H. 2012. A
breath test for malignant mesothelioma using an electronic nose. Eur Respir J, 40,
448-54.
CHEN, J., CHEN, G., YAN, Z., GUO, Y., YU, M., FENG, L., JIANG, Z., GUO, W. &
TIAN, W. 2014. TGF-beta1 and FGF2 stimulate the epithelial-mesenchymal
transition of HERS cells through a MEK-dependent mechanism. J Cell Physiol,
229, 1647-59.
DRAGON, J., THOMPSON, J., MACPHERSON, M. & SHUKLA, A. 2015. Differential
Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos
Exposure. J Cell Biochem, 116, 1540-52.
FORONI, L., VASURI, F., VALENTE, S., GUALANDI, C., FOCARETE, M. L.,
CAPRARA, G., SCANDOLA, M., D'ERRICO-GRIGIONI, A. & PASQUINELLI,
G. 2013. The role of 3D microenvironmental organization in MCF-7 epithelialmesenchymal transition after 7 culture days. Exp Cell Res, 319, 1515-22.
181

FUCHSHOFER, R., STEPHAN, D. A., RUSSELL, P. & TAMM, E. R. 2009. Gene
expression profiling of TGFbeta2- and/or BMP7-treated trabecular meshwork cells:
Identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp Eye Res,
88, 1020-32.
HENDERSON, D. W., REID, G., KAO, S. C., VAN ZANDWIJK, N. & KLEBE, S. 2013.
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytologyonly diagnosis, biopsies, immunohistochemistry, discrimination between
mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol,
66, 847-53.
HIBI, K., GOTO, T., SHIRAHATA, A., SAITO, M., KIGAWA, G., NEMOTO, H. &
SANADA, Y. 2011a. Detection of TFPI2 methylation in the serum of colorectal
cancer patients. Cancer Lett, 311, 96-100.
HIBI, K., GOTO, T., SHIRAHATA, A., SAITO, M., KIGAWA, G., NEMOTO, H. &
SANADA, Y. 2011b. Detection of TFPI2 methylation in the serum of gastric cancer
patients. Anticancer Res, 31, 3835-8.
HILLEGASS, J. M., MILLER, J. M., MACPHERSON, M. B., WESTBOM, C. M.,
SAYAN, M., THOMPSON, J. K., MACURA, S. L., PERKINS, T. N.,
BEUSCHEL, S. L., ALEXEEVA, V., PASS, H. I., STEELE, C., MOSSMAN, B.
T. & SHUKLA, A. 2013. Asbestos and erionite prime and activate the NLRP3
inflammasome that stimulates autocrine cytokine release in human mesothelial
cells. Part Fibre Toxicol, 10, 39.
HILLEGASS, J. M., SHUKLA, A., LATHROP, S. A., MACPHERSON, M. B.,
BEUSCHEL, S. L., BUTNOR, K. J., TESTA, J. R., PASS, H. I., CARBONE, M.,
STEELE, C. & MOSSMAN, B. T. 2010a. Inflammation precedes the development
of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y
Acad Sci, 1203, 7-14.
HILLEGASS, J. M., SHUKLA, A., MACPHERSON, M. B., BOND, J. P., STEELE, C. &
MOSSMAN, B. T. 2010b. Utilization of gene profiling and proteomics to
determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1). J
Toxicol Environ Health A, 73, 423-36.
JANSSEN, Y. M., BARCHOWSKY, A., TREADWELL, M., DRISCOLL, K. E. &
MOSSMAN, B. T. 1995. Asbestos induces nuclear factor kappa B (NF-kappa B)
DNA-binding activity and NF-kappa B-dependent gene expression in tracheal
epithelial cells. Proc Natl Acad Sci U S A, 92, 8458-62.
KAO, S. C., PAVLAKIS, N., HARVIE, R., VARDY, J. L., BOYER, M. J., VAN
ZANDWIJK, N. & CLARKE, S. J. 2010. High blood neutrophil-to-lymphocyte
ratio is an indicator of poor prognosis in malignant mesothelioma patients
undergoing systemic therapy. Clin Cancer Res, 16, 5805-13.
KOLB, R., LIU, G. H., JANOWSKI, A. M., SUTTERWALA, F. S. & ZHANG, W. 2014.
Inflammasomes in cancer: a double-edged sword. Protein Cell, 5, 12-20.
LEE, C. H., CHANG, J. S., SYU, S. H., WONG, T. S., CHAN, J. Y., TANG, Y. C., YANG,
Z. P., YANG, W. C., CHEN, C. T., LU, S. C., TANG, P. H., YANG, T. C., CHU,
P. Y., HSIAO, J. R. & LIU, K. J. 2015. IL-1beta promotes malignant transformation
and tumor aggressiveness in oral cancer. J Cell Physiol, 230, 875-84.
182

LEE, J. G. & KAY, E. P. 2012. NF-kappaB is the transcription factor for FGF-2 that causes
endothelial mesenchymal transformation in cornea. Invest Ophthalmol Vis Sci, 53,
1530-8.
LEE, J. G., KO, M. K. & KAY, E. P. 2012. Endothelial mesenchymal transformation
mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res, 95,
35-9.
LINTON, A., VAN ZANDWIJK, N., REID, G., CLARKE, S., CAO, C. & KAO, S. 2012.
Inflammation in malignant mesothelioma - friend or foe? Ann Cardiothorac Surg,
1, 516-22.
LO NIGRO, C., WANG, H., MCHUGH, A., LATTANZIO, L., MATIN, R., HARWOOD,
C., SYED, N., HATZIMICHAEL, E., BRIASOULIS, E., MERLANO, M.,
EVANS, A., THOMPSON, A., LEIGH, I., FLEMING, C., INMAN, G. J., PROBY,
C. & CROOK, T. 2013. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA
in serum is a biomarker of metastatic melanoma. J Invest Dermatol, 133, 1278-85.
MAREK, L. A., HINZ, T. K., VON MASSENHAUSEN, A., OLSZEWSKI, K. A.,
KLECZKO, E. K., BOEHM, D., WEISER-EVANS, M. C., NEMENOFF, R. A.,
HOFFMANN, H., WARTH, A., GOZGIT, J. M., PERNER, S. & HEASLEY, L.
E. 2014. Nonamplified FGFR1 is a growth driver in malignant pleural
mesothelioma. Mol Cancer Res, 12, 1460-9.
MILLER, J. & SHUKLA, A. 2012. The Role of Inflammation in the Development and
Therapy of Malignant Mesothelioma. Am. Med. J., 3, 240-248.
MITSUI, A., SAJI, H., SHIMMYO, T., MOCHIZUKI, A., KURIMOTO, N. &
NAKAMURA, H. 2015. Malignant pleural mesothelioma presenting as a
spontaneous pneumothorax. Respirol Case Rep, 3, 9-12.
MOSSMAN, B. T., SHUKLA, A., HEINTZ, N. H., VERSCHRAEGEN, C. F., THOMAS,
A. & HASSAN, R. 2013. New insights into understanding the mechanisms,
pathogenesis, and management of malignant mesotheliomas. Am J Pathol, 182,
1065-77.
MURPHY, F. A., POLAND, C. A., DUFFIN, R., AL-JAMAL, K. T., ALI-BOUCETTA,
H., NUNES, A., BYRNE, F., PRINA-MELLO, A., VOLKOV, Y., LI, S.,
MATHER, S. J., BIANCO, A., PRATO, M., MACNEE, W., WALLACE, W. A.,
KOSTARELOS, K. & DONALDSON, K. 2011. Length-dependent retention of
carbon nanotubes in the pleural space of mice initiates sustained inflammation and
progressive fibrosis on the parietal pleura. Am J Pathol, 178, 2587-600.
MUTSAERS, S. E., MCANULTY, R. J., LAURENT, G. J., VERSNEL, M. A.,
WHITAKER, D. & PAPADIMITRIOU, J. M. 1997. Cytokine regulation of
mesothelial cell proliferation in vitro and in vivo. Eur J Cell Biol, 72, 24-9.
MUZES, G. & SIPOS, F. 2015. Inflammasome, inflammation and cancer: an interrelated
pathobiological triad. Curr Drug Targets, 16, 249-57.
NEUMANN, V., LOSEKE, S., NOWAK, D., HERTH, F. J. & TANNAPFEL, A. 2013.
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and
occupational health. Dtsch Arztebl Int, 110, 319-26.

183

RIBARSKA, T., INGENWERTH, M., GOERING, W., ENGERS, R. & SCHULZ, W. A.
2010. Epigenetic inactivation of the placentally imprinted tumor suppressor gene
TFPI2 in prostate carcinoma. Cancer Genomics Proteomics, 7, 51-60.
RODRIGUEZ PANADERO, F. 2015. Diagnosis and treatment of malignant pleural
mesothelioma. Arch Bronconeumol, 51, 177-84.
RUF, W., SEFTOR, E. A., PETROVAN, R. J., WEISS, R. M., GRUMAN, L. M.,
MARGARYAN, N. V., SEFTOR, R. E., MIYAGI, Y. & HENDRIX, M. J. 2003.
Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma
vasculogenic mimicry. Cancer Res, 63, 5381-9.
SCHELCH, K., HODA, M. A., KLIKOVITS, T., MUNZKER, J., GHANIM, B.,
WAGNER, C., GARAY, T., LASZLO, V., SETINEK, U., DOME, B., FILIPITS,
M., PIRKER, C., HEFFETER, P., SELZER, E., TOVARI, J., TOROK, S.,
KENESSEY, I., HOLZMANN, K., GRASL-KRAUPP, B., MARIAN, B.,
KLEPETKO, W., BERGER, W., HEGEDUS, B. & GRUSCH, M. 2014. Fibroblast
growth factor receptor inhibition is active against mesothelioma and synergizes
with radio- and chemotherapy. Am J Respir Crit Care Med, 190, 763-72.
SHUKLA, A., GULUMIAN, M., HEI, T. K., KAMP, D., RAHMAN, Q. & MOSSMAN,
B. T. 2003. Multiple roles of oxidants in the pathogenesis of asbestos-induced
diseases. Free Radic Biol Med, 34, 1117-29.
STRUTZ, F., ZEISBERG, M., ZIYADEH, F. N., YANG, C. Q., KALLURI, R., MULLER,
G. A. & NEILSON, E. G. 2002. Role of basic fibroblast growth factor-2 in
epithelial-mesenchymal transformation. Kidney Int, 61, 1714-28.
SUN, F. K., FAN, Y. C., ZHAO, J., ZHANG, F., GAO, S., ZHAO, Z. H., SUN, Q. &
WANG, K. 2013. Detection of TFPI2 methylation in the serum of hepatocellular
carcinoma patients. Dig Dis Sci, 58, 1010-5.
SUN, F. K., SUN, Q., FAN, Y. C., GAO, S., ZHAO, J., LI, F., JIA, Y. B., LIU, C., WANG,
L. Y., LI, X. Y., JI, X. F. & WANG, K. 2016. Methylation of tissue factor pathway
inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma after
hepatectomy. J Gastroenterol Hepatol, 31, 484-92.
TAKADA, H., WAKABAYASHI, N., DOHI, O., YASUI, K., SAKAKURA, C.,
MITSUFUJI, S., TANIWAKI, M. & YOSHIKAWA, T. 2010. Tissue factor
pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter
hypermethylation in gastric cancer. Cancer Genet Cytogenet, 197, 16-24.
WANG, H., WANG, Y., DU, Q., LU, P., FAN, H., LU, J. & HU, R. 2016. Inflammasomeindependent NLRP3 is required for epithelial-mesenchymal transition in colon
cancer cells. Exp Cell Res, 342, 184-92.
WANG, W., WANG, X., CHUN, J., VILAYSANE, A., CLARK, S., FRENCH, G.,
BRACEY, N. A., TRPKOV, K., BONNI, S., DUFF, H. J., BECK, P. L. &
MURUVE, D. A. 2013. Inflammasome-independent NLRP3 augments TGF-beta
signaling in kidney epithelium. J Immunol, 190, 1239-49.
WESTBOM, C., THOMPSON, J. K., LEGGETT, A., MACPHERSON, M., BEUSCHEL,
S., PASS, H., VACEK, P. & SHUKLA, A. 2015. Inflammasome Modulation by
Chemotherapeutics in Malignant Mesothelioma. PLoS One, 10, e0145404.
184

YAZDI, A. S. & DREXLER, S. K. 2015. The two faces of the inflammasome adaptor ASC
in epithelial skin carcinogenesis. Clin Exp Rheumatol, 33, S94-6.
ZITVOGEL, L., KEPP, O., GALLUZZI, L. & KROEMER, G. 2012. Inflammasomes in
carcinogenesis and anticancer immune responses. Nat Immunol, 13, 343-51.

185

COMPREHENSIVE BIBLIOGRAPHY
ABAKAY, O., TANRIKULU, A. C., PALANCI, Y. & ABAKAY, A. 2014. The value of
inflammatory parameters in the prognosis of malignant mesothelioma. J Int Med
Res, 42, 554-65.

ACENCIO, M. M., SOARES, B., MARCHI, E., SILVA, C. S., TEIXEIRA, L. R. &
BROADDUS, V. C. 2015. Inflammatory Cytokines Contribute to AsbestosInduced Injury of Mesothelial Cells. Lung, 193, 831-7.

ALJANDALI, A., POLLACK, H., YELDANDI, A., LI, Y., WEITZMAN, S. A. &
KAMP, D. W. 2001. Asbestos causes apoptosis in alveolar epithelial cells: role of
iron-induced free radicals. J Lab Clin Med, 137, 330-9.

ALLEN, I. C., TEKIPPE, E. M., WOODFORD, R. M., URONIS, J. M., HOLL, E. K.,
ROGERS, A. B., HERFARTH, H. H., JOBIN, C. & TING, J. P. 2010. The
NLRP3 inflammasome functions as a negative regulator of tumorigenesis during
colitis-associated cancer. J Exp Med, 207, 1045-56.

ARAKAWA, N., KOBAYASHI, H., YONEMOTO, N., MASUISHI, Y., INO, Y.,
SHIGETOMI, H., FURUKAWA, N., OHTAKE, N., MIYAGI, Y., HIRAHARA,
F., HIRANO, H. & MIYAGI, E. 2016. Clinical Significance of Tissue Factor
Pathway Inhibitor 2, a Serum Biomarker Candidate for Ovarian Clear Cell
Carcinoma. PLoS One, 11, e0165609.

ARAKAWA, N., MIYAGI, E., NOMURA, A., MORITA, E., INO, Y., OHTAKE, N.,
MIYAGI, Y., HIRAHARA, F. & HIRANO, H. 2013. Secretome-based
identification of TFPI2, a novel serum biomarker for detection of ovarian clear
cell adenocarcinoma. J Proteome Res, 12, 4340-50.

AREND, W. P. 2002. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth
Factor Rev, 13, 323-40.

AREND, W. P., WELGUS, H. G., THOMPSON, R. C. & EISENBERG, S. P. 1990.
Biological properties of recombinant human monocyte-derived interleukin 1
receptor antagonist. J Clin Invest, 85, 1694-7.
186

BALLAN, G., DEL BROCCO, A., LOIZZO, S., FABBRI, A., MAROCCIA, Z.,
FIORENTINI, C. & TRAVAGLIONE, S. 2014. Mode of action of fibrous
amphiboles: the case of Biancavilla (Sicily, Italy). Ann Ist Super Sanita, 50, 1338.

BATRA, H. & ANTONY, V. B. 2015. Pleural mesothelial cells in pleural and lung
diseases. J Thorac Dis, 7, 964-80.

BATRA, H. & ANTONY, V. B. 2015. Pleural mesothelial cells in pleural and lung
diseases. J Thorac Dis, 7, 964-80.

BECKLAKE, M. R., BAGATIN, E. & NEDER, J. A. 2007. Asbestos-related diseases of
the lungs and pleura: uses, trends and management over the last century. Int J
Tuberc Lung Dis, 11, 356-69.

BEEBE-DIMMER, J. L., FRYZEK, J. P., YEE, C. L., DALVI, T. B., GARABRANT, D.
H., SCHWARTZ, A. G. & GADGEEL, S. 2016. Mesothelioma in the United
States: a Surveillance, Epidemiology, and End Results (SEER)-Medicare
investigation of treatment patterns and overall survival. Clin Epidemiol, 8, 743750.

BENVENUTO, M., MATTERA, R., TAFFERA, G., GIGANTI, M. G., LIDO, P.,
MASUELLI, L., MODESTI, A. & BEI, R. 2016. The Potential Protective Effects
of Polyphenols in Asbestos-Mediated Inflammation and Carcinogenesis of
Mesothelium. Nutrients, 8.

BIANCHI, C. & BIANCHI, T. 2007. Malignant mesothelioma: global incidence and
relationship with asbestos. Ind Health, 45, 379-87.

BLACKWELL, C., SHERK, C., FRICKO, M., GANJI, G., BARNETTE, M., HOANG,
B., TUNSTEAD, J., SKEDZIELEWSKI, T., ALSAID, H., JUCKER, B. M.,
MINTHORN, E., KUMAR, R. & DEYOUNG, M. P. 2016. Inhibition of
FGF/FGFR autocrine signaling in mesothelioma with the FGF ligand trap, FP1039/GSK3052230. Oncotarget, 7, 39861-39871.

187

BOTT, M., BREVET, M., TAYLOR, B. S., SHIMIZU, S., ITO, T., WANG, L.,
CREANEY, J., LAKE, R. A., ZAKOWSKI, M. F., REVA, B., SANDER, C.,
DELSITE, R., POWELL, S., ZHOU, Q., SHEN, R., OLSHEN, A., RUSCH, V. &
LADANYI, M. 2011. The nuclear deubiquitinase BAP1 is commonly inactivated
by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat
Genet, 43, 668-72.

BROADDUS, V. C., EVERITT, J. I., BLACK, B. & KANE, A. B. 2011. Non-neoplastic
and neoplastic pleural endpoints following fiber exposure. J Toxicol Environ
Health B Crit Rev, 14, 153-78.

BROADDUS, V. C., YANG, L., SCAVO, L. M., ERNST, J. D. & BOYLAN, A. M.
1996. Asbestos induces apoptosis of human and rabbit pleural mesothelial cells
via reactive oxygen species. J Clin Invest, 98, 2050-9.

BRUCHARD, M., MIGNOT, G., DERANGERE, V., CHALMIN, F., CHEVRIAUX, A.,
VEGRAN, F., BOIREAU, W., SIMON, B., RYFFEL, B., CONNAT, J. L.,
KANELLOPOULOS, J., MARTIN, F., REBE, C., APETOH, L. &
GHIRINGHELLI, F. 2013. Chemotherapy-triggered cathepsin B release in
myeloid-derived suppressor cells activates the Nlrp3 inflammasome and promotes
tumor growth. Nat Med, 19, 57-64.

BUDER-HOFFMANN, S., PALMER, C., VACEK, P., TAATJES, D. & MOSSMAN, B.
2001. Different accumulation of activated extracellular signal-regulated kinases
(ERK 1/2) and role in cell-cycle alterations by epidermal growth factor, hydrogen
peroxide, or asbestos in pulmonary epithelial cells. Am J Respir Cell Mol Biol, 24,
405-13.

CALABRESE, L. H. 2002. Anakinra treatment of patients with rheumatoid arthritis. Ann
Pharmacother, 36, 1204-9.

CAO, Z., LIVAS, T. & KYPRIANOU, N. 2016. Anoikis and EMT: Lethal "Liaisons"
during Cancer Progression. Crit Rev Oncog, 21, 155-168.

CARBONE, M. & YANG, H. 2012. Molecular pathways: targeting mechanisms of
asbestos and erionite carcinogenesis in mesothelioma. Clin Cancer Res, 18, 598604.
188

CHAND, H. S., FOSTER, D. C. & KISIEL, W. 2005. Structure, function and biology of
tissue factor pathway inhibitor-2. Thromb Haemost, 94, 1122-30.

CHAO, C. C., PARK, S. H. & AUST, A. E. 1996. Participation of nitric oxide and iron in
the oxidation of DNA in asbestos-treated human lung epithelial cells. Arch
Biochem Biophys, 326, 152-7.

CHAPMAN, E. A., THOMAS, P. S., STONE, E., LEWIS, C. & YATES, D. H. 2012. A
breath test for malignant mesothelioma using an electronic nose. Eur Respir J, 40,
448-54.

CHEKOL, S. S. & SUN, C. C. 2012. Malignant mesothelioma of the tunica vaginalis
testis: diagnostic studies and differential diagnosis. Arch Pathol Lab Med, 136,
113-7.

CHEN, J., CHEN, G., YAN, Z., GUO, Y., YU, M., FENG, L., JIANG, Z., GUO, W. &
TIAN, W. 2014. TGF-beta1 and FGF2 stimulate the epithelial-mesenchymal
transition of HERS cells through a MEK-dependent mechanism. J Cell Physiol,
229, 1647-59.

CHEW, S. H., OKAZAKI, Y., NAGAI, H., MISAWA, N., AKATSUKA, S.,
YAMASHITA, K., JIANG, L., YAMASHITA, Y., NOGUCHI, M., HOSODA,
K., SEKIDO, Y., TAKAHASHI, T. & TOYOKUNI, S. 2014. Cancer-promoting
role of adipocytes in asbestos-induced mesothelial carcinogenesis through
dysregulated adipocytokine production. Carcinogenesis, 35, 164-72.

CHEW, S. H. & TOYOKUNI, S. 2015. Malignant mesothelioma as an oxidative stressinduced cancer: An update. Free Radic Biol Med, 86, 166-78.

COLL, R. C., ROBERTSON, A. A., CHAE, J. J., HIGGINS, S. C., MUNOZPLANILLO, R., INSERRA, M. C., VETTER, I., DUNGAN, L. S., MONKS, B.
G., STUTZ, A., CROKER, D. E., BUTLER, M. S., HANEKLAUS, M.,
SUTTON, C. E., NUNEZ, G., LATZ, E., KASTNER, D. L., MILLS, K. H.,
MASTERS, S. L., SCHRODER, K., COOPER, M. A. & O'NEILL, L. A. 2015. A
small-molecule inhibitor of the NLRP3 inflammasome for the treatment of
inflammatory diseases. Nat Med, 21, 248-55.
189

COLL, R. C., ROBERTSON, A. A., CHAE, J. J., HIGGINS, S. C., MUNOZPLANILLO, R., INSERRA, M. C., VETTER, I., DUNGAN, L. S., MONKS, B.
G., STUTZ, A., CROKER, D. E., BUTLER, M. S., HANEKLAUS, M.,
SUTTON, C. E., NUNEZ, G., LATZ, E., KASTNER, D. L., MILLS, K. H.,
MASTERS, S. L., SCHRODER, K., COOPER, M. A. & O'NEILL, L. A. 2015. A
small-molecule inhibitor of the NLRP3 inflammasome for the treatment of
inflammatory diseases. Nat Med, 21, 248-55.

COMAR, M., ZANOTTA, N., BONOTTI, A., TOGNON, M., NEGRO, C.,
CRISTAUDO, A. & BOVENZI, M. 2014. Increased levels of C-C chemokine
RANTES in asbestos exposed workers and in malignant mesothelioma patients
from an hyperendemic area. PLoS One, 9, e104848.

COMAR, M., ZANOTTA, N., ZANCONATI, F., CORTALE, M., BONOTTI, A.,
CRISTAUDO, A. & BOVENZI, M. 2016. Chemokines involved in the early
inflammatory response and in pro-tumoral activity in asbestos-exposed workers
from an Italian coastal area with territorial clusters of pleural malignant
mesothelioma. Lung Cancer, 94, 61-7.

CRAIGHEAD, J. E. 2011. Epidemiology of mesothelioma and historical background.
Recent Results Cancer Res, 189, 13-25.

CRONAUER, M. V., STADLMANN, S., KLOCKER, H., ABENDSTEIN, B., EDER, I.
E., ROGATSCH, H., ZEIMET, A. G., MARTH, C. & OFFNER, F. A. 1999.
Basic fibroblast growth factor synthesis by human peritoneal mesothelial cells:
induction by interleukin-1. Am J Pathol, 155, 1977-84.

DICK, M. S., SBORGI, L., RUHL, S., HILLER, S. & BROZ, P. 2016. ASC filament
formation serves as a signal amplification mechanism for inflammasomes. Nat
Commun, 7, 11929.

DIEPENBRUCK, M. & CHRISTOFORI, G. 2016. Epithelial-mesenchymal transition
(EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol, 43, 7-13.

DIKENSOY, O. 2008. Mesothelioma due to environmental exposure to erionite in
Turkey. Curr Opin Pulm Med, 14, 322-5.
190

DONALDSON, K., MURPHY, F. A., DUFFIN, R. & POLAND, C. A. 2010. Asbestos,
carbon nanotubes and the pleural mesothelium: a review of the hypothesis
regarding the role of long fibre retention in the parietal pleura, inflammation and
mesothelioma. Part Fibre Toxicol, 7, 5.

DONALDSON, K., POLAND, C. A., MURPHY, F. A., MACFARLANE, M.,
CHERNOVA, T. & SCHINWALD, A. 2013. Pulmonary toxicity of carbon
nanotubes and asbestos - similarities and differences. Adv Drug Deliv Rev, 65,
2078-86.

DOPP, E., YADAV, S., ANSARI, F. A., BHATTACHARYA, K., VON
RECKLINGHAUSEN, U., RAUEN, U., RODELSPERGER, K., SHOKOUHI,
B., GEH, S. & RAHMAN, Q. 2005. ROS-mediated genotoxicity of asbestoscement in mammalian lung cells in vitro. Part Fibre Toxicol, 2, 9.

DOSTERT, C. & PETRILLI, V. 2008. [Asbestos triggers inflammation by activating the
Nalp3 inflammasome]. Med Sci (Paris), 24, 916-8.

DOSTERT, C., PETRILLI, V., VAN BRUGGEN, R., STEELE, C., MOSSMAN, B. T.
& TSCHOPP, J. 2008. Innate immune activation through Nalp3 inflammasome
sensing of asbestos and silica. Science, 320, 674-7.

DRAGON, J., THOMPSON, J., MACPHERSON, M. & SHUKLA, A. 2015. Differential
Susceptibility of Human Pleural and Peritoneal Mesothelial Cells to Asbestos
Exposure. J Cell Biochem, 116, 1540-52.

FANG, C. C., HUANG, J. W., SHYU, R. S., YEN, C. J., SHIAO, C. H., CHIANG, C.
K., HU, R. H. & TSAI, T. J. 2012. Fibrin-Induced epithelial-to-mesenchymal
transition of peritoneal mesothelial cells as a mechanism of peritoneal fibrosis:
effects of pentoxifylline. PLoS One, 7, e44765.

FAUX, S. P. & HOWDEN, P. J. 1997. Possible role of lipid peroxidation in the induction
of NF-kappa B and AP-1 in RFL-6 cells by crocidolite asbestos: evidence
following protection by vitamin E. Environ Health Perspect, 105 Suppl 5, 112730.

191

FORONI, L., VASURI, F., VALENTE, S., GUALANDI, C., FOCARETE, M. L.,
CAPRARA, G., SCANDOLA, M., D'ERRICO-GRIGIONI, A. &
PASQUINELLI, G. 2013. The role of 3D microenvironmental organization in
MCF-7 epithelial-mesenchymal transition after 7 culture days. Exp Cell Res, 319,
1515-22.

FUCHSHOFER, R., STEPHAN, D. A., RUSSELL, P. & TAMM, E. R. 2009. Gene
expression profiling of TGFbeta2- and/or BMP7-treated trabecular meshwork
cells: Identification of Smad7 as a critical inhibitor of TGF-beta2 signaling. Exp
Eye Res, 88, 1020-32.

FUJIKAWA, K., TAKAI, K., SUGA, A., NAITO, K., OHATA, A., NAKASONE, S. &
HORIUCHI, T. 2003. Expression of mRNA for growth factors and extracellular
matrix proteins after injury to cultured peritoneal cells: does the healing process
contribute to peritoneal ultrastructural alteration? J Artif Organs, 6, 253-9.

FUKAGAWA, N. K., LI, M., SABO-ATTWOOD, T., TIMBLIN, C. R., BUTNOR, K. J.,
GAGNE, J., STEELE, C., TAATJES, D. J., HUBER, S. & MOSSMAN, B. T.
2008. Inhaled asbestos exacerbates atherosclerosis in apolipoprotein E-deficient
mice via CD4+ T cells. Environ Health Perspect, 116, 1218-25.

FUNG, H., KOW, Y. W., VAN HOUTEN, B. & MOSSMAN, B. T. 1997. Patterns of 8hydroxydeoxyguanosine formation in DNA and indications of oxidative stress in
rat and human pleural mesothelial cells after exposure to crocidolite asbestos.
Carcinogenesis, 18, 825-32.

GAVETT, S. H., PARKINSON, C. U., WILLSON, G. A., WOOD, C. E., JARABEK, A.
M., ROBERTS, K. C., KODAVANTI, U. P. & DODD, D. E. 2016. Persistent
effects of Libby amphibole and amosite asbestos following subchronic inhalation
in rats. Part Fibre Toxicol, 13, 17.

GAZZANO, E., FORESTI, E., LESCI, I. G., TOMATIS, M., RIGANTI, C., FUBINI, B.,
ROVERI, N. & GHIGO, D. 2005. Different cellular responses evoked by natural
and stoichiometric synthetic chrysotile asbestos. Toxicology and applied
pharmacology, 206, 356-64.

192

GAZZANO, E., TURCI, F., FORESTI, E., PUTZU, M. G., ALDIERI, E., SILVAGNO,
F., LESCI, I. G., TOMATIS, M., RIGANTI, C., ROMANO, C., FUBINI, B.,
ROVERI, N. & GHIGO, D. 2007. Iron-loaded synthetic chrysotile: a new model
solid for studying the role of iron in asbestos toxicity. Chem Res Toxicol, 20, 3807.

GHIO, A. J., STONEHUERNER, J., RICHARDS, J. & DEVLIN, R. B. 2008. Iron
homeostasis in the lung following asbestos exposure. Antioxid Redox Signal, 10,
371-7.

GOTH, L. 2006. [The hydrogen peroxide paradox]. Orvosi hetilap, 147, 887-93.
HAEGENS, A., BARRETT, T. F., GELL, J., SHUKLA, A., MACPHERSON, M.,
VACEK, P., POYNTER, M. E., BUTNOR, K. J., JANSSEN-HEININGER, Y.
M., STEELE, C. & MOSSMAN, B. T. 2007. Airway epithelial NF-kappaB
activation modulates asbestos-induced inflammation and mucin production in
vivo. J Immunol, 178, 1800-8.

HAEGENS, A., VAN DER VLIET, A., BUTNOR, K. J., HEINTZ, N., TAATJES, D.,
HEMENWAY, D., VACEK, P., FREEMAN, B. A., HAZEN, S. L., BRENNAN,
M. L. & MOSSMAN, B. T. 2005. Asbestos-induced lung inflammation and
epithelial cell proliferation are altered in myeloperoxidase-null mice. Cancer Res,
65, 9670-7.

HANSEN, J. M., GO, Y. M. & JONES, D. P. 2006. Nuclear and mitochondrial
compartmentation of oxidative stress and redox signaling. Annu Rev Pharmacol
Toxicol, 46, 215-34.

HEINTZ, N. H., JANSSEN-HEININGER, Y. M. & MOSSMAN, B. T. 2010. Asbestos,
lung cancers, and mesotheliomas: from molecular approaches to targeting tumor
survival pathways. Am J Respir Cell Mol Biol, 42, 133-9.

HENDERSON, D. W., REID, G., KAO, S. C., VAN ZANDWIJK, N. & KLEBE, S.
2013. Challenges and controversies in the diagnosis of malignant mesothelioma:
Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular
and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J
Clin Pathol, 66, 854-61.

193

HENDERSON, D. W., REID, G., KAO, S. C., VAN ZANDWIJK, N. & KLEBE, S.
2013. Challenges and controversies in the diagnosis of mesothelioma: Part 1.
Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination
between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J
Clin Pathol, 66, 847-53.

HIBI, K., GOTO, T., SHIRAHATA, A., SAITO, M., KIGAWA, G., NEMOTO, H. &
SANADA, Y. 2011. Detection of TFPI2 methylation in the serum of colorectal
cancer patients. Cancer Lett, 311, 96-100.

HIBI, K., GOTO, T., SHIRAHATA, A., SAITO, M., KIGAWA, G., NEMOTO, H. &
SANADA, Y. 2011. Detection of TFPI2 methylation in the serum of gastric
cancer patients. Anticancer Res, 31, 3835-8.

HILLEGASS, J. M., MILLER, J. M., MACPHERSON, M. B., WESTBOM, C. M.,
SAYAN, M., THOMPSON, J. K., MACURA, S. L., PERKINS, T. N.,
BEUSCHEL, S. L., ALEXEEVA, V., PASS, H. I., STEELE, C., MOSSMAN, B.
T. & SHUKLA, A. 2013. Asbestos and erionite prime and activate the NLRP3
inflammasome that stimulates autocrine cytokine release in human mesothelial
cells. Part Fibre Toxicol, 10, 39.

HILLEGASS, J. M., SHUKLA, A., LATHROP, S. A., MACPHERSON, M. B.,
BEUSCHEL, S. L., BUTNOR, K. J., TESTA, J. R., PASS, H. I., CARBONE, M.,
STEELE, C. & MOSSMAN, B. T. 2010. Inflammation precedes the development
of human malignant mesotheliomas in a SCID mouse xenograft model. Ann N Y
Acad Sci, 1203, 7-14.

HILLEGASS, J. M., SHUKLA, A., MACPHERSON, M. B., BOND, J. P., STEELE, C.
& MOSSMAN, B. T. 2010. Utilization of gene profiling and proteomics to
determine mineral pathogenicity in a human mesothelial cell line (LP9/TERT-1).
J Toxicol Environ Health A, 73, 423-36.

HILLEGASS, J. M., SHUKLA, A., MACPHERSON, M. B., LATHROP, S. A.,
ALEXEEVA, V., PERKINS, T. N., VAN DER VLIET, A., VACEK, P. M.,
GUNTER, M. E. & MOSSMAN, B. T. 2010. Mechanisms of oxidative stress and
alterations in gene expression by Libby six-mix in human mesothelial cells. Part
Fibre Toxicol, 7, 26.
194

HIRAKU, Y., KAWANISHI, S., ICHINOSE, T. & MURATA, M. 2010. The role of
iNOS-mediated DNA damage in infection- and asbestos-induced carcinogenesis.
Ann N Y Acad Sci, 1203, 15-22.

HIRAKU, Y., SAKAI, K., SHIBATA, E., KAMIJIMA, M., HISANAGA, N., MA, N.,
KAWANISHI, S. & MURATA, M. 2014. Formation of the nitrative DNA lesion
8-nitroguanine is associated with asbestos contents in human lung tissues: a pilot
study. J Occup Health, 56, 186-96.

HOWDEN, P. J. & FAUX, S. P. 1996. Fibre-induced lipid peroxidation leads to DNA
adduct formation in Salmonella typhimurium TA104 and rat lung fibroblasts.
Carcinogenesis, 17, 413-9.

HUANG, S. X., JAURAND, M. C., KAMP, D. W., WHYSNER, J. & HEI, T. K. 2011.
Role of mutagenicity in asbestos fiber-induced carcinogenicity and other diseases.
J Toxicol Environ Health B Crit Rev, 14, 179-245.

HUANG, S. X., PARTRIDGE, M. A., GHANDHI, S. A., DAVIDSON, M. M.,
AMUNDSON, S. A. & HEI, T. K. 2012. Mitochondria-derived reactive
intermediate species mediate asbestos-induced genotoxicity and oxidative stressresponsive signaling pathways. Environ Health Perspect, 120, 840-7.

INAMURA, K., NINOMIYA, H., NOMURA, K., TSUCHIYA, E., SATOH, Y.,
OKUMURA, S., NAKAGAWA, K., TAKATA, A., KOHYAMA, N. &
ISHIKAWA, Y. 2014. Combined effects of asbestos and cigarette smoke on the
development of lung adenocarcinoma: different carcinogens may cause different
genomic changes. Oncol Rep, 32, 475-82.

IWAGAKI, A., CHOE, N., LI, Y., HEMENWAY, D. R. & KAGAN, E. 2003. Asbestos
inhalation induces tyrosine nitration associated with extracellular signal-regulated
kinase 1/2 activation in the rat lung. Am J Respir Cell Mol Biol, 28, 51-60.

JANKOVICHOVA, T., JANKOVICH, M., ONDRUS, D., KAJO, K., DUBRAVICKY,
J. & BREZA, J. 2015. Extremely rare tumour--malignant mesothelioma of tunica
vaginalis testis. Bratisl Lek Listy, 116, 574-6.

195

JANSSEN, Y. M., BARCHOWSKY, A., TREADWELL, M., DRISCOLL, K. E. &
MOSSMAN, B. T. 1995. Asbestos induces nuclear factor kappa B (NF-kappa B)
DNA-binding activity and NF-kappa B-dependent gene expression in tracheal
epithelial cells. Proc Natl Acad Sci U S A, 92, 8458-62.

JANSSEN, Y. M., DRISCOLL, K. E., HOWARD, B., QUINLAN, T. R., TREADWELL,
M., BARCHOWSKY, A. & MOSSMAN, B. T. 1997. Asbestos causes
translocation of p65 protein and increases NF-kappa B DNA binding activity in
rat lung epithelial and pleural mesothelial cells. Am J Pathol, 151, 389-401.

JIANG, L., ZHANG, L., KANG, K., FEI, D., GONG, R., CAO, Y., PAN, S., ZHAO, M.
& ZHAO, M. 2016. Resveratrol ameliorates LPS-induced acute lung injury via
NLRP3 inflammasome modulation. Biomed Pharmacother, 84, 130-138.

JUDGE, S., THOMAS, P., GOVINDARAJAN, V., SHARMA, P. & LOGGIE, B. 2016.
Malignant Peritoneal Mesothelioma: Characterization of the Inflammatory
Response in the Tumor Microenvironment. Ann Surg Oncol, 23, 1496-500.

KADARIYA, Y., CHEUNG, M., XU, J., PEI, J., SEMENTINO, E., MENGES, C. W.,
CAI, K. Q., RAUSCHER, F. J., KLEIN-SZANTO, A. J. & TESTA, J. R. 2016.
Bap1 Is a Bona Fide Tumor Suppressor: Genetic Evidence from Mouse Models
Carrying Heterozygous Germline Bap1 Mutations. Cancer Res, 76, 2836-44.

KADARIYA, Y., MENGES, C. W., TALARCHEK, J., CAI, K. Q., KLEIN-SZANTO,
A. J., PIETROFESA, R. A., CHRISTOFIDOU-SOLOMIDOU, M., CHEUNG,
M., MOSSMAN, B. T., SHUKLA, A. & TESTA, J. R. 2016. InflammationRelated IL1beta/IL1R Signaling Promotes the Development of Asbestos-Induced
Malignant Mesothelioma. Cancer Prev Res (Phila), 9, 406-14.

KAO, S. C., PAVLAKIS, N., HARVIE, R., VARDY, J. L., BOYER, M. J., VAN
ZANDWIJK, N. & CLARKE, S. J. 2010. High blood neutrophil-to-lymphocyte
ratio is an indicator of poor prognosis in malignant mesothelioma patients
undergoing systemic therapy. Clin Cancer Res, 16, 5805-13.

KIM, J., KONG, J., CHANG, H., KIM, H. & KIM, A. 2016. EGF induces epithelialmesenchymal transition through phospho-Smad2/3-Snail signaling pathway in
breast cancer cells. Oncotarget.
196

KOLB, M., MARGETTS, P. J., ANTHONY, D. C., PITOSSI, F. & GAULDIE, J. 2001.
Transient expression of IL-1beta induces acute lung injury and chronic repair
leading to pulmonary fibrosis. J Clin Invest, 107, 1529-36.

KOLB, R., LIU, G. H., JANOWSKI, A. M., SUTTERWALA, F. S. & ZHANG, W.
2014. Inflammasomes in cancer: a double-edged sword. Protein Cell, 5, 12-20.

LANDRIGAN, P. J. & COLLEGIUM, R. 2016. Comments on the Causation of
Malignant Mesothelioma: Rebutting the False Concept That Recent Exposures to
Asbestos Do Not Contribute to Causation of Mesothelioma. Ann Glob Health, 82,
214-6.

LEE, C. H., CHANG, J. S., SYU, S. H., WONG, T. S., CHAN, J. Y., TANG, Y. C.,
YANG, Z. P., YANG, W. C., CHEN, C. T., LU, S. C., TANG, P. H., YANG, T.
C., CHU, P. Y., HSIAO, J. R. & LIU, K. J. 2015. IL-1beta promotes malignant
transformation and tumor aggressiveness in oral cancer. J Cell Physiol, 230, 87584.

LEE, J. G. & KAY, E. P. 2012. NF-kappaB is the transcription factor for FGF-2 that
causes endothelial mesenchymal transformation in cornea. Invest Ophthalmol Vis
Sci, 53, 1530-8.

LEE, J. G., KO, M. K. & KAY, E. P. 2012. Endothelial mesenchymal transformation
mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res,
95, 35-9.

LEE, J. G., KO, M. K. & KAY, E. P. 2012. Endothelial mesenchymal transformation
mediated by IL-1beta-induced FGF-2 in corneal endothelial cells. Exp Eye Res,
95, 35-9.

LEE, J. M., DEDHAR, S., KALLURI, R. & THOMPSON, E. W. 2006. The epithelialmesenchymal transition: new insights in signaling, development, and disease. J
Cell Biol, 172, 973-81.

LEMEN, R. A., DEMENT, J. M. & WAGONER, J. K. 1980. Epidemiology of asbestosrelated diseases. Environ Health Perspect, 34, 1-11.
197

LI, X., BROWNLEE, N. A., SPORN, T. A., MAHAR, A. & ROGGLI, V. L. 2015.
Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A
Clinicopathologic Study of 45 Cases. Arch Pathol Lab Med, 139, 1129-36.

LINTON, A., VAN ZANDWIJK, N., REID, G., CLARKE, S., CAO, C. & KAO, S.
2012. Inflammation in malignant mesothelioma - friend or foe? Ann Cardiothorac
Surg, 1, 516-22.

LIU, G., BERI, R., MUELLER, A. & KAMP, D. W. 2010. Molecular mechanisms of
asbestos-induced lung epithelial cell apoptosis. Chem Biol Interact, 188, 309-18.

LO NIGRO, C., WANG, H., MCHUGH, A., LATTANZIO, L., MATIN, R.,
HARWOOD, C., SYED, N., HATZIMICHAEL, E., BRIASOULIS, E.,
MERLANO, M., EVANS, A., THOMPSON, A., LEIGH, I., FLEMING, C.,
INMAN, G. J., PROBY, C. & CROOK, T. 2013. Methylated tissue factor
pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic
melanoma. J Invest Dermatol, 133, 1278-85.

LUDWIG-PORTUGALL, I., BARTOK, E., DHANA, E., EVERS, B. D., PRIMIANO,
M. J., HALL, J. P., FRANKLIN, B. S., KNOLLE, P. A., HORNUNG, V.,
HARTMANN, G., BOOR, P., LATZ, E. & KURTS, C. 2016. An NLRP3-specific
inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.
Kidney Int, 90, 525-39.

MALESZEWSKA, M., MOONEN, J. R., HUIJKMAN, N., VAN DE SLUIS, B.,
KRENNING, G. & HARMSEN, M. C. 2013. IL-1beta and TGFbeta2
synergistically induce endothelial to mesenchymal transition in an NFkappaBdependent manner. Immunobiology, 218, 443-54.

MANNING, C. B., VALLYATHAN, V. & MOSSMAN, B. T. 2002. Diseases caused by
asbestos: mechanisms of injury and disease development. Int Immunopharmacol,
2, 191-200.

MARCZYNSKI, B., ROZYNEK, P., KRAUS, T., SCHLOSSER, S., RAITHEL, H. J. &
BAUR, X. 2000. Levels of 8-hydroxy-2'-deoxyguanosine in DNA of white blood
cells from workers highly exposed to asbestos in Germany. Mutat Res, 468, 195202.
198

MAREK, L. A., HINZ, T. K., VON MASSENHAUSEN, A., OLSZEWSKI, K. A.,
KLECZKO, E. K., BOEHM, D., WEISER-EVANS, M. C., NEMENOFF, R. A.,
HOFFMANN, H., WARTH, A., GOZGIT, J. M., PERNER, S. & HEASLEY, L.
E. 2014. Nonamplified FGFR1 is a growth driver in malignant pleural
mesothelioma. Mol Cancer Res, 12, 1460-9.

MATSUZAKI, H., MAEDA, M., LEE, S., NISHIMURA, Y., KUMAGAI-TAKEI, N.,
HAYASHI, H., YAMAMOTO, S., HATAYAMA, T., KOJIMA, Y., TABATA,
R., KISHIMOTO, T., HIRATSUKA, J. & OTSUKI, T. 2012. Asbestos-induced
cellular and molecular alteration of immunocompetent cells and their relationship
with chronic inflammation and carcinogenesis. J Biomed Biotechnol, 2012,
492608.

MILLER, J. & SHUKLA, A. 2012. The Role of Inflammation in the Development and
Therapy of Malignant Mesothelioma. Am. Med. J., 3, 240-248.

MILLER, J. M., THOMPSON, J. K., MACPHERSON, M. B., BEUSCHEL, S. L.,
WESTBOM, C. M., SAYAN, M. & SHUKLA, A. 2014. Curcumin: a double hit
on malignant mesothelioma. Cancer Prev Res (Phila), 7, 330-40.

MISAWA, T., SAITOH, T., KOZAKI, T., PARK, S., TAKAHAMA, M. & AKIRA, S.
2015. Resveratrol inhibits the acetylated alpha-tubulin-mediated assembly of the
NLRP3-inflammasome. Int Immunol, 27, 425-34.

MISEROCCHI, G., SANCINI, G., MANTEGAZZA, F. & CHIAPPINO, G. 2008.
Translocation pathways for inhaled asbestos fibers. Environ Health, 7, 4.

MITSUI, A., SAJI, H., SHIMMYO, T., MOCHIZUKI, A., KURIMOTO, N. &
NAKAMURA, H. 2015. Malignant pleural mesothelioma presenting as a
spontaneous pneumothorax. Respirol Case Rep, 3, 9-12.

MOOLGAVKAR, S. H., BROWN, R. C. & TURIM, J. 2001. Biopersistence, fiber
length, and cancer risk assessment for inhaled fibers. Inhal Toxicol, 13, 755-72.

MOORE, A. J., PARKER, R. J. & WIGGINS, J. 2008. Malignant mesothelioma.
Orphanet J Rare Dis, 3, 34.
199

MOSSMAN, B. T. & CHURG, A. 1998. Mechanisms in the pathogenesis of asbestosis
and silicosis. Am J Respir Crit Care Med, 157, 1666-80.

MOSSMAN, B. T., LIPPMANN, M., HESTERBERG, T. W., KELSEY, K. T.,
BARCHOWSKY, A. & BONNER, J. C. 2011. Pulmonary endpoints (lung
carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol
Environ Health B Crit Rev, 14, 76-121.

MOSSMAN, B. T., SHUKLA, A., HEINTZ, N. H., VERSCHRAEGEN, C. F.,
THOMAS, A. & HASSAN, R. 2013. New insights into understanding the
mechanisms, pathogenesis, and management of malignant mesotheliomas. Am J
Pathol, 182, 1065-77.

MURATA, M., THANAN, R., MA, N. & KAWANISHI, S. 2012. Role of nitrative and
oxidative DNA damage in inflammation-related carcinogenesis. J Biomed
Biotechnol, 2012, 623019.

MURPHY, F. A., POLAND, C. A., DUFFIN, R., AL-JAMAL, K. T., ALI-BOUCETTA,
H., NUNES, A., BYRNE, F., PRINA-MELLO, A., VOLKOV, Y., LI, S.,
MATHER, S. J., BIANCO, A., PRATO, M., MACNEE, W., WALLACE, W. A.,
KOSTARELOS, K. & DONALDSON, K. 2011. Length-dependent retention of
carbon nanotubes in the pleural space of mice initiates sustained inflammation
and progressive fibrosis on the parietal pleura. Am J Pathol, 178, 2587-600.

MURPHY, F. A., POLAND, C. A., DUFFIN, R. & DONALDSON, K. 2013. Lengthdependent pleural inflammation and parietal pleural responses after deposition of
carbon nanotubes in the pulmonary airspaces of mice. Nanotoxicology, 7, 115767.

MURPHY, F. A., SCHINWALD, A., POLAND, C. A. & DONALDSON, K. 2012. The
mechanism of pleural inflammation by long carbon nanotubes: interaction of long
fibres with macrophages stimulates them to amplify pro-inflammatory responses
in mesothelial cells. Part Fibre Toxicol, 9, 8.

MUTSAERS, S. E. 2002. Mesothelial cells: their structure, function and role in serosal
repair. Respirology, 7, 171-91.
200

MUTSAERS, S. E., BIRNIE, K., LANSLEY, S., HERRICK, S. E., LIM, C. B. &
PRELE, C. M. 2015. Mesothelial cells in tissue repair and fibrosis. Front
Pharmacol, 6, 113.

MUTSAERS, S. E., MCANULTY, R. J., LAURENT, G. J., VERSNEL, M. A.,
WHITAKER, D. & PAPADIMITRIOU, J. M. 1997. Cytokine regulation of
mesothelial cell proliferation in vitro and in vivo. Eur J Cell Biol, 72, 24-9.

MUTSAERS, S. E., PRELE, C. M., PENGELLY, S. & HERRICK, S. E. 2016.
Mesothelial cells and peritoneal homeostasis. Fertil Steril, 106, 1018-1024.

MUZES, G. & SIPOS, F. 2015. Inflammasome, inflammation and cancer: an interrelated
pathobiological triad. Curr Drug Targets, 16, 249-57.

MYERS, R. 2012. Asbestos-related pleural disease. Curr Opin Pulm Med, 18, 377-81.

NAGAI, H. & TOYOKUNI, S. 2010. Biopersistent fiber-induced inflammation and
carcinogenesis: lessons learned from asbestos toward safety of fibrous
nanomaterials. Arch Biochem Biophys, 502, 1-7.

NAPOLITANO, A., PELLEGRINI, L., DEY, A., LARSON, D., TANJI, M., FLORES,
E. G., KENDRICK, B., LAPID, D., POWERS, A., KANODIA, S., PASTORINO,
S., PASS, H. I., DIXIT, V., YANG, H. & CARBONE, M. 2016. Minimal
asbestos exposure in germline BAP1 heterozygous mice is associated with
deregulated inflammatory response and increased risk of mesothelioma.
Oncogene, 35, 1996-2002.

NASU, M., EMI, M., PASTORINO, S., TANJI, M., POWERS, A., LUK, H.,
BAUMANN, F., ZHANG, Y. A., GAZDAR, A., KANODIA, S., TIIRIKAINEN,
M., FLORES, E., GAUDINO, G., BECICH, M. J., PASS, H. I., YANG, H. &
CARBONE, M. 2015. High Incidence of Somatic BAP1 alterations in sporadic
malignant mesothelioma. J Thorac Oncol, 10, 565-76.

NEUMANN, V., LOSEKE, S., NOWAK, D., HERTH, F. J. & TANNAPFEL, A. 2013.
Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and
occupational health. Dtsch Arztebl Int, 110, 319-26.
201

NGAMWONG, Y., TANGAMORNSUKSAN, W., LOHITNAVY, O.,
CHAIYAKUNAPRUK, N., SCHOLFIELD, C. N., REISFELD, B. &
LOHITNAVY, M. 2015. Additive Synergism between Asbestos and Smoking in
Lung Cancer Risk: A Systematic Review and Meta-Analysis. PLoS One, 10,
e0135798.

NISHIMURA, Y., MAEDA, M., KUMAGAI-TAKEI, N., LEE, S., MATSUZAKI, H.,
WADA, Y., NISHIIKE-WADA, T., IGUCHI, H. & OTSUKI, T. 2013. Altered
functions of alveolar macrophages and NK cells involved in asbestos-related
diseases. Environ Health Prev Med, 18, 198-204.

NISHIMURA, Y., NISHIIKE-WADA, T., WADA, Y., MIURA, Y., OTSUKI, T. &
IGUCHI, H. 2007. Long-lasting production of TGF-beta1 by alveolar
macrophages exposed to low doses of asbestos without apoptosis. Int J
Immunopathol Pharmacol, 20, 661-71.

NORBET, C., JOSEPH, A., ROSSI, S. S., BHALLA, S. & GUTIERREZ, F. R. 2015.
Asbestos-related lung disease: a pictorial review. Curr Probl Diagn Radiol, 44,
371-82.

NORBET, C., JOSEPH, A., ROSSI, S. S., BHALLA, S. & GUTIERREZ, F. R. 2015.
Asbestos-related lung disease: a pictorial review. Curr Probl Diagn Radiol, 44,
371-82.

NYMARK, P., WIKMAN, H., HIENONEN-KEMPAS, T. & ANTTILA, S. 2008.
Molecular and genetic changes in asbestos-related lung cancer. Cancer Lett, 265,
1-15.

OHAR, J. A., CHEUNG, M., TALARCHEK, J., HOWARD, S. E., HOWARD, T. D.,
HESDORFFER, M., PENG, H., RAUSCHER, F. J. & TESTA, J. R. 2016.
Germline BAP1 Mutational Landscape of Asbestos-Exposed Malignant
Mesothelioma Patients with Family History of Cancer. Cancer Res, 76, 206-15.

OKADA, F. 2007. Beyond foreign-body-induced carcinogenesis: impact of reactive
oxygen species derived from inflammatory cells in tumorigenic conversion and
tumor progression. Int J Cancer, 121, 2364-72.
202

OKADA, F. 2014. Inflammation-related carcinogenesis: current findings in
epidemiological trends, causes and mechanisms. Yonago Acta Med, 57, 65-72.

ONISHI, Y., NAKAHARA, Y., HIRANO, K., SASAKI, S., KAWAMURA, T. &
MOCHIDUKI, Y. 2016. IgG4-related disease in asbestos-related pleural disease.
Respirol Case Rep, 4, 22-4.

O'REILLY, K. M., MCLAUGHLIN, A. M., BECKETT, W. S. & SIME, P. J. 2007.
Asbestos-related lung disease. Am Fam Physician, 75, 683-8.

PANDURI, V., SURAPUREDDI, S., SOBERANES, S., WEITZMAN, S. A.,
CHANDEL, N. & KAMP, D. W. 2006. P53 mediates amosite asbestos-induced
alveolar epithelial cell mitochondria-regulated apoptosis. Am J Respir Cell Mol
Biol, 34, 443-52.

PASCOLO, L., GIANONCELLI, A., SCHNEIDER, G., SALOME, M., SCHNEIDER,
M., CALLIGARO, C., KISKINOVA, M., MELATO, M. & RIZZARDI, C. 2013.
The interaction of asbestos and iron in lung tissue revealed by synchrotron-based
scanning X-ray microscopy. Scientific reports, 3, 1123.

PEACOCK, C., COPLEY, S. J. & HANSELL, D. M. 2000. Asbestos-related benign
pleural disease. Clin Radiol, 55, 422-32.

PEREZ, L., MUNOZ-DURANGO, N., RIEDEL, C. A., ECHEVERRIA, C.,
KALERGIS, A. M., CABELLO-VERRUGIO, C. & SIMON, F. 2016.
Endothelial-to-mesenchymal transition: Cytokine-mediated pathways that
determine endothelial fibrosis under inflammatory conditions. Cytokine Growth
Factor Rev.

PETRILLI, V. 2017. The multifaceted roles of inflammasome proteins in cancer. Curr
Opin Oncol, 29, 35-40.

PFAU, J. C., SERVE, K. M. & NOONAN, C. W. 2014. Autoimmunity and asbestos
exposure. Autoimmune Dis, 2014, 782045.
203

PIETROFESA, R. A., VELALOPOULOU, A., ARGUIRI, E., MENGES, C. W., TESTA,
J. R., HWANG, W. T., ALBELDA, S. M. & CHRISTOFIDOU-SOLOMIDOU,
M. 2016. Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent
acute asbestos-induced peritoneal inflammation in mice. Carcinogenesis, 37, 17787.

PILARSKI, R., RAI, K., CEBULLA, C. & ABDEL-RAHMAN, M. 1993. BAP1 Tumor
Predisposition Syndrome. In: PAGON, R. A., ADAM, M. P., ARDINGER, H. H.,
WALLACE, S. E., AMEMIYA, A., BEAN, L. J. H., BIRD, T. D., LEDBETTER,
N., MEFFORD, H. C., SMITH, R. J. H. & STEPHENS, K. (eds.)
GeneReviews(R). Seattle (WA).

PRAZAKOVA, S., THOMAS, P. S., SANDRINI, A. & YATES, D. H. 2014. Asbestos
and the lung in the 21st century: an update. Clin Respir J, 8, 1-10.

PRIMIANO, M. J., LEFKER, B. A., BOWMAN, M. R., BREE, A. G., HUBEAU, C.,
BONIN, P. D., MANGAN, M., DOWER, K., MONKS, B. G., CUSHING, L.,
WANG, S., GUZOVA, J., JIAO, A., LIN, L. L., LATZ, E., HEPWORTH, D. &
HALL, J. P. 2016. Efficacy and Pharmacology of the NLRP3 Inflammasome
Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary
Inflammation. J Immunol, 197, 2421-33.

PUTTABYATAPPA, M., AL-ALEM, L. F., ZAKERKISH, F., ROSEWELL, K. L.,
BRANNSTROM, M. & CURRY, T. E., JR. 2016. Induction of Tissue Factor
Pathway Inhibitor 2 by hCG regulates Periovulatory Gene Expression and
Plasmin Activity. Endocrinology, en20161544.

QI, F., CARBONE, M., YANG, H. & GAUDINO, G. 2011. Simian virus 40
transformation, malignant mesothelioma and brain tumors. Expert Rev Respir
Med, 5, 683-97.

QIU, J., WANG, M., ZHANG, J., CAI, Q., LU, D., LI, Y., DONG, Y., ZHAO, T. &
CHEN, H. 2016. The neuroprotection of Sinomenine against ischemic stroke in
mice by suppressing NLRP3 inflammasome via AMPK signaling. Int
Immunopharmacol, 40, 492-500.

204

RHEE, S. G. & WOO, H. A. 2011. Multiple functions of peroxiredoxins: peroxidases,
sensors and regulators of the intracellular messenger H(2)O(2), and protein
chaperones. Antioxid Redox Signal, 15, 781-94.

RIBARSKA, T., INGENWERTH, M., GOERING, W., ENGERS, R. & SCHULZ, W. A.
2010. Epigenetic inactivation of the placentally imprinted tumor suppressor gene
TFPI2 in prostate carcinoma. Cancer Genomics Proteomics, 7, 51-60.

RIGANTI, C., ALDIERI, E., BERGANDI, L., FENOGLIO, I., COSTAMAGNA, C.,
FUBINI, B., BOSIA, A. & GHIGO, D. 2002. Crocidolite asbestos inhibits
pentose phosphate oxidative pathway and glucose 6-phosphate dehydrogenase
activity in human lung epithelial cells. Free Radic Biol Med, 32, 938-49.

RIGANTI, C., ALDIERI, E., BERGANDI, L., TOMATIS, M., FENOGLIO, I.,
COSTAMAGNA, C., FUBINI, B., BOSIA, A. & GHIGO, D. 2003. Long and
short fiber amosite asbestos alters at a different extent the redox metabolism in
human lung epithelial cells. Toxicology and applied pharmacology, 193, 106-15.

RODRIGUEZ PANADERO, F. 2015. Diagnosis and treatment of malignant pleural
mesothelioma. Arch Bronconeumol, 51, 177-84.

ROM, W. N. & PALMER, P. E. 1974. The spectrum of asbestos-related diseases. West J
Med, 121, 10-21.

RUF, W., SEFTOR, E. A., PETROVAN, R. J., WEISS, R. M., GRUMAN, L. M.,
MARGARYAN, N. V., SEFTOR, R. E., MIYAGI, Y. & HENDRIX, M. J. 2003.
Differential role of tissue factor pathway inhibitors 1 and 2 in melanoma
vasculogenic mimicry. Cancer Res, 63, 5381-9.

SAFI, A., SADMI, M., MARTINET, N., MENARD, O., VAILLANT, P., GALLATI, H.,
HOSANG, M. & MARTINET, Y. 1992. Presence of elevated levels of plateletderived growth factor (PDGF) in lung adenocarcinoma pleural effusions. Chest,
102, 204-7.

SANCHEZ, V. C., PIETRUSKA, J. R., MISELIS, N. R., HURT, R. H. & KANE, A. B.
2009. Biopersistence and potential adverse health impacts of fibrous
205

nanomaterials: what have we learned from asbestos? Wiley Interdiscip Rev
Nanomed Nanobiotechnol, 1, 511-29.

SCAPOLI, L., RAMOS-NINO, M. E., MARTINELLI, M. & MOSSMAN, B. T. 2004.
Src-dependent ERK5 and Src/EGFR-dependent ERK1/2 activation is required for
cell proliferation by asbestos. Oncogene, 23, 805-13.

SCHELCH, K., HODA, M. A., KLIKOVITS, T., MUNZKER, J., GHANIM, B.,
WAGNER, C., GARAY, T., LASZLO, V., SETINEK, U., DOME, B., FILIPITS,
M., PIRKER, C., HEFFETER, P., SELZER, E., TOVARI, J., TOROK, S.,
KENESSEY, I., HOLZMANN, K., GRASL-KRAUPP, B., MARIAN, B.,
KLEPETKO, W., BERGER, W., HEGEDUS, B. & GRUSCH, M. 2014.
Fibroblast growth factor receptor inhibition is active against mesothelioma and
synergizes with radio- and chemotherapy. Am J Respir Crit Care Med, 190, 76372.

SCHINWALD, A., MURPHY, F. A., PRINA-MELLO, A., POLAND, C. A., BYRNE,
F., MOVIA, D., GLASS, J. R., DICKERSON, J. C., SCHULTZ, D. A.,
JEFFREE, C. E., MACNEE, W. & DONALDSON, K. 2012. The threshold length
for fiber-induced acute pleural inflammation: shedding light on the early events in
asbestos-induced mesothelioma. Toxicol Sci, 128, 461-70.

SHUKLA, A., FLANDERS, T., LOUNSBURY, K. M. & MOSSMAN, B. T. 2004. The
gamma-glutamylcysteine synthetase and glutathione regulate asbestos-induced
expression of activator protein-1 family members and activity. Cancer Res, 64,
7780-6.

SHUKLA, A., GULUMIAN, M., HEI, T. K., KAMP, D., RAHMAN, Q. & MOSSMAN,
B. T. 2003. Multiple roles of oxidants in the pathogenesis of asbestos-induced
diseases. Free Radic Biol Med, 34, 1117-29.

SHUKLA, A., HILLEGASS, J. M., MACPHERSON, M. B., BEUSCHEL, S. L.,
VACEK, P. M., BUTNOR, K. J., PASS, H. I., CARBONE, M., TESTA, J. R.,
HEINTZ, N. H. & MOSSMAN, B. T. 2011. ERK2 is essential for the growth of
human epithelioid malignant mesotheliomas. Int J Cancer, 129, 1075-86.

206

SHUKLA, A., JUNG, M., STERN, M., FUKAGAWA, N. K., TAATJES, D. J.,
SAWYER, D., VAN HOUTEN, B. & MOSSMAN, B. T. 2003. Asbestos induces
mitochondrial DNA damage and dysfunction linked to the development of
apoptosis. Am J Physiol Lung Cell Mol Physiol, 285, L1018-25.

SHUKLA, A., LOUNSBURY, K. M., BARRETT, T. F., GELL, J., RINCON, M.,
BUTNOR, K. J., TAATJES, D. J., DAVIS, G. S., VACEK, P., NAKAYAMA, K.
I., NAKAYAMA, K., STEELE, C. & MOSSMAN, B. T. 2007. Asbestos-induced
peribronchiolar cell proliferation and cytokine production are attenuated in lungs
of protein kinase C-delta knockout mice. Am J Pathol, 170, 140-51.

SHUKLA, A., MACPHERSON, M. B., HILLEGASS, J., RAMOS-NINO, M. E.,
ALEXEEVA, V., VACEK, P. M., BOND, J. P., PASS, H. I., STEELE, C. &
MOSSMAN, B. T. 2009. Alterations in gene expression in human mesothelial
cells correlate with mineral pathogenicity. Am J Respir Cell Mol Biol, 41, 114-23.

SHUKLA, A. & MOSSMAN, B. T. 2004. Asbestosis and Asbestos Related Cancers:
Role of Reactive Oxygen and Nitrogen Species. In: VALLYATHAN, V.,
CASTRANOVA, V. & SHI, X. (eds.) Oxygen/Nitrogen Radicals Lung Injury and
Disease. New York: Marcel Dekker Inc.

SHUKLA, A. & MOSSMAN, B. T. 2005. Molecular mechanisms of environmental
particulates in lung inflammation and fibrosis. Recent Res. Devel. Mol. Cell.
Biochem, 2, 35-48.

SHUKLA, A. & MOSSMAN, B. T. 2008. Cell Signaling by Oxidants: Pathways leading
to activation of Mitogen-activated Protein Kinases (MAPK) and Activator
Protein-1 (AP-1). Current Topics in Membranes. Elsevier Inc.

SHUKLA, A., RAMOS-NINO, M. & MOSSMAN, B. 2003. Cell signaling and
transcription factor activation by asbestos in lung injury and disease. Int J
Biochem Cell Biol, 35, 1198-209.

SHUKLA, A., STERN, M., LOUNSBURY, K. M., FLANDERS, T. & MOSSMAN, B.
T. 2003. Asbestos-induced apoptosis is protein kinase C delta-dependent. Am J
Respir Cell Mol Biol, 29, 198-205.
207

SRIVASTAVA, R. K., LOHANI, M., PANT, A. B. & RAHMAN, Q. 2010. Cytogenotoxicity of amphibole asbestos fibers in cultured human lung epithelial cell
line: role of surface iron. Toxicol Ind Health, 26, 575-82.

STRIZZI, L., CATALANO, A., VIANALE, G., ORECCHIA, S., CASALINI, A.,
TASSI, G., PUNTONI, R., MUTTI, L. & PROCOPIO, A. 2001. Vascular
endothelial growth factor is an autocrine growth factor in human malignant
mesothelioma. J Pathol, 193, 468-75.

STRUTZ, F., ZEISBERG, M., ZIYADEH, F. N., YANG, C. Q., KALLURI, R.,
MULLER, G. A. & NEILSON, E. G. 2002. Role of basic fibroblast growth
factor-2 in epithelial-mesenchymal transformation. Kidney Int, 61, 1714-28.

SU, T., LI, X., LIU, N., PAN, S., LU, J., YANG, J. & ZHANG, Z. 2012. Real-time
imaging elucidates the role of H2O2 in regulating kinetics of epidermal growth
factor-induced and Src-mediated tyrosine phosphorylation signaling. Journal of
biomedical optics, 17, 076015.

SULLIVAN, D. E., FERRIS, M., POCIASK, D. & BRODY, A. R. 2008. The latent form
of TGFbeta(1) is induced by TNFalpha through an ERK specific pathway and is
activated by asbestos-derived reactive oxygen species in vitro and in vivo. J
Immunotoxicol, 5, 145-9.

SUN, F. K., FAN, Y. C., ZHAO, J., ZHANG, F., GAO, S., ZHAO, Z. H., SUN, Q. &
WANG, K. 2013. Detection of TFPI2 methylation in the serum of hepatocellular
carcinoma patients. Dig Dis Sci, 58, 1010-5.

SUN, F. K., SUN, Q., FAN, Y. C., GAO, S., ZHAO, J., LI, F., JIA, Y. B., LIU, C.,
WANG, L. Y., LI, X. Y., JI, X. F. & WANG, K. 2016. Methylation of tissue
factor pathway inhibitor 2 as a prognostic biomarker for hepatocellular carcinoma
after hepatectomy. J Gastroenterol Hepatol, 31, 484-92.

SWIATKOWSKA, B., SZUBERT, Z., SOBALA, W. & SZESZENIA-DABROWSKA,
N. 2015. Predictors of lung cancer among former asbestos-exposed workers. Lung
Cancer, 89, 243-8.

208

TAIOLI, E., WOLF, A. S., CAMACHO-RIVERA, M., KAUFMAN, A., LEE, D. S.,
NICASTRI, D., ROSENZWEIG, K. & FLORES, R. M. 2015. Determinants of
Survival in Malignant Pleural Mesothelioma: A Surveillance, Epidemiology, and
End Results (SEER) Study of 14,228 Patients. PLoS One, 10, e0145039.

TAKADA, H., WAKABAYASHI, N., DOHI, O., YASUI, K., SAKAKURA, C.,
MITSUFUJI, S., TANIWAKI, M. & YOSHIKAWA, T. 2010. Tissue factor
pathway inhibitor 2 (TFPI2) is frequently silenced by aberrant promoter
hypermethylation in gastric cancer. Cancer Genet Cytogenet, 197, 16-24.

TESTA, J. R., CHEUNG, M., PEI, J., BELOW, J. E., TAN, Y., SEMENTINO, E., COX,
N. J., DOGAN, A. U., PASS, H. I., TRUSA, S., HESDORFFER, M., NASU, M.,
POWERS, A., RIVERA, Z., COMERTPAY, S., TANJI, M., GAUDINO, G.,
YANG, H. & CARBONE, M. 2011. Germline BAP1 mutations predispose to
malignant mesothelioma. Nat Genet, 43, 1022-5.

THOMPSON, J. K., WESTBOM, C. M., MACPHERSON, M. B., MOSSMAN, B. T.,
HEINTZ, N. H., SPIESS, P. & SHUKLA, A. 2014. Asbestos modulates
thioredoxin-thioredoxin interacting protein interaction to regulate inflammasome
activation. Part Fibre Toxicol, 11, 24.

THOMPSON, J. K., WESTBOM, C. M. & SHUKLA, A. 2014. Malignant mesothelioma:
development to therapy. J Cell Biochem, 115, 1-7.

TRPKOV, K., BARR, R., KULAGA, A. & YILMAZ, A. 2011. Mesothelioma of tunica
vaginalis of "uncertain malignant potential" - an evolving concept: case report and
review of the literature. Diagn Pathol, 6, 78.

TURCI, F., COLONNA, M., TOMATIS, M., MANTEGNA, S., CRAVOTTO, G.,
GULINO, G., ALDIERI, E., GHIGO, D. & FUBINI, B. 2012. Surface reactivity
and cell responses to chrysotile asbestos nanofibers. Chem Res Toxicol, 25, 88494.

TURCI, F., TOMATIS, M., LESCI, I. G., ROVERI, N. & FUBINI, B. 2011. The ironrelated molecular toxicity mechanism of synthetic asbestos nanofibres: a model
study for high-aspect-ratio nanoparticles. Chemistry, 17, 350-8.
209

VAN MEERBEECK, J. P., SCHERPEREEL, A., SURMONT, V. F. & BAAS, P. 2011.
Malignant pleural mesothelioma: the standard of care and challenges for future
management. Crit Rev Oncol Hematol, 78, 92-111.

VAN, T. T., HANIBUCHI, M., GOTO, H., KURAMOTO, T., YUKISHIGE, S.,
KAKIUCHI, S., SATO, S., SAKAGUCHI, S., DAT LE, T., NISHIOKA, Y.,
AKIYAMA, S. & SONE, S. 2012. SU6668, a multiple tyrosine kinase inhibitor,
inhibits progression of human malignant pleural mesothelioma in an orthotopic
model. Respirology, 17, 984-90.

VORONOV, E., DOTAN, S., KRELIN, Y., SONG, X., ELKABETS, M., CARMI, Y.,
RIDER, P., IDAN, C., ROMZOVA, M., KAPLANOV, I. & APTE, R. N. 2013.
Unique Versus Redundant Functions of IL-1alpha and IL-1beta in the Tumor
Microenvironment. Front Immunol, 4, 177.

WAGNER, J. C. 1965. The sequelae of exposure to asbestos dust. Ann N Y Acad Sci,
132, 691-5.

WAGNER, J. C., SLEGGS, C. A. & MARCHAND, P. 1960. Diffuse pleural
mesothelioma and asbestos exposure in the North Western Cape Province. Br J
Ind Med, 17, 260-71.

WANG, H., WANG, Y., DU, Q., LU, P., FAN, H., LU, J. & HU, R. 2016.
Inflammasome-independent NLRP3 is required for epithelial-mesenchymal
transition in colon cancer cells. Exp Cell Res, 342, 184-92.

WANG, W., WANG, X., CHUN, J., VILAYSANE, A., CLARK, S., FRENCH, G.,
BRACEY, N. A., TRPKOV, K., BONNI, S., DUFF, H. J., BECK, P. L. &
MURUVE, D. A. 2013. Inflammasome-independent NLRP3 augments TGF-beta
signaling in kidney epithelium. J Immunol, 190, 1239-49.

WANG, X., WU, Y., STONEHUERNER, J. G., DAILEY, L. A., RICHARDS, J. D.,
JASPERS, I., PIANTADOSI, C. A. & GHIO, A. J. 2006. Oxidant generation
promotes iron sequestration in BEAS-2B cells exposed to asbestos. Am J Respir
Cell Mol Biol, 34, 286-92.
210

WESTBOM, C., THOMPSON, J. K., LEGGETT, A., MACPHERSON, M.,
BEUSCHEL, S., PASS, H., VACEK, P. & SHUKLA, A. 2015. Inflammasome
Modulation by Chemotherapeutics in Malignant Mesothelioma. PLoS One, 10,
e0145404.

WESTBOM, C. M., SHUKLA, A., MACPHERSON, M. B., YASEWICZ, E. C.,
MILLER, J. M., BEUSCHEL, S. L., STEELE, C., PASS, H. I., VACEK, P. M. &
SHUKLA, A. 2014. CREB-induced inflammation is important for malignant
mesothelioma growth. Am J Pathol, 184, 2816-27.

WILLIAMS, L., TUCKER, T. A., KOENIG, K., ALLEN, T., RAO, L. V., PENDURTHI,
U. & IDELL, S. 2012. Tissue factor pathway inhibitor attenuates the progression
of malignant pleural mesothelioma in nude mice. Am J Respir Cell Mol Biol, 46,
173-9.

YAMAGISHI, T., FUJIMOTO, N., NISHI, H., MIYAMOTO, Y., HARA, N., ASANO,
M., FUCHIMOTO, Y., WADA, S., KITAMURA, K., OZAKI, S. &
KISHIMOTO, T. 2015. Prognostic significance of the lymphocyte-to-monocyte
ratio in patients with malignant pleural mesothelioma. Lung Cancer, 90, 111-7.

YANG, G., LEE, H. E. & LEE, J. Y. 2016. A pharmacological inhibitor of NLRP3
inflammasome prevents non-alcoholic fatty liver disease in a mouse model
induced by high fat diet. Sci Rep, 6, 24399.

YANG, H., RIVERA, Z., JUBE, S., NASU, M., BERTINO, P., GOPARAJU, C.,
FRANZOSO, G., LOTZE, M. T., KRAUSZ, T., PASS, H. I., BIANCHI, M. E. &
CARBONE, M. 2010. Programmed necrosis induced by asbestos in human
mesothelial cells causes high-mobility group box 1 protein release and resultant
inflammation. Proc Natl Acad Sci U S A, 107, 12611-6.

YANG, H., TESTA, J. R. & CARBONE, M. 2008. Mesothelioma epidemiology,
carcinogenesis, and pathogenesis. Curr Treat Options Oncol, 9, 147-57.
YAZDI, A. S. & DREXLER, S. K. 2015. The two faces of the inflammasome adaptor
ASC in epithelial skin carcinogenesis. Clin Exp Rheumatol, 33, S94-6.
211

ZANELLA, C. L., POSADA, J., TRITTON, T. R. & MOSSMAN, B. T. 1996. Asbestos
causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated
protein kinase cascade after phosphorylation of the epidermal growth factor
receptor. Cancer Res, 56, 5334-8.

ZANELLA, C. L., TIMBLIN, C. R., CUMMINS, A., JUNG, M., GOLDBERG, J.,
RAABE, R., TRITTON, T. R. & MOSSMAN, B. T. 1999. Asbestos-induced
phosphorylation of epidermal growth factor receptor is linked to c-fos and
apoptosis. The American journal of physiology, 277, L684-93.

ZHANG, X. H., ZHU, R. M., XU, W. A., WAN, H. J. & LU, H. 2007. Therapeutic
effects of caspase-1 inhibitors on acute lung injury in experimental severe acute
pancreatitis. World J Gastroenterol, 13, 623-7.

ZHANG, Y., LEE, T. C., GUILLEMIN, B., YU, M. C. & ROM, W. N. 1993. Enhanced
IL-1 beta and tumor necrosis factor-alpha release and messenger RNA expression
in macrophages from idiopathic pulmonary fibrosis or after asbestos exposure. J
Immunol, 150, 4188-96.

ZHU, S., MANUEL, M., TANAKA, S., CHOE, N., KAGAN, E. & MATALON, S.
1998. Contribution of reactive oxygen and nitrogen species to particulate-induced
lung injury. Environ Health Perspect, 106 Suppl 5, 1157-63.

ZITVOGEL, L., KEPP, O., GALLUZZI, L. & KROEMER, G. 2012. Inflammasomes in
carcinogenesis and anticancer immune responses. Nat Immunol, 13, 343-51.

212

